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1G E N E R A L I N T R O D U C T I O N
1.1 regulation of eukaryotic transcription
Tightly regulated processes such as differentiation, development, mor-
phogenesis and reaction to external stimuli are made possible by the
precise and careful control of gene expression. With the advent of high-
throughput genomic techniques, it has become possible to study the
mechanisms of regulation at an unprecedented scale and resolution.
Instead of experiments involving a limited set of genes, the complete
genome can be interrogated, for instance, to determine gene expression
levels, binding events of regulatory proteins or characteristics of the
chromatin environment.
RNA Polymerase II (RNAPII) is recruited to the promoter of genes,
which is followed by initiation of transcription, escape of the promoter,
transcript elongation and termination. While transcription initiation
forms the most critical rate-limiting step, control of gene expression
is regulated at all these stages of gene transcription. As a result, the
final expression level of a gene is determined by multiple layered and
interconnected regulatory mechanisms.
There are numerous additional levels of control that focus on post-
transcriptional and post-translational regulation, such mRNA splicing,
export and degradation, protein localization and post-translational
modifications (reviewed in Mata et al. (2005); Halbeisen et al. (2008))
Furthermore, it has become clear that non-coding RNA’s (ncRNAs),
many of which are conserved in mammalian genomes (Guttman et al.,
2009), have an important regulatory role (Goodrich and Kugel, 2006,
2009). Different species of ncRNAs include microRNA’s (Bartel, 2004)
and large ncRNAs (Ponting et al., 2009), involved in processes such
as X inactivation and spatial expression patterns during development
(Rinn et al., 2007; Senner and Brockdorff, 2009).
Together, all these regulatory mechanisms form a fascinating picture
of dizzying complexity, enabling regulation and control in a highly
dynamic cellular environment. However, this thesis will mainly focus on
the regulatory steps that control transcription. Even these mechanisms
are complex as they are determined by interactions between a large
and varied number of protein complexes that influence each other at
almost every step. In the next section I will describe the regulation of
gene expression from three different angles. Together the following
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processes determine at least a large fraction of the eukaryotic control of
gene expression:
1. Binding of activators and assembly of the transcription machinery,
the basal transcription factors and RNA Polymerase II, on the
core promoter and transcription initiation and elongation.
2. Sequence-specific transcription factors that bind to specific reg-
ulatory DNA sequences in promoter or enhancer regions and
influence expression.
3. The structural and epigenetic environment, involving DNA dy-
namics, the organization of nucleosomes, chromatin state and
modifications and DNA methylation.
Naturally, these processes are not isolated components, but are largely
interconnected. This means that a tidy division such as presented here
will never do complete justice to the biological complexity.
1.2 mechanisms of regulation
1.2.1 Transcription by RNA Polymerase II
1.2.1.1 Assembly of the pre-initiation complex at the core promoter
RNAPII is recruited to the core promoter and initiates transcription at
the transcription start site (TSS). The core promoter serves as the essen-
tial scaffold where all the necessary components of the transcription
complex are recruited. In general two different types of promoters can
be characterized: those with a single transcription start site (“focused“
or “sharp“ promoters), and those with a collection of transcription start
sites in a wider region (“dispersed“ or “broad“ promoters) (Carninci
et al., 2006; Juven-Gershon et al., 2008b; Juven-Gershon and Kadonaga,
2010). Dispersed promoters are common in vertebrates and are mostly
localized in CpG islands (Carninci et al., 2006; Sandelin et al., 2007).
These broad CpG-island promoters are associated with constitutively
expressed genes, so-called housekeeping genes, involved in for instance
metabolic processes. The focused promoters are found in many con-
served, tissue-specific genes and genes that need to be rapidly activated
or shutdown in response to external stimuli (Weake and Workman,
2010).
In vitro experiments with purified nuclear proteins have shown that
in addition to RNAPII several other co-factors are required to initiate
transcription from a basal promoter. Accurate transcription initiation
involves the basal transcription factor TFIID (Transcription Factor for
RNA Polymerase II D), a complex of TATA-binding protein (TBP) and
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several TBP associated factors (TAFs), TFIIA, TFIIB, TFIIE, TFIIF and
TFIIH (Matsui et al., 1980; Sayre et al., 1992; Thomas and Chiang,
2006). Together, these proteins assemble on the core promoter and
form the Pre-Initiation Complex (PIC). Different components of the PIC
recognize specific DNA sequences or core promoter elements.
The TBP subunit of TFIID binds to the TATA box, the first identified
and most widely studied core promoter element (Goldberg, 1979). This
element is relatively sharply positioned between -28 and -33 relative
to the transcription initiation site (Carninci et al., 2006). Contrary to
early results with a limited number of genes, genome-wide experiments
show that actually only a minority of the genes in eukaryotes have a
TATA box, with estimates around 10% in a wide variety of organisms
(Ohler et al., 2002; Basehoar et al., 2004; Molina and Grotewold, 2005;
Carninci et al., 2006). Most TATA box genes are associated with highly
regulated rapid-response and tissue-specific genes.
In addition to TBP, the PIC contains many other components that
specifically interact with core promoter elements. The TAF1 and TAF2
subunits of TFIID recognize the Initiator (Inr), present at the site of
transcription initiation (Chalkley and Verrijzer, 1999), and TFIIB binds
the BREu and BREd elements, present upstream and downstream of the
TSS (Lagrange et al., 1998; Deng and Roberts, 2005). TFIID can also bind
to the Downstream Promoter Element (DPE), a core promoter element
identified in Drosophila that is present in the promoters of nearly all
Hox genes, via the TAF6 and TAF9 subunits (Burke and Kadonaga,
1996; Kutach and Kadonaga, 2000; Juven-Gershon et al., 2008a). Inter-
estingly, TATA-dependent and DPE-dependent transcription seem to
be mutually exclusive. TBP activates transcription by binding to the
TATA box, but represses DPE-dependent transcription. In contrast, NC2
(Negative Cofactor 2) and the TBP-dependent ATPase Mot1 (Modifier
of Transcription 1) cooperate to restrict TBP activity and activate tran-
scription from DPE promoters (Pugh, 2000; Hsu et al., 2008; van Werven
et al., 2008).
While the function of TFIID is central to the expression of most
genes, many stress-induced genes in yeast, usually containing the
canonical TATA box, are dependent on the SAGA (Spt-Ada-Gcn5-
Acetyltransferase) complex (Huisinga and Pugh, 2004). SAGA contains
several TAFs and can bind TBP (Grant et al., 1997; Lee et al., 2000;
Sermwittayawong and Tan, 2006; Mohibullah and Hahn, 2008). The
ATAC (Ada Two-A containing) complex, which is essential for mam-
malian development, can also directly interact with TBP (Wang et al.,
2008a; Guelman et al., 2009).
In addition to the basal transcription factors mentioned above, one
other important component of the PIC is the large, multi-subunit Media-
tor complex (Kornberg, 2005). Mediator is not essential for transcription
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in vitro, but is able to stimulate transcription even in the absence of other
activating factors. It can function as either co-activator or co-repressor
and seems to serve as a bridge between gene-specific transcription
factors and the basal transcription machinery. It is currently unclear
if Mediator is recruited to enhancers in an activator-specific manner
or if it functions as a real general transcription factor (Fan et al., 2006;
Andrau et al., 2006; Ansari et al., 2009; Fan and Struhl, 2009).
It has gradually become clear that the universal general transcription
machinery does not exist. The exact PIC composition is not universal
and seems to be promoter-specific and dependent on the cellular con-
text (Sikorski and Buratowski, 2009). Many alternative, homologous
initiation factors are differentially expressed in various tissues and at
specific stages in development. Examples are the TBP-related factors
TBP2 and TLF (TBP-like factor) (Jallow et al., 2004; Jacobi et al., 2007)
or cell-type and tissue specific TAFs (Goodrich and Tjian, 2010). This
dynamic composition of the PIC thereby serves as a mechanism to
regulate cell-specific transcriptional programs.
1.2.1.2 Transcription initiation and elongation
After assembly of the PIC on the transcription start site, the carboxy-
terminal domain (CTD) of RNAPII plays a major role in elongation,
mRNA 5’ capping, splicing of introns, and 3’ cleavage and polyadeny-
lation (Fong and Bentley, 2001). TFIIH phosphorylates the Serine 5
(Ser5) residue of the CTD and unwinds the DNA around the TSS to a
single-stranded DNA template in an ATP-dependent fashion (Moreland
et al., 1999). Subsequently, RNAPII clears the promoter and passes into
the elongation phase.
Phosphorylated Ser5 interacts with multitude of factors essential for
transcription and links elongating RNAPII to histone modifications.
The PAF (RNA Polymerase Associated Factor) complex is recruited to
phosphorylated Ser5 CTD residues and regulates monoubiquitination
of histone 2B (H2B), which clears the nucleosomal barrier and enables
efficient elongation (Zhu et al., 2005; Xiao et al., 2005; Pavri et al., 2006;
Kim et al., 2009). Ubiquitination of H2B directly stimulates H3K4 di-
and tri-methylation, histone marks associated with active transcription
(Kim et al., 2009). After promoter clearance, the Ser2 residues of the
CTD are phosphorylated. Phosphorylated Ser2 recruits multiple mRNA-
processing factors and is linked to chromatin modifiers and nucleosome
remodelers that facilitate passage of RNAPII (Kizer et al., 2005).
Recent experiments show that effective elongation of RNAPII seems
to be a rate-limiting step in transcription. This suggests an important
role for control of RNAPII elongation in gene regulation (Core and Lis,
2008; Weake and Workman, 2010). Some studies have shown paused or
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stalled RNAPII at rapid-response genes. These genes are characterized
by RNAPII recruitment specifically at the promoter, suggesting that
RNAPII is poised for activation (Margaritis and Holstege, 2008; Guen-
ther et al., 2007; Core and Lis, 2008; Price, 2008). However this is not
a general phenomenon and seems to be mainly a feature of expressed
genes, with only a small group of silent genes showing promoter-
proximal RNAPII enrichment without any evidence of transcription
(Core et al., 2008).
1.2.2 Transcription factors
In vitro, purified RNAPII in combination with the basal transcription
factors can bind to the core promoter and accurately and efficiently
transcribe the DNA template. However, in vivo the DNA is packaged
as nucleosomes into chromatin, consisting of 147 basepairs of DNA
wrapped around the histone octamer (Kornberg, 1974; Luger et al.,
1997; Richmond and Davey, 2003). The three-dimensional chromatin
structure generally suppresses transcriptional activity (reviewed below
in section 1.2.3). To transcriptionally activate these genes, and to en-
hance transcriptional activity above the intrinsic level offered by the
basal transcription machinery, transcription factors are needed. This
mechanism confers specificity of transcription activity by suppressing
spurious transcription.
Transcription factors (TFs) are major regulators of gene expression.
They are recruited to the DNA, mostly to specific DNA elements in
a sequence-dependent manner. TFs can function as an activator or
repressor, potentially recruiting additional proteins such as co-activators
or co-repressors. Activation can occur through various mechanisms.
TFs or co-activators can directly recruit RNAPII and interact with the
general transcription machinery, recruit histone modifying enzymes
such as the histone acetyl transferases p300 and CBP or guide ATP-
dependent chromatin remodelers, which induce the structural changes
necessary for efficient transcription (Roeder, 2005; Spiegelman and
Heinrich, 2004).
TF binding elements are located in promoters, but also in more dis-
tant enhancer regions. Enhancers are often well-conserved and consist
of clusters of DNA elements for specific TFs. They play an important
role in tissue-specific and developmental control of gene expression.
Enhancer regions can be located quite distantly relative to the gene
body and interact with the promoter and the transcription complex
through a looping mechanism (Gondor and Ohlsson, 2008; Fullwood
et al., 2009). Multiple genes can be regulated by a single enhancer,
forming regulatory domains separated by insulator elements that pre-
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vent inappropriate interactions between the neighboring regions of the
genome (Gaszner and Felsenfeld, 2006; Cuddapah et al., 2009).
The combinatorial regulatory potential offered by TFs is enormous
and may well be a major determinant of organismal complexity (Levine
and Tjian, 2003). Genomic approaches to understand such issues as
transcription factor selectivity (Pan et al., 2010), combinatorial control
(Adryan and Teichmann, 2010; Tomancak and Ohler, 2010) and reg-
ulatory networks (Grove et al., 2009) will help to to understand the
intricate mechanisms of precise regulation of gene expression.
1.2.3 Epigenetic regulation
The chromatin environment is another key factor in the regulation of
gene expression. In chromatin, nucleosomes are composed of a tetramer
of two dimers of H3 and H4, flanked by two heterodimers of H2A and
H2B (Kornberg, 1974; Luger et al., 1997). This chromatin structure rep-
resents a dynamic environment. It is tightly regulated by a multitude
of protein complexes and effects all stages of transcription, from assem-
bly of the initiation complex to elongation of RNAPII (Workman and
Kingston, 1998). The three-dimensional architecture of chromatin deter-
mines accessibility of the DNA to TFs and the transcription machinery.
On a global level the chromatin environment is usually classified as
either euchromatic, corresponding to an open configuration that is
gene-rich and easily transcribed, or heterochromatic, which is heavily
condensed and mostly transcriptionally silent (Figure 1A).
The tails and globular domains of the histone proteins are extensively
modified by posttranslational modifications (PTMs), which influence
chromatin structure and gene transcription. These modifications include
methylation, acetylation, phosphorylation, sumoylation and ubiquitina-
tion (Kuo and Allis, 1998; Bernstein et al., 2007). A profusion of different
modifications exists (for an extensive overview see Kouzarides, 2007).
While many histone PTMs have been characterized, their exact, pos-
sibly combinatorial roles are still not completely understood. A large
fraction is correlated to transcription, either positively or negatively, but
others have been linked to different processes such as the DNA damage
response (Tjeertes et al., 2009). Histone modifications can directly in-
fluence chromatin stability by a charge neutralization effect (Roth and
Allis, 1992). More important however, is their effector-mediated effect.
Different modifications serve as interaction interfaces for proteins and
complexes involved in transcription activation, repression, nucleosome
remodeling and chromatin condensation (Taverna et al., 2007).
Two of the most well-understood modifications are acetylation and
methylation. Acetylation at H3 and H4, controlled by the antagonistic
actions of histone acetyltransferases (HATs) and deacetylases (HDACs),
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Figure 1: (A) Nucleosomes in euchromatic regions are marked by histone PTMs asso-
ciated with active transcription such as H3K4me3 (top panel). Transcription-
ally silent heterochromatin is heavily condensed, with nucleosomes marked
by histone PTMs associated with repression such as H3K27me3 (bottom
panel). Original image from Sha and Boyer, 2009. (B) Enrichment profiles
of histone variant H2AZ and several histone modifications in relation to
active genes (green lines) and inactive genes (red lines). Data is based on the
normalized read counts of histone modifications around the 5000 most active
and 5000 least active genes respectively, based on RNAPII enrichment. Data
was obtained from Barski et al. and Wang et al. (Barski et al., 2007; Wang
et al., 2008b)
is generally correlated with accessible chromatin and active transcrip-
tion (Shahbazian and Grunstein, 2007). Several co-activators actively
involved in transcriptional activation such as GCN5, p300 and CBP be-
long to the HAT family of enzymes. The complex interplay of HATs and
HDACs, which are both recruited to active genes, serves to illustrate a
general feature of histone PTMs (Wang et al., 2009). These modifications
are reversible and consequently a result of the balanced activities of
modification-depositing and -removing enzymes.
The transcriptional effect of lysine methylation is greatly dependent
on which residue is modified. Methylation of histone H3 at lysine 4
(H3K4), lysine 36 (H3K36) and lysine 79 (H3K79) is correlated with
expression, while H3K9, H3K27 and H4K20 methylation usually coin-
cides with repression (Schübeler et al., 2004; Bernstein et al., 2007; Li
et al., 2007b). See Figure 1B for several examples of histone modification
profiles in relation to the expression level of genes. Two examples that
illustrate the varying effects and combinatorial functions are H3K4 and
H3K27 methylation.
There are three possible methylation states for a lysine residue: mono-,
di- or tri-methylation, which can have different functional consequences.
Tri-methylation at H3K4 (H3K4me3) is generally found at the tran-
scription start site of active genes and is correlated with expression
(Guenther et al., 2007). This modification can be bound by the PHD
domain of the TAF3 subunit of TFIID, which directly links this modifi-
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cation to RNAPII-mediated transcription (Vermeulen et al., 2007). In
addition, H3K4me3 can be bound by the NURF complex, involved in
chromatin remodeling, (Wysocka et al., 2006) and CHD1, with a func-
tion in transcription elongation and pre-mRNA splicing (Sims III et al.,
2007). H3K4 dimethylation (H3K4me2) is also located at active genes
and recruits the Set3 complex, which suppresses histone acetylation
levels and remodeling near 5’ ends of genes (Kim and Buratowski,
2009). Finally, H3K4 mono-methylation (H3K4me1) seems to be mainly
localized to enhancers, which are depleted of H3K4me3 (Heintzman
et al., 2007).
The repressive modification H3K27me3 is located in broad domains at
and around mostly important developmental genes, such as the home-
obox genes (Francis and Kingston, 2001). This modification is bound
by the PRC1 complex, which blocks access of nucleosome remodeling
factors leading to a repressive chromatin state (Shao et al., 1999). The
deposition of H3K27me3 is regulated by the PRC2 complex, with an
important function for JARID2 (jumonji). This factor is required for
efficient binding of PRC2, but may inhibit the PRC2 methyltransferase
ability (Shen et al., 2009; Peng et al., 2009).
Further characterization of different modifications and their interac-
tors in combination with high-throughput genomic approaches will be
necessary to fully understand their roles (Berger, 2007; Taverna et al.,
2007).
1.3 high-throughput genome analysis
1.3.1 ChIP-chip and ChIP-sequencing
With the introduction of high-throughput sequencing technologies in
combination with antibody-mediated pulldown of specific proteins, it
has become possible and cost-effective to profile protein-DNA interac-
tions on a genome-wide scale.
The central technique enabling these genome-wide studies is Chro-
matin Immunoprecipitation (ChIP) which allows study of in vivo protein-
DNA interactions (Solomon et al., 1988; Hebbes et al., 1988). In ChIP,
DNA-protein interactions are stably crosslinked, usually with formalde-
hyde, and the chromatin is isolated. The chromatin is sheared by son-
ication or enzymatic digestion and the pool of fragments is enriched
with an antibody specific for a protein of interest. The crosslinking is
reversed and the sequences can subsequently be analyzed. Alternatively,
in the native ChIP protocol, the crosslinking step is omitted and the
chromatin is enzymatically digested using MNase (O’Neill and Turner,
2003; Thorne et al., 2004). Native ChIP is especially suited for histone
proteins.
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A completely different approach, DamID, incorporates targeted DNA
methylation (van Steensel et al., 2001). In this procedure the E.coli DNA
adenine methyltransferase (Dam) is fused to a protein of interest. This
leads to preferential methylation of adenines near the binding sites of
the protein. The advantage of this technique is that DamID does not
rely on a specific antibody for a protein of interest.
The first global ChIP analyses were performed using microarrays
(ChIP-on-chip) containing a genome-wide collection of sequences (Ren
et al., 2000). DNA sequences recovered from ChIP were labeled with
a fluorescent dye and hybridized to the array together with a non-
enriched input sample labeled with a different fluorophore. Sequences
bound by the protein of interest could be identified by a high ChIP/in-
put ratio. This approach was extended with high-density tiling mi-
croarrays, covering complete chromosomes or even the whole genome
(Cawley et al., 2004; Kim et al., 2005). While this method provided an
unprecedented level of detail, there were also several practical short-
comings. First, the hybridizations contained a lot of noise due to hy-
bridization artefacts, influenced by the GC content, length of the probes,
concentration and secondary structures. The resolution of the obtained
binding sites was limited from 500 to 1000 bps. In addition, the method
of amplification influenced the results, although this could partially
be overcome by a different amplification procedure (van Bakel et al.,
2008). Finally, one of the really limiting downsides was the prohibitive
cost. A tiling array covering the whole human genome, tiled at 100 bp
resolution, consisted of 36 slides (Hatzis et al., 2008).
With the advent of next-generation sequencing technologies, it has
become feasible to sequence hundreds of millions of DNA sequences in
a single run. In ChIP-sequencing (ChIP-seq) ChIP is followed by direct
sequencing of the enriched DNA fragments. One of the limitations
of the current generation of sequencers is the relatively short read
length, although this has been steadily improving. However, for ChIP-
seq experiments the read length is not a limiting factor. Reads with
a length of ~35 bp can be accurately mapped to the genome and
provide a high-resolution profile of protein-DNA interactions. Many
of the disadvantages of ChIP-chip do not apply to ChIP-seq. Due to
the precise mapping of immunoprecipitated sequences, binding sites
can be determined with very high accuracy. There is no hybridization
step and the dynamic range is higher than with arrays. However, the
amplification procedure, necessary for current platforms such as the
widely used Illumina Genome Analyzer, can still introduce a bias in
the sequences. This can be lessened by reducing the number of PCR
cycles or by adapting the amplification protocol. This will likely change
in the future, as multiple single-molecule sequencing techniques are in
development (Harris et al., 2008; Clarke et al., 2009; Eid et al., 2009).
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Since the first ChIP-seq experiments were published in 2007, de-
termining the genome-wide binding sites of the human transcription
factor STAT1 and NRSF (Robertson et al., 2007; Johnson et al., 2007),
the adoption of the technique has been rapid. Numerous transcription
factors have been profiled (Jothi et al., 2008; Chen et al., 2008; Val-
ouev et al., 2008; Welboren et al., 2009; Tallack et al., 2010; Schmidt
et al., 2010), but other successful applications include profiling of the
enhancer-associated protein p300 (Visel et al., 2009), the insulating fac-
tor CTCF (Cuddapah et al., 2009), RNA Polymerase (Welboren et al.,
2009; Raha et al., 2010), histone modifications and variants (Barski et al.,
2007; Wang et al., 2008b, 2009), histone deacetylases (HDACs) and
histone acetyltransferases (HATs) (Wang et al., 2009) and chromatin
remodeling enzymes (Schnetz et al., 2010; Peng et al., 2009; Liu et al.,
2010; Ho et al., 2009).
1.3.2 ChIP-seq data analysis
With the rapidly growing capacity and output of the next-generation
sequence platforms, storing, processing and analyzing the deluge of
data becomes the most significant bottleneck (McPherson, 2009). The
analysis of ChIP-seq data usually starts with the obvious and simple
question: where does my protein of interest bind? The functional im-
plications and biological follow-up questions are often less clear and
standardized methodologies or software tools are not yet developed.
However, several generally applicable steps can be defined, which to-
gether form a more-or-less default ChIP-seq analysis pipeline: mapping
reads to the reference genome, finding peaks or enriched regions, iden-
tifying associated genes, functional annotation and identification of
transcription factor binding motifs (Figure 2).
The requirements for mapping reads to the reference genome in a
ChIP-seq experiment are relatively simple: fast and accurate alignment
of unique single reads. There is usually no desire to call SNPs or indels,
or to analyze non-unique reads in repeat-rich regions. As all current
algorithms obtain high mapping accuracy the main determinants are
speed and ease of use. Widely used algorithms are ELAND (Illumina)
and Bowtie (Langmead et al., 2009) for Illumina data, and BWA for all
current platforms (Li and Durbin, 2009).
Once reads are mapped to the genome, the profiles can be visualized,
using for instance the UCSC Genome Browser (Rhead et al., 2010) or
SAVANT (Fiume et al., 2010). To identify regions of interest where the
number of mapped reads is significantly higher than the surrounding
regions, peaks or enriched regions, a multitude of algorithms have been
developed. While initial approaches simply counted the number of
overlapping reads in a region (Robertson et al., 2007; Johnson et al.,
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TAACGTGAACCCCTCTATCTTCCTTCACAGATTGTAGTTTCTCACTTCAAGTTATCCAGCAACCTTGGATTTGAACATCATGTTCCTGCATGTTTTGGTGCTTG
GCTTTTTACATTCGGACCACTTAATAAATGACTAG
TGTGGTATTTTATCAAATACATGTTTAAACAAATGTCCCTATCTTTAAAATCCAGTGCACTAAAGAATTG
CTGCTAAATGTCAATAACTATAATAGCTATGATTTCAGAACAGGAATGAGGGGTCTCTAAATGGCTGATA
TCCTTATCCTATGCTCTTATACCCCATATTACTGC
GACTGCTAATATCCTTATCATTTACAAAAGGGTAC
Map reads to the 
reference genome
Determine enriched 
regions (peaks)
Assign peaks to genes
Gene Ontology analysis
Functional enrichment
Correlation to expression
Short reads from a 
ChIP-seq experiment
biological process
cellular process
programmed cell death
cell growthcell death
Find overrepresented
transcription factor
binding motifs
Figure 2: Schematic overview of a standard ChIP-seq analysis pipeline.
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TBP
H3K4me3
RNAPII
H3K27me3
RNAseq
Gene
Figure 3: Examples of different ChIP-seq profiles in Xenopus embryos. Shown
are the transcription factor TBP, the active histone modification
H3K4me3, the repressive histone modification H3K27me3 and
RNAPII. The lower two tracks show the RNAseq expression levels
and the gene annotation.
2007), more sophisticated algorithms have been introduced. Recent
ChIP-seq peak-finding tools incorporate the reads mapping to the
different strands to determine the exact peak center, and rank the peaks
by p-value or false discovery rate (FDR), which are calculated based
on statistical methods or on comparisons of the ChIP and a control
sample. For a review of different methods and initial, mostly qualitative
benchmark studies, see Laajala et al., Pepke et al. and Wilbanks and
Facciotti (Laajala et al., 2009; Pepke et al., 2009; Wilbanks and Facciotti,
2010). One of the complicating factors is that the profiles and peak
shapes can be quite different, depending on the specific factor. The
specific enrichment of sequence-specific transcription factors at well-
defined binding sites results in sharp peaks, while histone modifications
on the other hand, can give broadly enriched regions. An example of
different profiles is shown in Figure 3. This variety in ChIP-seq profiles
makes it difficult to use a single approach for peak definition as there
are at this moment no algorithms that can cope with these differences.
After enriched regions are defined, two main approaches can be
taken. First, these regions can be correlated to genes. This allows charac-
terization of the biological function of putative affected genes. With the
current data derived from ChIP-seq experiments, it is not possible to
accurately define these target genes, as information about (long-range)
interactions is not present in the data. More advanced techniques such
as variants of Chromosome Conformation Capture (4C and 5C ) (Si-
monis et al., 2006; Dostie and Dekker, 2007) or chromatin interaction
analysis by paired-end tag sequencing (ChIA-PET) (Fullwood et al.,
2009) allow detection of interactions between different loci, but cur-
rently such techniques are still quite laborious and difficult to get up
and running. In practice, mapping peaks to genes for ChIP-seq data is
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done by either locating the closest gene, or assigning all genes within a
specified distance to a peak.
Having defined putative target genes, the ChIP-seq data can be
integrated with gene expression experiments, either microarrays or
RNA-seq data, which allows more direct interpretation of binding
events. For instance, in the case of transcription factors this allows to
identify directly regulated genes. In addition, functional annotation
of target genes can be carried out with tools based on Gene Ontology
classification and enrichment analysis (the Gene Ontology, 2010) or
the Database for Annotation, Visualization and Integrated Discovery
(DAVID) (Huang et al., 2009). Another option is Genomic Regions
Enrichment of Annotations Tool (GREAT), which can incorporate distal
binding sites (McLean et al., 2010).
The peak regions can also be analyzed directly for known and novel
transcription factor binding motifs. The next section (section 1.4) de-
scribes this in more detail.
While the steps described here are generally applicable for most ChIP-
seq experiments, the analyses and available tools are still under heavy
development (see Horner et al. and Pepke et al. for a more extended
review (Horner et al., 2010; Pepke et al., 2009)). As the amount of avail-
able data increases, more sophisticated approaches will be necessary,
to be able to integrate and analyze data from multiple high-throughput
experiments.
1.4 transcription factor binding motifs
1.4.1 Protein-DNA interactions
Transcription factors play a major regulatory role by influencing gene
expression through either activation or inhibition of the transcription
machinery. These proteins bind non-covalently to DNA in regulatory
regions associated with one or multiple genes. Generally, binding occurs
through multiple sequence-specific interactions between specific amino
acids in structural motifs of the protein and the exposed nucleotides and
backbone of the the DNA double helix (Luscombe and Thornton, 2002;
Siggers et al., 2005; Sathyapriya et al., 2008). On average this involves
around 12 nucleotides and 24 amino acids, often located in different
protein domains (Janin et al., 2007). The DNA-binding specifity of
transcription factors is determined by a varying combination of multiple
mechanisms, involving both base readout in the major groove and the
local DNA shape readout (Parker et al., 2009; Rohs et al., 2009, 2010).
While the majority of proteins bind in the major groove of the DNA,
several factors have been described that bind exclusively in the minor
groove, usually to distort the backbone and induce conformational
14 general introduction
class # of # of examples
families matrices
in jaspar
Beta-Hairpin-Ribbon 2 20 Mbd, Eomes
Beta-sheet 1 3 TBP
Ig-fold 3 23 Nfkb1, Stat
Helix-Turn-Helix 3 350 Gsc, Hox, Irx
Other Alpha-Helix 4 44 Sox, Srf NFY
Winged Helix-Turn-Helix 7 122 Ets, Fox, E2F
Zinc-coordinating 8 223 Klf, Sp1, p53
GATA, PPAR
Zipper-Type 2 195 MyoD, Myc
Creb, Fos, Jun
Other 11 33 NFI, CP2
Table 1: Motif classes from JASPAR (Portales-Casamar et al., 2010)
changes in the DNA (Bewley et al., 1998). One such example is TBP
which bends the DNA at the TATA box and facilitates local melting of
the DNA by TFIIH (Kim et al., 1993a,b).
Oligomerization and cooperativity is a common phenomenon in
transcription factor binding. Many regulatory proteins bind as hetero-
or homo-dimers. For example, members of the AP-1 family of tran-
scription factors, which modulate the cellular response to growth and
stress signals, are formed by dimers of the Fos, Jun, ATF and JDP
protein families (Hess et al., 2004). These hetero-dimers have different
characteristics with regard to binding and co-factor recruitment, which
enables AP-1 function to be cell type-specific, as all these individual
proteins are differentially expressed and regulated. Another example is
the tumor suppressor protein p53, which binds as a tetramer. This is
reflected in its DNA binding sequence that consists of two palindromic
half-sites (Kitayner et al., 2006; Tidow et al., 2007).
Transcription factors are routinely classified in a distinct number of
groups on basis of the characteristics of the domains determining DNA-
binding specificity. A classification of transcription factors according
to the JASPAR database (Portales-Casamar et al., 2010) is shown in
Table 1. The largest structural transcription factor families in humans
are formed by the C2H2 zinc finger-, Homeobox- (helix-turn-helix),
HLH-(zipper) and bZip-proteins (zipper) (Tupler et al., 2001).
1.4 transcription factor binding motifs 15
The largest class of transcription factors in metazoans consists of the
C2H2 Zinc fingers. These proteins bind through a domain containing
two conserved cysteines and two conserved histidines (C2H2) wrapped
around a zinc ion (Iuchi, 2001; Laity et al., 2001). Hundreds of C2H2
transcription factors are present in mammals, many with as-of-yet un-
characterized functions. Examples include the Sp/Krüppel-like family
of transcription factors.
The homeobox group of TFs contain a 60 amino acid homeodomain
which is responsible for DNA binding via a helix-turn-helix motif
(Kissinger et al., 1990; Gehring et al., 1990). These factors play an
essential role in development and patterning, such as the strictly evo-
lutionarily conserved Hox genes first discovered in Drosophila (Lewis,
1978).
The basic helix-loop-helix (bHLH) proteins form large family of
transcriptional regulators and are involved in developmental processes
such as sex determination and the development of the nervous system
and muscles. They typically contain two protein domains, the basic
domain, responsible for DNA-binding through the consensus sequence
called the E-box and the HLH domain which facilitates protein-protein
interactions (Jones, 2004).
These three examples of important transcription factor families show
a variety of different protein-DNA binding mechanisms. While the the
individual members of a family share common protein domains and
bind similar DNA consensus sites, they each have their own specificity
and selectivity. This is nicely illustrated by a systematic study of DNA-
binding profiles of the ETS family of transcription factors (Wei et al.,
2010). These TFs share a highly similar DNA-binding domain but
have widely varying functions. One way to characterize the binding
specificities of a transcription factor, necessary to understand the in vivo
functionality, is to study the DNA consensus binding sites or sequence
motifs.
1.4.2 Motif representation
Sequence motifs, such as TF binding elements, can be represented
in several different ways (Figure 4). All these representations try to
capture the specifity of the protein-DNA interaction that distinguishes
it from the surrounding sequence. The most straightforward model
is the consensus sequence, where every position is characterized by
the preferred nucleotide: A (adenine), C (cytosine), G (guanine) or T
(thymine). However, not all positions in a sequence motif are equally
conserved. For instance, the TBP protein recognizes both the TATAAA
and the TATATA sequence. The IUPAC codes representing ambiguous
nucleotides can be used to reflect the affinity for more than one distinct
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   1    2    3    4    5 
A  0.00 1.00 0.00 0.55 1.00
C  0.00 0.00 0.00 0.00 0.00
G  0.00 0.00 0.00 0.00 0.00
T  1.00 0.00 1.00 0.45 0.00
C D
TATAWAB
A
or
TATATA
TATAAA
Figure 4: Examples of different motif representations. (A) The preferred nucleotide
sequence. (B) The consensus sequence using IUPAC symbols representing
ambiguous nucleotides. (C) A position-specific scoring matrix (PSSM), de-
picting the frequencies of each nucleotide for each position. (D) The sequence
logo (Crooks et al., 2004) of the PSSM depicted in C) .
nucleotide (Table 2). The consensus model can further be extended by
introducing a certain number of possible mismatches.
One other widely used representation is a matrix of frequencies or
likelihoods: the position-specific scoring matrix (PSSM), also referred to
as a position frequency matrix (PFM) or position weight matrix (PWM).
Each position in the motif is represented by a column in a matrix,
detailing the likelihood of observing the nucleotide at that specific
position for every nucleotide. The advantage over consensus sequences
is that much more nuanced specificities can be expressed. A PSSM can
be graphically represented as a sequence logo, which enables an easily
interpreted visual appreciation of the motif (Schneider and Stephens,
1990). Each column in the logo consists of the stacked nucleotides A,
C, G and T. The total height of the stack indicates the conservation at
that position, while the relative height of each individual nucleotide
indicates the frequency of that nucleotide (Crooks et al., 2004). The
vertical y-axis shows the conservation as information content in bits, a
measure derived from communications theory (Shannon, 1948).
One of the assumptions of the PSSM model is that the individual
motif positions are independent. However, there is evidence that this
assumption does not hold true. Experimental measurements using
different techniques such as protein binding microarrays (PBMs), a
quantitative multiple fluorescence relative affinity assay and a microflu-
idic platform have shown that there is evidence for motif interdepen-
dency (Man and Stormo, 2001; Bulyk et al., 2002; Maerkl and Quake,
2007; Badis et al., 2009). Other representations have been developed to
model this interdependency of motif positions. These include Markov
chains (Zhao et al., 2005; Ellrott et al., 2002), Bayesian networks (Zhou
and Liu, 2004), a non-parametric representation capable of modeling
arbitrary dependencies between positions (King and Roth, 2003), k-
mer graphs (Naughton et al., 2006), probabilistic feature motif models
(FMMs) (Sharon et al., 2008) and dinucleotides weight matrices (DWMs)
(Siddharthan, 2010). However, none of these methods have yet gained
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char comments nucleotides
R Purine A,G
Y Pyrimidine C,T
S Strong (3 H bonds) C,G
W Weak(2 H bonds) A,T
K Keto G,T
M Amino A,C
V Not T A,C,G
H Not G A,C,T
D Not C A,G,T
B Not A C,G,T
N Any A,C,G,T
Table 2: IUPAC codes
a widespread acceptance comparable to the PSSM model. There are
several theoretical as well as practical reasons to explain this.
Most of the models that try to deal with interdependency between
different positions are quite complex. They incorporate a multitude of
parameters and have underlying assumptions that may not hold true
in practice. This complexity has a significant impact on the size of the
dataset needed to train the model, as well as the required computation
time. While the large amount of data obtained in ChIP-seq experiments
as well as the ever-increasing computing performance can partly allevi-
ate these obstacles, they still remain a practical concern. Additionally,
most of these alternative models are not exhaustively tested or bench-
marked, as this is challenging even for the simpler PSSM model (see
section 1.4.4). These methods are routinely tested on synthetic datasets.
While this is tractable and straightforward it has not been satisfyingly
demonstrated that this equates to similar benefits in real-world bio-
logical datasets. Last, there is an important pragmatic reason for the
popularity of the PSSM: the simplicity. The information can easily be
visualized in a sequence logo, and is intuitively understood.
In conclusion, while incorporation of interdependency constraints
would be theoretically correct, the independent additive model of the
PSSM is a good, intuitively understood approximation, which performs
well in practice (Benos et al., 2002).
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1.4.3 Motif identification
In a biological context a motif is basically a pattern of nucleotides
that has a functional, or structural significance. Computationally, a
motif may be defined as a pattern of nucleotides that is overrepre-
sented compared to the sequence background, which may or may not
be an indication of biological meaning. This motif sequence will be
statistically overrepresented compared to the surrounding sequence,
the background or genomic noise. The overrepresentation and high
relative frequency can be exploited by computational algorithms to
determine the motif without any prior knowledge (de novo). However,
in a biological context, the division between signal and noise is not
well-defined. While many transcription factor motifs have a conserved
“core” of essential nucleotides, for instance those involved in protein-
DNA contact, other proteins on the other hand bind to much more
degenerate sequences. In addition, there is evidence that the sequence
surrounding the core motif does have an influence on binding (Sid-
dharthan, 2010). Furthermore, individual motifs are not always clearly
separated in a biological context. Motifs for different factors might
partially overlap, thereby introducing possibilities for cooperation en
competition between different factors enabling the potential for regu-
latory complexity (Hermsen et al., 2006; Wu et al., 2008; Manna and
Stocco, 2007). To further complicate matters, transcription factors rou-
tinely bind distinctly different motifs (Badis et al., 2009). Another issue
concerns the surrounding sequence landscape of the motif. While this
is treated as background by most algorithms, it is not just random
noise. It can contain other binding motifs, regulatory signals such as
nucleosome positioning signals, CpG islands, splicing signals and likely
other currently unknown biologically relevant sequence characteristics.
The elucidation of a sequence motif is a computationally complex
task. It usually starts from a set of sequences that are assumed to be
bound by a specific transcription factor. Traditionally these sequences
were derived from SELEX experiments (Pollock and Treisman, 1990), ex-
perimentally determined in vivo binding regions or sets of co-regulated
genes (Aerts et al., 2003b; Pavesi et al., 2006). Recently, the rapid ad-
vances of high-throughput methods such as ChIP-on-chip and ChIP-
sequencing have enabled the collection of binding sites in a global
genome-wide context. A plethora of computational strategies have
been developed to deal with the problem, but they can roughly be di-
vided in two groups: word-based enumeration or probabilistic methods
(MacIsaac and Fraenkel, 2006; Das and Dai, 2007).
The first category formulates the motif finding problem as an overrep-
resentation of specific words or strings in a set of background sequences.
These overrepresented sequences can be determined exhaustively in
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a global manner. The advantage of this technique is that the optimal
global solution can usually be determined. With optimized data struc-
tures such as suffix trees the searches are relatively fast. However, with
the exact matches necessitated by this approach, it is only possible
to find relatively short, non-degenerate sequences. This can pose a
problem for large, degenerate motifs. The addition of possible errors or
mismatches partly takes care of this problem in exchange for increased
complexity and a longer computational running time. The output is
often post-processed where overrepresented words are combined or
clustered to form PSSMs. Examples of motif finders incorporating this
methodology are the oligo/dyad analysis presented by van Helden
et al. (van Helden et al., 1998, 2000), YMF (Sinha and Tompa, 2002),
MITRA (Eskin and Pevzner, 2002) and Weeder (Pavesi et al., 2004).
The other major category of motif finders is characterized by a prob-
abilistic approach where the final motifs are obtained through an itera-
tion of optimization steps. The two major techniques are Expectation
Maximization (EM) and Gibbs sampling.
The EM algorithm for motif discovery was first developed for protein
sequences (Lawrence and Reilly, 1990), adapted for DNA sequences
(Cardon and Stormo, 1992) and implemented in MEME, one of the most
well-known motif prediction algorithms (Bailey and Elkan, 1994). EM
consists of an iteration of two steps, an expectation step where an ex-
pected likelihood function is calculated and a maximization step where
the parameters of the model are updated to maximize the expected
likelihood function. Because this algorithm is a local optimization proce-
dure that is not guaranteed to give the best global solution, it is usually
restarted multiple times to improve the chances of finding the correct
motifs. Other implementations are Improbizer (Ao et al., 2004), which
is based on a variation of the EM algorithm and GADEM (Li, 2009)
which combines a spaced dyads model and a genetic algorithm with
EM optimization.
The Gibbs sampling technique involves drawing random samples
from a distribution, which in practice correspond to the starting posi-
tions of the motif in the set of sequences. Many implementations of the
Gibbs Sampling technique have been suggested. Examples include, but
are not limited to, AlignACE (Hughes et al., 2000), ANNSpec (Workman
and Stormo, 2000), MotifSampler (Thijs et al., 2001), BioProspector (Liu
et al., 2001), GLAM (Frith et al., 2004) and SeSiMCMC (Favorov et al.,
2005). Variations include the incorporation of a background model, mo-
tif models that incorporate spacing or repeats and automatic adjustment
of the motif width.
Other hybrid approaches and different strategies have been devel-
oped. MotifRegressor (Conlon et al., 2003) combines MDscan with gene
expression to find motifs that best explain the expression patterns.
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Wijaya et al. developed SPACE, which identifies spaced motifs using
submotif pattern mining (Wijaya et al., 2007). A novel approach was
presented by Sharon et al. who use feature motif models as a novel prob-
abilistic method for modeling TF-DNA interactions, based on log-linear
models (Sharon et al., 2008).
While great improvements have been made in the computational
identification of sequence motifs, the real-world performance of these
algorithms on biologically relevant datasets is generally rather poor
(Tompa et al., 2005). Likely, the biological parameters that govern tran-
scription factor binding motifs, and maybe equally important, the
characteristics of the background sequence, are still not completely un-
derstood. This effectively means that current models are incomplete and
that important assumptions might be incorrect. However, even given the
relatively limited knowledge concerning the complete characteristics of
the sequence landscape, improvements have been suggested.
One recent development, made possible by the growing availability
of full genome sequences, is phylogenetic footprinting. The general
premise is that important regulatory regions will be conserved between
organisms and that this conservation can be incorporated in the mo-
tif finding procedure. Examples include Footprinter (Blanchette and
Tompa, 2003), PhyloCon (Wang and Stormo, 2003), CompareProspector
(Liu et al., 2004), Converge (Harbison et al., 2004), PhyME (Sinha
et al., 2004), PhyloGibbs (Siddharthan et al., 2005), the Phylogenetic
Gibbs sampler of Newberg et al. (Newberg et al., 2007) and Phyloscan
(Palumbo and Newberg, 2010). Most methods need a set of aligned
orthologous sequences, although Gordan et al. have shown that using
unaligned ortholog sequences will also result in improved performance
(Gordan et al., 2010).
However, there are practical limitations to the phylogenetic approach.
Compelling experiments using ChIP-sequencing of ortholog transcrip-
tion factors in five different species show that not all important regula-
tory sites are conserved (Schmidt et al., 2010). Actually, most binding is
species-specific, and aligned binding events in all five species were rare.
Practically this means that phylogenetic footprinting will be limited to
closely related species, or a small subset of conserved sites.
New algorithms and methods continue to be developed, aiming to
solve the motif discovery problem. However, it has been suggested that
combining different computational techniques, rather than focusing on
a single method should increase motif prediction effectiveness (Har-
bison et al., 2004; Hu et al., 2005; Tompa et al., 2005). Indeed, several
ensemble methods have shown to improve upon their individual com-
ponents. The most straightforward approach is to cluster similar motifs
of each different algorithm, and report a representative or best-scoring
motif per cluster. Examples are RgS-Miner (Huang et al., 2004), WebMO-
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TIFS (Romer et al., 2007; Gordon et al., 2005) and MultiFinder (Huber
and Bulyk, 2006). Other approaches such as Binding-site Estimation
Suite of Tools (BEST) (Jensen and Liu, 2004; Che et al., 2005) and SCOPE
(Chakravarty et al., 2007; Carlson et al., 2007) use an independent scor-
ing function to score and rerank all the predicted motifs and report the
best motif according to this score.
A few more sophisticated methods have been reported. The EMD
algorithm incorporates a different approach (Hu et al., 2006). Predicted
sites are grouped by their statistical score for each component algorithm,
and subsequently grouped across the results of different algorithms.
Hereby more trust will be placed in motifs that are high-scoring in
different algorithms. Finally, motifs are placed on the sequence and
the final motifs are called according to how often a specific position
is included. MotifVoter (Wijaya et al., 2008) carries these ideas a step
further and incorporates a scoring function that requires a cluster of
motifs to share as many binding sites as possible and gives greater
weight to motifs that are contributed by as many motif finders as
possible.
Although many methods have been developed, there still remains
ample room for improvement. Some algorithms have practical draw-
backs such as running time, most will be only be really suitable for a
particular type of problem and many have not been adequately tested
on real, biologically relevant input data. The next section deals with the
evaluation of different algorithms and highlights the fact that no motif
discovery program shows adequate performance on a wide variety of
inputs.
1.4.4 Performance evaluation of motif discovery algorithms
As has been discussed in the previous section, a large variety of method-
ologies, algorithms and implementations have been developed to deal
with the motif discovery problem. Given the considerable number of
options, it is currently challenging to choose the best available method
for a specific purpose. This practical dilemma is not easily solved.
While many methods include a scoring function to rank and evaluate
predicted motifs, these are not comparable. In addition, the statistical
significance score of the algorithms does not correlate well to biological
motif accuracy (Hu et al., 2005). Therefore, it is essential to have non-
biased, systematic and standardized evaluation methodologies to be
able to judge the merits of each approach. Due to the complex nature
of motif discovery and evaluation, both in an algorithmic as well as
a biological sense, a comparison is not trivial. Here, I will discuss the
practical difficulties and give an overview of the current widely used
benchmarks.
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Although some small benchmark and performance studies had been
published (Pevzner and Sze, 2000; Benítez-Bellón et al., 2002; Sinha and
Tompa, 2003; Osada et al., 2004), the first systematic large-scale bench-
mark was presented by Tompa et al. in their seminal paper comparing
the performance of 13 motif-discovery tools (Tompa et al., 2005). To
compare the different tools, they prepared different benchmark datasets
using “planted” motifs. In this approach known, annotated motifs from
a database such as RegulonDB (Salgado et al., 2004), JASPAR (Portales-
Casamar et al., 2010) or TRANSFAC (Matys et al., 2006) are planted
with a known position and orientation into a background sequence.
This background can be the original genomic location, a randomly
chosen promoter or a randomly generated sequence according to a
Markov chain. The advantage of this procedure is that the algorithmic
objective, the motif location and identity, is exactly known.
To compare performance they introduced several performance met-
rics that have been widely adopted. These metrics define the perfor-
mance at the nucleotide- and binding-site levels. The first deals with
the precise delimitation of the motif: Is every position that should be
part of the motif included and are background positions excluded? The
second considers the identified binding sites.
Several important observations and conclusions can be drawn from
this study. All algorithms show relatively poor performance on meta-
zoan sequences compared to the simpler eukaryotic yeast model system.
While the various algorithms show performance differences for differ-
ent datasets, there is no clear superior approach. Motif algorithms show
complementary behavior, suggesting that no single approach is able to
correctly model the biological data. Finally, one of the main conclusions
was that it is surprisingly hard to design a good assessment study.
Other benchmark studies have been published (Singh et al., 2008;
Li and Tompa, 2006). Hu et al. use nucleotide-level metrics similar
to Tompa et al. and define some additional motif-level statistics (Hu
et al., 2005). MTAP was proposed as a general software platform to
enable systematic evaluation of motif prediction algorithms (Quest et al.,
2008). Different algorithms are benchmarked using planted database
motifs. The benchmark approach has been extended to the evaluation
of prediction of combinations of binding sites (cis-regulatory modules)
(Klepper et al., 2008). Sandve et al. argue that maximum discrimination
between positive and negative instances with the common motif models
should be possible in test datasets. They construct evaluation data sets
explicitly based on that criterion (Sandve et al., 2007).
One surprising finding by Tompa et al. was that most tools per-
formed worse on the “real” datasets, where the motif is present in
the “natural” sequence background. This means that using the origi-
nal sequence background resulted in worse algorithmic performance
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compared to synthetic, artificially generated nucleotide background se-
quences. Based on these results, they recommended leaving the dataset
with the real, natural sequence background out of future benchmarks.
While this makes sense in their benchmark environment where algo-
rithms finding unknown but real motifs are heavily penalized, it is
somewhat worrisome to conclude that algorithms should just be tested
on (semi-)synthetic datasets. While the objectives can be tightly con-
trolled, there are also several disadvantages. Any artificial background
will likely be different from the real biological context. This can be
partly alleviated by using the original sequence, or a similar sequence
selected from the genome. However, the analysis is still dependent on
the quality of the motif annotation in the database. It has been shown
that these collections are biased and contain inaccuracies (Bergman
et al., 2005; Fogel et al., 2005). In addition, annotated motifs are often
based on just a few sequences. This raises the question whether the
motifs in the databases are representative of the full range of biological
motifs. Finally, the manner in which a motif is planted in a sequence can
also influence the benchmark. Sinha and Tompa found that algorithms
perform better when the motif is planted according to their own motif
representation model (Sinha and Tompa, 2003).
Another approach is to use real sequences to evaluate motif predic-
tions. The advantage of this method that it’s based on biological data:
the sequence motifs in their natural context. However, in this case the
“gold-standard”, a set of positive sequences all with a motif, can never
be obtained as it is unknown which motifs are present at what posi-
tion. As mentioned, this is a downside with certain evaluation metrics,
as programs that correctly predict unannotated or unknown binding
sites would be penalized (Tompa et al., 2005). However, especially with
the large amounts of binding data resulting from for instance ChIP-
sequencing experiments, this approach can still be valuable. A collection
of sequences determined to be bound by a certain factor, such as peaks
from a ChIP-seq experiment, is regarded as the positive set and a back-
ground set is defined. The objective is then to maximize the number of
motifs in the ”true positive“ set while minimizing the matches in the
background set. One of the ways to visualize and quantify this, is the
Receiver Operator Characteristic (ROC) Curve. Other metrics such as
the F-measure or rank-based methods such as the Mean Normalized
Conditional Probability (MNCP) (Clarke and Granek, 2003) can also be
used. The advantage of this approach is that the true motif does not
need to be defined, and there is no dependence on existing databases
with possibly inaccurate motif definitions. The downside is that this
approach determines algorithmic performance on the sequence level
(”Does a sequence contain a motif?’), not on the motif or nucleotide
level (“Is the exact definition of the motif correct?”).
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Finally, performance is sometimes evaluated by comparing a de novo
identified motif to the known motif from literature or motif databases.
However, this method has several serious limitations. First, this assumes
the literature motif is the best possible, golden standard motif, while
this motif is often derived from a limited set of sequences by a specific
method. Second, it is greatly dependent on the way similarity between
motifs is defined. As described in subsection 1.4.5, choosing and evalu-
ating a suitable similarity metric for motif comparison is an issue in its
own right.
In short, different methodologies to evaluate motif prediction algo-
rithm performance have been proposed. However, there is no clearly
defined standard. From synthetic sets that enable a carefully controlled
environment but do not correspond to the real biological complexity
to real-world datasets that are not completely characterized, the choice
will have to depend on the context. Further models and methodologies
will need to be developed as one thing has become clear: the current
generation of motif finding algorithms cannot yet accurately determine
all the biologically relevant regulatory elements in the complex genomic
sequence environment.
1.4.5 Motif comparison
After the prediction of transcription factor binding motifs de novo from
a set of sequences, these predicted motifs often need to be compared to
other motifs. Frequently, many redundant motifs are produced, either
by a single approach, or by combining the output of multiple prediction
algorithms. Related motifs can be grouped based on their similarity.
Additionally, to discover characteristics of newly identified motifs, such
as the identity of the motif or the family of proteins known to bind to a
specific consensus, they need to be matched to known motifs present in
databases. For both purposes accurate and sensitive measures of motif
similarity are required.
Usually, motif similarity is assessed by pairwise comparison of single
motif columns. Individual column scores are summed to produce the
total score for a specific alignment of two motifs. The maximal scoring
alignment can be computed using alignment strategies such as the
Smith-Waterman or the Needleman-Wunsch algorithms (Needleman
and Wunsch, 1970; Smith and Waterman, 1981; Mahony et al., 2007).
Various metrics to compare PFM columns have been proposed. Well-
known distance or correlation metrics such as the Euclidean distance
(ED) (Choi et al., 2004; Harbison et al., 2004), Spearman rank correlation
coefficient (Pietrokovski, 1996) and the Pearson correlation coefficient
(PCC) (Pietrokovski, 1996; Hughes et al., 2000; Benos et al., 2002; Ma-
hony et al., 2005; Xie et al., 2005) have been applied to binding motifs.
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Other methods use statistical tests including the Pearson chi2 (Schones
et al., 2005) and the Fisher-Irwin exact test (Schones et al., 2005).
Other metrics have been developed specifically to compare motifs.
The Average log-likelihood (ALLR) statistic proposed by Wang and
Stormo is based on the likelihood ratio, a standard statistic to measure
the probability that the observed data belongs to one distribution versus
the other (Wang and Stormo, 2003). The Kullback-Leiber distance is
based on information theory (Thijs et al., 2002; Benos et al., 2002; Aerts
et al., 2003a; Roepcke et al., 2005). Recently, the FIsim similarity mea-
sure incorporated fuzzy set theory into the motif comparison problem
(Garcia et al., 2009). Gupta et al. developed a method that allows any
column-to-column measure. They calculate the statistical significance
of a score for a specific query motif and a particular target motif, which
is independent of the specific scoring metric that is used (Gupta et al.,
2007).
All these methods are column-based and dependent upon a specific
alignment, with the motif similarity score usually defined as the score
of the best possible alignment. Another approach was explored by Pape
et al., where the similarity of two motifs is based on the asymptotic
covariance between the number of hits with each motif in a set of
sequences. In this approach, motifs are more similar if they share a
high number of overlapping hits on a set of (random) target sequences.
Another alignment-free method converts the PSSM’s into k-mer vectors
and measures the similarity of two motifs as the similarity of the
corresponding k-mer vectors (Xu and Su, 2010).
Similar to the performance of motif prediction algorithms, systematic
benchmark studies comparing different similarity metrics remain scarce.
The exhaustive comparison carried out by (Mahony et al., 2007) indi-
cates that the PCC generally performs well, while Gupta et al. obtained
good results with the ED.
While the current methods generally seem to perform well, there is
still room for improvement. One important aspect that most of these
scoring systems do not take into account, is the relative importance of
specific motif positions. Specifically, positions with nucleotide frequen-
cies close to background have a similar contributions to the score as
well-conserved, important positions. Only a few recent scoring metrics
try to alleviate this issue (Habib et al., 2008; Garcia et al., 2009).
1.5 outline of this thesis
This thesis describes the analysis of transcription regulation by high-
throughput genome-wide methods: ChIP-on-chip and ChIP-seq. Where
do specific factors bind? What are the underlying sequences? What de-
termines binding specificity? How does binding regulate and influence
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the transcriptional outcome? To gain an insight into these questions
we have looked at the regulation of transcription from two different
angles, in two different model systems, with a strong focus on binding
of transcription factors.
As a recurring aim in transcriptional studies, especially those in-
volving ChIP-seq, is to identify transcription factor binding sites, we
developed a method towards this purpose. GimmeMotifs, a compu-
tational analysis pipeline for de novo motif prediction, is described in
Chapter 2.
Chapter 3 and Chapter 4 describe transcriptional regulation during
early development in Xenopus. The African clawed frog Xenopus laevis
and western clawed frog Xenopus tropicalis are widely used as a model
for vertebrate embryonic development. The animals are easy to raise,
embryos can be obtained in large quantities and all important genetic
tools are available (Hirsch et al., 2002). In addition, the genome of
X. tropicalis is published (Hellsten et al., 2010) and the coverage of
expressed sequence tags (ESTs) is the highest for all model organisms
except human and mouse (Amaya, 2005), which make it an ideal model
for genomic approaches.
In Chapter 3 Xenopus core promoters are analyzed. The aim of this
chapter is to identify all important regulatory sequence motifs in a col-
lection of Xenopus core promoters and compare and contrast these with
human promoters. While similar motifs are identified in both verte-
brates, exemplifying the similarity in the core transcriptional machinery,
the relative abundance is different. This highlights a likely evolution-
ary adaptive process to deal with the varying nucleotide background
characteristics of these organisms.
In Chapter 4 we look at early gene regulation, characterizing both the
transcriptome by RNAseq and ChIP-seq of RNAPII as well as the epi-
genetic marks H3K4me3 and H3K27me3. By this approach transcribed
genes and promoters are identified, which are marked by active and
repressive histone modifications in a spatially regulated manner.
We switch model systems in Chapter 5 and Chapter 6. These chap-
ters describe the analysis of the genome-wide binding profiles of two
members of the p53 family. The tumor suppressor p53 is one of most
well-studied human proteins. It is essential in the maintenance of
genomic integrity, and failure to carry out that function, due to for
instance inactivating mutations, has severe consequences; most human
cancers do not have a normally functioning p53 (Vogelstein et al., 2000).
The pathways controlled by p53 are plentiful and varied, linking p53
to metabolism, reproduction and development in addition to disease
(Hu et al., 2008; Vousden and Prives, 2009; Vousden and Ryan, 2009).
How is a single protein able to regulate such a wide variety of tran-
scriptional programs? The elucidation of the genome-wide binding
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repertoire of p53 and the characterization of the binding motif, essential
steps towards an answer to that question, are described in Chapter 5.
Chapter 6 describes a similar approach for the p53 family member p73.
This closely related protein is an important developmental regulator,
cooperates with p53, but can also function as a tumor suppressor in
its own right (Tomasini et al., 2008; Rosenbluth and Pietenpol, 2008).
Here we go one step further and identify a co-factor binding site by
bioinformatic methods that is validated by molecular experiments and
helps to explain why two isoforms of the same protein, TAp73α and
TAp73β, can have different transcriptional responses.
Finally, Chapter 7, summarizes the lessons in transcriptional and
computational complexity that have been learned from these different
models, and looks forward to what we can possibly expect in the
near future. The impressive rapid technological improvements create
interesting times for transcriptional research, with great bioinformatic
challenges and opportunities.
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P I P E L I N E F O R C H I P - S E Q U E N C I N G E X P E R I M E N T S
Simon J. van Heeringen, Gert Jan C. Veenstra
Accurate prediction of transcription factor binding motifs that are enriched in
a collection of sequences remains a computational challenge. Here we report
on GimmeMotifs, a pipeline that incorporates an ensemble of computational
tools to predict motifs de novo from ChIP-sequencing (ChIP-seq) data. Simi-
lar, redundant motifs are compared using the Weighted Information Content
similarity score and clustered using an iterative procedure. A comprehensive
output report is generated with several different evaluation metrics to compare
and evaluate the results. Benchmarks show that the method performs well
on human and mouse ChIP-seq datasets. GimmeMotifs consists of a suite of
command-line scripts that can be easily implemented in a ChIP-seq analysis
pipeline.
Supplemental material is available online at http://www.ncmls.eu/bioinfo/
gimmemotifs.
Published in Bioinformatics, 2011.
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2.1 introduction
The spectacular development of sequencing technology has enabled
rapid and cost-efficient profiling of DNA binding proteins. Chromatin
Immunoprecipitation followed by high-throughput deep sequencing
(ChIP-seq) delivers high-resolution binding profiles of transcription
factors (TFs) (Park, 2009). The elucidation of the binding characteristics
of these TFs is one of the obvious follow-up questions. However, the de
novo identification of DNA sequence motifs remains a challenging com-
putational task. Although many methods have been developed with
varying degrees of success, no single method consistently performs
well on real biological eukaryotic data (Tompa et al., 2005). The combi-
nation of different algorithmic approaches, each with its own strengths
and weaknesses, has been shown to improve prediction accuracy and
sensitivity over single methods (Hu et al., 2005).
Here, we report on GimmeMotifs, a motif prediction pipeline using
a ensemble of existing computational tools. This pipeline has been
specifically developed to predict TF motifs from ChIP-seq data. It uses
the wealth of sequences (binding peaks) usually resulting from ChIP-
seq experiments to both predict motifs de novo, as well as validate these
motifs in an independent fraction of the dataset.
GimmeMotifs incorporates the Weighted Information Content (WIC)
similarity metric in an iterative clustering procedure to cluster similar
motifs and reduce the redundancy that is the result of combining the
output of different tools. It produces an extensive graphical report with
several evaluation metrics to enable interpretion of the results (Fig. 5).
2.2 methods
2.2.1 Overview
The input for GimmeMotifs is a file in BED format containing ge-
nomic coordinates, e.g. peaks from a ChIP-seq experiment. While
GimmeMotifs was developed with ChIP-seq in mind, any FASTA or
BED file can be used for motif prediction. This dataset is split: a predic-
tion set contains randomly selected sequences from the input dataset
(20% of the sequences by default) and is used for motif prediction with
several different computational tools (see Supplementary Information
for details). Predicted motifs are filtered for significance using all re-
maining sequences (the validation set), clustered using the WIC score
as described below, and a list of non-redundant motifs is generated.
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2.2.2 Motif similarity and clustering
The WIC similarity score is based on the Information Content (IC) and
is defined for position i in motif X compared to position j of motif Y as:
WIC(Xi, Yj) =
√
IC(Xi) · IC(Yj) − c ·DIC(Xi, Yj) (2.1)
where c is 2.5, and DIC(Xi, Yj) is the differential IC defined in equation
2.3. The Information Content (IC) of a specific motif position is defined
as:
IC(Xi) =
∑
n∈{A,C,G,T}
fxi,n · log2(
fxi,n
fbg
) (2.2)
where IC(Xi) is the IC of position i of motif X, fxi,n is the frequency of
nucleotide n at position i and fbg is the background frequency (0.25).
The differential IC (DIC) of position i in motif X and position j in motif
Y is defined as:
DIC(Xi, Yj) =
∑
n∈{A,C,G,T}
|fxi,n · log2(
fxi,n
fbg
) − fyj,n · log2(
f
y
j,n
fbg
)| (2.3)
The WIC score of all individual positions in the alignment is summed
to determine the total WIC score of two aligned motifs. To calculate the
maximum WIC score of two motifs, all possible scores of all alignments
are calculated, and the maximum scoring alignment is kept. To cluster
similar motifs all pairwise scores between motifs are calculated. If the
best alignment has a score higher than a predefined threshold, the
two best matching motifs are merged. These two steps, pairwise score
calculation and merging of the most similar motifs, are repeated, until
there is no alignment matching the threshold.
2.2.3 Evaluation
The motifs can be evaluated using several different statistics: the ab-
solute enrichment, the hypergeometric p-value, a Receiver Operator
Characteristic (ROC) graph, the ROC Area Under the Curve (AUC) and
the Mean Normalized Conditional Probability (MNCP) (Clarke and
Granek, 2003). In addition to these evaluation metrics GimmeMotifs
generates a histogram of the motif position relative to the peak summit,
the positional preference plot. Especially in case of high-resolution
ChIP-seq data, this gives valuable information on the motif location.
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Figure 5: An example of the GimmeMotifs output for p63 (Kouwenhoven et al.,
2010). Shown are the sequence logo of the predicted motif (Schneider and
Stephens, 1990), the best matching motif in the JASPAR database (Sandelin
et al., 2004), the ROC curve, the positional preference plot and several statis-
tics to evaluate the motif performance. See the Supplementary Information
for a complete example.
2.2.4 Implementation
The GimmeMotifs package is implemented in Python, while the sim-
ilarity metrics are written as a C extension module for performance
reasons. It is freely available under the MIT license. Sequence logos are
generated using WebLogo (Schneider and Stephens, 1990).
2.3 benchmark results
We performed a benchmark study of GimmeMotifs on ChIP-seq datasets
of 18 different TFs. The ROC AUC and MNCP of the best performing
motif were calculated and compared to the best motif of two other
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ensemble methods: SCOPE (Carlson et al., 2007), and W-ChipMotifs
(Jin et al., 2009) (Supplementary Tables S1,S2) . The results show that
GimmeMotifs consistently produces accurate results (median ROC
AUC 0.830). The method also significantly improves on the results
of SCOPE (ROC AUC 0.613). The recently developed W-ChIPmotifs
shows comparable results to GimmeMotifs (ROC AUC 0.824), although
this tool does not cluster similar redundant motifs. In addition, the
focus of GimmeMotifs is different. While the web-interface of W-
ChipMotifs might be more useful for casual use, the command-line tools
of GimmeMotifs can be implemented in more sophisticated analysis
pipelines.
2.4 conclusion
We present GimmeMotifs, a de novo motif prediction pipeline ideally
suited to predict transcription factor binding motifs from ChIP-seq
datasets. GimmeMotifs clusters the results of several different tools and
produces a comprehensive report to evaluate the predicted motifs. We
show that GimmeMotifs performs well on biologically relevant datasets
of different TFs and compares favourably to other methods.
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Simon J. van Heeringen*, Waseem Akhtar*, Ulrike G. Jacobi, Robert
C. Akkers, Yutaka Suzuki, Gert Jan C. Veenstra
Transcription initiation involves the recruitment of basal transcription factors
to the core promoter. A variety of core promoter elements exists, however for
most of these motifs the distribution across species is unknown. Here we report
on the comparison of human and amphibian promoter sequences. We have
used oligo-capping in combination with deep sequencing to determine tran-
scription start sites in Xenopus tropicalis. To systematically predict regulatory
elements we have developed a de novo motif finding pipeline using an ensemble
of computational tools. A comprehensive comparison of human and amphibian
promoter sequences revealed both similarities and differences in core promoter
architecture. Some of the differences stem from a highly divergent nucleotide
composition of Xenopus and human promoters. Whereas the distribution of
some core promoter motifs is conserved independent of species-specific nu-
cleotide bias, the frequency of another class of motifs correlates with the single
nucleotide frequencies. This class includes the well-known TATA box and SP1
motifs, which are more abundant in Xenopus and human promoters, respec-
tively. While these motifs are enriched above the local nucleotide background
in both organisms, their frequency varies in step with this background. These
differences are likely adaptive as these motifs can recruit TFIID to either CpG
island or sharply initiating promoters. Our results highlight both conserved and
diverged aspects of vertebrate transcription, most notably showing co-opted
motif usage to recruit the transcriptional machinery to promoters with diverg-
ing nucleotide composition. This shows how sweeping changes in nucleotide
composition are compatible with highly conserved mechanisms of transcription
initiation.
Supplemental material is available online at http://genome.cshlp.org.
Published in Genome Research, 2011.
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3.1 introduction
An essential step in the regulation of gene expression is initiation of
transcription, which involves the recruitment of the basal transcription
machinery to the core promoter. The core promoter is defined as the
∼100 bp sequence around the transcription start site (TSS) that is min-
imally required for the assembly of the core transcription machinery
and initiation of transcription. A number of core promoter elements
have been identified and their contribution to basal transcription has
been documented (Juven-Gershon et al., 2006; Smale and Kadonaga,
2003). Each of these motifs is present in only a subset of core promoters
and there are many core promoters which do not feature any of these
motifs. Amongst the most studied motifs are the TATA box (Wasylyk
et al., 1980; Mathis and Chambon, 1981), the initiator (Inr, Smale and
Baltimore, 1989), TFIIB recognition elements (BREs, Lagrange et al.,
1998; Deng and Roberts, 2005) and the downstream promoter element
(DPE, Kadonaga, 2002).
Recent large-scale promoter analyses have shown that the initiator
is the most prevalent motif in Drosophila and mammalian promoters,
whereas the TATA box is present in 10-20% of promoters, most of
which represent tissue-specific promoters with precise transcription
start sites (TSSs, Gershenzon et al., 2006; Sandelin et al., 2007). These
core promoter motifs are specifically recognized by components of the
basal transcription machinery. TATA box binding proteins and TFIIB
bind to the TATA box and the BREs respectively, whereas TAF subunits
of TFIID interact with the Inr and the DPE (Smale and Kadonaga, 2003;
Jallow et al., 2004). These core promoter motifs work cooperatively and
exhibit synergy with each other (Juven-Gershon et al., 2008b). Other core
promoter elements have also been identified which include the Motif
10 Element (MTE, Lim et al., 2004) and the X core promoter element
1 and 2 (XCPE1 and XCPE2, Anish et al., 2009; Tokusumi et al., 2007).
Recent computational analyses have also identified a number of other
sequence elements that cluster in promoters (FitzGerald et al., 2004; Xie
et al., 2005; Gershenzon et al., 2006; FitzGerald et al., 2006; Carninci
et al., 2006; Vardhanabhuti et al., 2007; Frith et al., 2008; Tharakaraman
et al., 2008; Yokoyama et al., 2009).
The TATA box is the only known core promoter element that is con-
served from yeast to human. DPE and Inr elements are shared between
human and fly, although the fly initiator has a stricter consensus than
the human Inr. On the other hand, the DCE and XCPE1 motifs have only
been identified in human promoters, indicating that core promoter ele-
ments have different representations in different species. This raises the
question how promoter sequences compare among vertebrates. Up to
now, most genome-wide promoter studies have focused on mammalian
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promoters, human and mouse in particular. To gain more insight in
vertebrate promoter architecture we decided to systematically compare
Xenopus tropicalis and human core promoters. The draft genome of the
western clawed frog, Xenopus tropicalis, an important model organism
for vertebrate development, has recently been published. Xenopus is
phylogenetically well positioned to compare to other vertebrates and its
genome shows significant long-range synteny with the human genome
(Hellsten et al., 2010).
To date there is no genome-wide dataset of promoter sequences
available for Xenopus; therefore such a collection needs to be determined
in order to perform a comparative analysis of human and amphibian
promoter motifs. In addition, a robust motif finding and comparison
pipeline needs to be established. The identification of enriched sequence
motifs from a set of sequences is computationally complex and a variety
of tools and techniques have been developed to deal with this problem
(reviewed in Zhang, 2007; Das and Dai, 2007). However, performance
of these methods remains poor, especially when used on eukaryotic
sequences (Tompa et al., 2005). It has been suggested that combining
different computational techniques, rather than focusing on a single
method should improve the effectiveness of motif prediction (Hu et al.,
2005). Indeed, several so-called ensemble methods have been shown to
perform better than their individual components (Wijaya et al., 2008;
Carlson et al., 2007).
Ensemble methods that combine different de novo methods gener-
ally identify multiple redundant motifs. These highly related motifs
need to be clustered to remove this redundancy. Transcription factor
binding elements such as core promoter motifs are commonly rep-
resented as matrices that reflect the frequency of each nucleotide at
every position in the motif, the Position Frequency Matrix (PFM). One
relatively straightforward approach to combine the results of different
methods in an ensemble approach is to cluster the PFMs, however,
this demands a sensitive motif similarity metric. Various metrics have
been proposed (Mahony et al., 2007), but one important aspect that
most of these scoring systems do not take into account, is the relative
importance of individual motif positions. Specifically, positions with
nucleotide frequencies close to the background have a similar contri-
bution to the score as well-conserved, important positions that show a
preference towards a single nucleotide. We propose a similarity metric,
the Weighted Information Content (WIC) score, that incorporates the
relative entropy or information content (Schneider and Stephens, 1990;
Shannon, 1948) of the motif positions into the comparison. This metric
compares favorably to existing methods.
In order to compare the core promoter structure between Xenopus
and human we have obtained a collection of Xenopus tropicalis TSSs
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by TSS-seq, a deep-sequencing-adjusted method to determine the 5’
ends of capped transcripts (Tsuchihara et al., 2009) similar to the CAGE
approach (The FANTOM Consortium and Riken Omics Science Cen-
ter, 2009). To predict core promoter motifs using this TSS dataset, we
developed a de novo motif discovery pipeline which incorporates the
new WIC motif similarity metric to cluster similar motifs. Using this
pipeline, we have identified a number of sequence elements in Xeno-
pus promoters including motifs shared with mammals. Intriguingly,
Xenopus promoters feature distinctly different nucleotide frequences
and sequence motifs around the TSS as compared to human promoters.
We highlight the different behaviour of promoter motifs with respect
to this nucleotide background and have identified several Xenopus-
specific promoter motifs. The findings reported here reveal a nucleotide
composition-linked plasticity of core promoter architecture.
3.2 results
3.2.1 Selection of transcription start sites
A key issue in the analysis of core promoter sequences is the reliabil-
ity and the positional precision with which TSSs can be determined.
Using RNA from oocytes and gastrula stage embryos, we obtained a
high-quality collection of Xenopus tropicalis TSSs by high-throughput se-
quencing of 5’ cap-specific transcripts (TSS-seq, Tsuchihara et al., 2009).
After oligo-capping, cDNA was synthesized, amplified and sequenced
using an Illumina Genome Analyzer. The reads were mapped to the
Xenopus genome to obtain a dataset of precise TSS coordinates. This
resulted in a total of 2.5 million mapped positions.
As intra-exonic and other non-promoter reads have been observed
for CAGE data (Mercer et al., 2010), we used ChIP-sequencing to
determine the genomic binding sites of the TATA-binding protein (TBP)
for verification of the core promoter positions. TBP is a key factor in the
assembly of the transcription pre-initiation complex and is expected
to bind to the core promoter. The location of the TBP reads relative to
all annotated 5’ ends of genes is visualized in Fig. S1. This distribution
clearly shows that the binding location of TBP is in the core promoter
just upstream of the annotated 5’ end.
Figs. 6A and B show two examples of the TSS-seq data together
with the ChIP-seq profile for TBP, as well as our previously published
data for RNA Polymerase II (RNAPII), the chromatin mark H3K4me3,
associated with the TSS of actively transcribed genes, and RNA-seq
(Akkers et al., 2009). Fig. 6A shows a site of focused transcription
initiation, while Fig. 6B illustrates dispersed initiation for the eif1ax
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Figure 6: TSS-seq accurately defines transcription start sites. (A) Focused tran-
scription initiation at the gmnn gene locus on scaffold_213, visualized using
the UCSC Genome Browser. Shown are ChIP-seq profiles for (from top to
bottom) H3K4me3 (green), TBP (blue) and RNAPII (purple), as well as
RNA-seq data (red). The reads obtained by sequencing the 5’ end of oligo
capped transcripts (TSS-seq) are shown in the lower two tracks. The lower
track shows a 90x magnification of the TSS-seq track. (B) Dispersed tran-
scription initiation at the eif1ax gene locus on scaffold_135, visualized using
the UCSC Genome Browser. (C) Histogram of the distance between TSS-seq
reads and the 5’ end of the closest EST, summarized for every TSS-seq read.
(D) ChIP-seq profiles of TBP (blue, upper left), H3K4me3 (green, upper
right) and RNAPII (purple, lower left), as well as RNA-seq (red, lower
right), around the start position of TSS-seq reads.
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gene. The ESTs at this locus support the broad pattern of transcription
start sites uncovered by the TSS-seq reads (data not shown).
As has been previously demonstrated, the oligo-cap method is a
reliable method for TSS identification (Tsuchihara et al., 2009). This is
further illustrated by the average distance between TSS-seq reads and
the 5’ end of the closest EST (Fig. 6C), as well as the profiles of the ChIP-
seq and RNA-seq data, all of which are associated with the TSS of genes
and indeed show a profile that peaks sharply around the TSS-seq reads,
as expected (Fig. 6D). Finally, to obtain a high-confidence set of TSSs,
covered by multiple TSS-seq reads, we filtered all positions with at least
20 overlapping TSS-seq reads. To exclude possible reads outside TSS
regions, these positions were intersected with TBP and H3K4me3 peaks
(Akkers et al., 2009). In total, this resulted in a collection of 4,183 TSSs
(Supplemental Table S1). For interspecies comparison between Xenopus
and human, we obtained a comparable collection of 5,561 human TSSs
based on CAGE data (Carninci et al., 2006).
Together these data indicate that we have obtained robust, high
confidence set of transcription start sites in Xenopus tropicalis, which
can be used for promoter motif discovery and analysis.
3.2.2 Systematic motif prediction and comparison
De novo prediction of eukaryotic regulatory elements remains a com-
putational challenge and no single method achieves high all-round
accuracy (Tompa et al., 2005). However, different computational tools
often show complementary behaviour and ensemble approaches that in-
corporate several tools show improvement over single methods (Tompa
et al., 2005; Wijaya et al., 2008; Carlson et al., 2007). Therefore, we
chose to use a number of different motif prediction tools to obtain a
comprehensive collection of Xenopus core promoter motifs.
To reduce the large motif redundancy resulting from predictions of
different methods we developed a motif similarity metric, the Weighted
Information Content (WIC), based upon the Information Content (IC
Shannon, 1948; Schneider and Stephens, 1990). The WIC score is a
function of both the similarity of the two positions in terms of IC,
as well as the similarity to the background nucleotide frequency (see
Equations 3.1 and 3.2 in Methods), and compares favorably to other
similarity metrics in several different benchmarks (Supplemental Figs.
S2 and S3, Supplemental Methods).
We implemented the WIC score and an iterative clustering approach
into a de novo motif discovery pipeline (Fig. 7). This pipeline uses the
provided sequence data to predict as well as validate de novo motifs
and is composed of the following steps:
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Figure 7: Schematic representation of the systematic de novo motif discovery
pipeline. A set of input sequences is partitioned into two sets: a predic-
tion set and a validation set. The prediction set is used as input for several
different motif prediction algorithms. The validation set is used to produce
a background set of random sequences generated with a 1st order Markov
model trained on the validation sequences. All predicted motifs are filtered
for significance based on the hypergeometric distribution in the validation
sequences compared to the random sequences. Only significant motifs with
a positional bias, determined using the Clustering Factor, are kept. Subse-
quently this set of redundant motifs is clustered using an iterative procedure
incorporating the new Weighted Information Content (WIC) motif similarity
score. To predict Xenopus promoter motifs, this pipeline was repeated 10
times.
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1. Split the data into two sets: a prediction and a validation set. The
first set of sequences is used to predict motifs, while the second
dataset is used to independently determine the significance of the
predicted motifs.
2. Predict motifs using four different de novo motif prediction algo-
rithms: Weeder (Pavesi et al., 2004), MDmodule (Liu et al., 2002),
MotifSampler (Thijs et al., 2001) and MEME (Bailey et al., 2009).
3. Filter by significance: All predicted motifs are filtered using a hy-
pergeometric enrichment test on the validation dataset, compared
to a random set of sequences generated by a 1st order Markov
model (similar dinucleotide frequency).
4. Filter by positional bias: As we expect core promoter motifs to be
significantly enriched close to the TSS, all significant motifs from
step 3 are filtered to select for motifs with a positional bias in the
core promoter area as compared to the upstream sequence, based
on the Clustering Factor (CF) (similar to FitzGerald et al., 2006).
5. Cluster similar motifs: All significant motifs are clustered using
the WIC similarity metric, to provide a final set of non-redundant
motifs.
3.2.3 Xenopus promoter elements
We proceeded to predict the core promoter elements in the Xenopus TSS
dataset using our comprehensive motif discovery pipeline (see Methods
for a detailed description and parameters). We first determined the CpG
content of the promoters and divided them into CpG-rich and non-CpG
subsets according to overlap of the core promoter (-60 to +40 relative
to the TSS) with CpG islands as predicted according to the method of
Gardiner-Garden and Frommer (Gardiner-Garden and Frommer, 1987).
The core promoter sequences of each subset, spanning -60 to +40 bp
relative to the TSS, were subsequently used as input for the pipeline. All
predicted motifs were further filtered for positional preference around
the transcription start site. To obtain robust motifs, this procedure was
repeated 10 times, and only motifs identified in at least half of the cases
(5 or more runs) were kept. All significant motifs were clustered and a
sequence logo (Schneider and Stephens, 1990; Crooks et al., 2004) was
generated for each cluster (Table 3 and Supplemental Table S2). For
comparison we used the human TSSs determined by CAGE as input
for the same pipeline which led to the identification of well-known
promoter motifs (Supplemental Tables S3 and S4). In addition, using
the sequences of the TBP ChIP-sequencing peaks as input results in a
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similar set of well-defined promoter motifs (Supplemental Tables S5
and S6).
We found 24 unique motifs that are enriched in Xenopus core promot-
ers (Table 3 and Supplemental Table S2). In addition to the TATA box,
several other well-known promoter elements were identified, some of
which are known to be enriched in human, but not Drosophila promot-
ers (FitzGerald et al., 2004, 2006). These include the cAMP-response
element (CRE), Ets and Nrf-1 binding sites (Buchwalter et al., 2004; Fe-
linski et al., 2001; Scarpulla, 2002), as well as the YY1/Kozak consensus
sequence, a motif which may act in both transcription and translation
(Xi et al., 2007). The NF-Y motif, known to be enriched in human pro-
moters (FitzGerald et al., 2004), also occurs in our Xenopus promoter
data sets. A reverse complement of the SP1-like element (Zhao and
Meng, 2005) is also identified.
In addition to these known elements we identified several unknown
motifs with no unambiguous match to known promoter motifs. The
relatively uncharacterized xt7 motif enriched in Xenopus promoters was
previously identified and called Clus1, because it clusters in human
promoters (FitzGerald et al., 2004). It is a conserved motif, present in
the promoters of many housekeeping genes (Wyrwicz et al., 2007), and
shown to be important for the human HNRNPK and FBN1 promoters
(Mikula et al., 2010; Guo et al., 2008). The identity of the protein that
binds this element is unknown, although ZBED1 (zinc finger, BED-type
containing 1) can bind to this element in the promoters of ribosomal
genes (Yamashita et al., 2007). The motif is also identified in our analysis
of human CAGE data (Supplemental Table S3).
One identified motif (xt17) resembles the upstream stimulatory factor
(USF) binding motif (FitzGerald et al., 2004), but more closely matches
the consensus of the helix-loop-helix transcription factor CBF1, a yeast
protein involved in nucleosome positioning (Kent et al., 2004). Several
newly identified motifs with a distinct consensus do not match any
known motif (xt14, xt15, xt16, xt19, xt21 and xt22). Furthermore, several
purine-rich motifs were identified (xt10, xt18, xt20, xt23 and xt24).
Some core promoter elements function in a specific orientation. To
evaluate this, we analyzed the difference in abundance and positional
distribution of the newly identified motifs between the plus strand
and the minus strand. The motifs with a different distribution between
the two strands are shown in Fig. 8A. Actually, most motifs are not
limited to a specific orientation (see Supplemental Fig. S4 for all motifs).
Several novel Xenopus elements (xt15, xt16, x19, xt21 and xt22) how-
ever, are very specifically oriented, with almost no enrichment at the
reverse orientation. The purine-rich motifs xt10 and xt24 also show an
orientation-specific peak just downstream of the TSS.
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motif logo enr. matches % matches % max. cf
name -60,40 -400,100 pos.
xt1_CRE 15.31 271 6.5 534 12.8 -50 28.58
xt2_Ets 4.03 582 13.9 1067 25.5 -10 18.87
xt3_YY1 47.04 127 3.0 246 5.9 10 24.79
xt4_NF-
Y
7.45 114 2.7 381 9.1 -60 11.24
xt5_Nrf-
1
51.18 87 2.1 213 5.1 -40 10.29
xt6_TATA 6.10 388 9.3 1702 40.7 -30 5.32
xt7_Clus1 57.06 97 2.3 144 3.4 0 56.08
xt8_SP1 12.70 202 4.8 683 16.3 20 18.95
xt9 3.39 384 9.2 1357 32.4 20 14.96
xt10 1.76 321 7.7 834 19.9 20 12.88
xt11 67.50 54 1.3 325 7.8 20 9.04
xt12 3.17 133 3.2 399 9.5 50 7.83
xt13 3.66 366 8.7 676 16.2 -50 17.18
xt14 1.55 551 13.2 1839 44.0 50 10.04
xt15 510.00 51 1.2 74 1.8 0 91.65
xt16 28.00 14 0.3 19 0.5 30 inf
xt17 15.18 126 3.0 300 7.2 -50 18.42
xt18 3.93 53 1.3 167 4.0 -50 10.23
xt19 6.34 59 1.4 76 1.8 10 51.39
xt20 3.44 196 4.7 439 10.5 30 20.30
xt21 inf 8 0.2 9 0.2 -50 inf
xt22 76.67 23 0.5 25 0.6 10 inf
xt23 5.60 56 1.3 192 4.6 50 7.51
xt24 2.06 166 4.0 568 13.6 30 6.67
Table 3: Sequence motifs enriched in Xenopus promoters.
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Figure 8: Differences in distribution of Xenopus promoter motifs. (A) Distribution
of predicted Xenopus promoter motifs (Table 3) in the + and the - orientation.
The matches in the region from -400 to +100 relative to the transcription
start site (TSS) are binned at 20 bp resolution for the forward (green) and the
reverse (red) orientation. Only motifs for which the distribution is different
are shown (see Supplemental Fig. S4 for all motifs). (B) Predicted motifs
containing a CpG dinucleotide are preferentially enriched in CpG-island
promoters (blue) versus non-CpG promoters (orange). (C) Predicted motifs
without a CpG dinucleotide preferentially enriched in either CpG-island
promoters (blue) or non-CpG promoters (orange).
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To evaluate the motif distribution in CpG-island and non-CpG pro-
moters, we analyzed the differences between those two classes of pro-
moters (Figs. 8B and C, Supplemental Fig. S5). As expected, all motifs
containing at least one CG dinucleotide are much more prevalent in
CpG-island promoters (Fig. 8B). This includes the known motifs YY1,
CRE and Nrf-1, as well as the newly identified motifs xt7, xt13, xt15,
xt16 and xt22. One motif does not contain a CpG (Fig. 8C) but is still
more abundant in CpG promoters as compared to non-CpG promoters
(xt19). Four motifs are preferentially enriched in non-CpG promoter
sequences, two C-rich motifs (xt8 and xt9), one motif (xt11) that consists
of a stretch of A’s and xt21, which is only present in 8 promoters.
3.2.4 Known core promoter elements
Some well-known human core promoter elements with degenerate con-
sensus sequences were not found in Xenopus promoters by our analysis,
including the human initiator (Inr, consensus YYAnWYY), the human
upstream TFIIB recognition element (BREu, consensus SSRCGCC), the
downstream TFIIB recognition element (BREd, consensus STDKKKK),
the human Downstream Promoter Element (DPE, consensus RGWYV),
the X Core Promoter Element 1 (XCPE1, consensus DSGYGGRASM)
and 2 (consensus VCYCRTTRCMY) and the Motif 10 Element (MTE,
consensus CSARCSSAACGS). We looked specifically for these elements
in Xenopus promoters (Fig. 9).
Both the human Inr and the more strict Inr element described as
the Drosophila Inr are clearly present and precisely positioned at the
TSS (Fig. 9A). The Drosophila Inr has a similar distribution in human
promoters (Supplemental Fig. S6). As described for human promoters,
the BREu and BREd elements are enriched upstream and downstream
of the TSS respectively in Xenopus (Fig. 9B). However, the frequency
of BREu is much lower than that in human promoters (11% and 34%
respectively).
The DPE is present in Xenopus and enriched downstream of the
TSS. The XCPE1 motif peaks broadly around the start site, but the
frequency is relatively low. Less than 4% of Xenopus promoters feature
this element in the -60 +40 region. This frequency and positional bias
is similar to that observed previously in human promoters (Tokusumi
et al., 2007). For XCPE2 and MTE we did not find any clustering in
Xenopus promoters (Supplemental Fig. S6).
It has been suggested that a downstream GC-rich sequence, also re-
ferred to as the gcg motif and similar to the YY1 motif, is the equivalent
of the MTE in mammalian promoters (Juven-Gershon et al., 2008b; Frith
et al., 2008). The YY1 motif does indeed show clear enrichment down-
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Figure 9: Distribution of known core promoter motifs in Xenopus promoters.
The distribution of the positions of the motifs within a region from -400 to
+100 relative to the TSS was determined by binning these positions at 10 bp
resolution.
stream of the TSS of Xenopus promoters and is specifically positioned
(peaking at approximately +10, Fig. 8 and Table 3).
3.2.5 Nucleotide frequencies differ between Xenopus and human promoters
To get more insight in the conservation of vertebrate core promoter
evolution we wanted to compare motif distribution in Xenopus and hu-
man promoters. One complicating matter in this comparative analysis
is the substantially different sequence composition of warm- and cold-
blooded vertebrates. Although the overall GC percentage of Xenopus
and human genomes is similar (40.1% vs. 40.9%), GC-rich isochores
are very scarce in Xenopus as compared to mammals and birds, possi-
bly due to the difference in body temperature (Costantini et al., 2009).
Indeed, the relative nucleotide frequencies of the Xenopus and human
promoter sets are clearly different (Fig. 10A). Additionally, the relative
frequencies of most dinucleotides differ between Xenopus and human
promoters, although the shape of the dinucleotide distribution patterns
around the TSS is mostly similar (Supplemental Fig. S7). As expected,
this has an effect on the DNA stability as predicted by the calculated 11
basepair melting temperature (Supplemental Fig. S8).
The different promoter nucleotide frequencies between the two organ-
isms have a large influence on motif distribution. While all predicted
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Figure 10: Normalization by nucleotide frequencies. (A) The nucleotide frequency
(mean nucleotide fraction in a 30 bp window) is plotted for Xenopus (left
panel) and human (right panel) promoters (A: green, C: blue, G: yellow, T:
red). (B) The effect of nucleotide frequency normalization on the distribution
of the xt20 motif. The distribution of the positions of the motif within a
region from -400 to +100 relative to the TSS was determined by binning
these positions at 20 bp resolution. Shown is the unnormalized (left panel)
and normalized (right panel) distribution in Xenopus (blue) and human
(orange) promoters. The frequencies in the right panel are normalized, based
on the motif consensus, using the nucleotide frequencies in that bin. (C)
The effect of nucleotide frequency normalization on the distribution of the
SP1 motif.
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Xenopus motifs are overrepresented compared to randomly generated
sequences with a similar dinucleotide composition, we wondered how
exactly the nucleotide background would influence the spatial motif
distribution around the TSS. As the single nucleotide frequencies are
significantly different between human and Xenopus promoters (Fig.
10A), we can use these frequencies to normalize the motif distributions
(see Methods for details). For every bin the motif frequency is normal-
ized to the local frequency of the nucleotides present in the motif. This
allows us to determine to what extent the positional bias of motifs
follows the positional bias of their nucleotide frequencies.
The effect of this normalization is shown for two examples, xt20 (con-
sensus RGAGGARG, Fig. 10B) and the well-known human promoter
motif SP1 (consensus GGGCGG, Fig. 10C). While xt20 has a higher
frequency in human promoters, it also strongly peaks around the TSS in
Xenopus promoters. The normalized frequencies, on the other hand, are
much more similar, with less apparent positional bias around the TSS.
The SP1 motif, known to be bound by the Sp1 family of transcriptional
activators (Zhao and Meng, 2005), is highly enriched in human promot-
ers compared to Xenopus. Strikingly, this difference disappears when
taking the nucleotide frequencies into account, suggesting that these
relative differences are reflective of the general sequence composition
characteristics of promoters in both species with no apparent selection
against these trends.
To further facilitate this analysis, sequence motifs can be classified
according to their distribution before and after normalization (Table
4). Promoter-enriched motifs that have a similar frequency and distri-
bution in both species before normalization can be considered ’con-
served’. Some of these motifs show differences after normalization
for nucleotide composition, other motifs in this group have a similar
frequency also after normalization. In both cases the positional bias
towards the core promoter and the frequency are similar regardless of a
changed nucleotide composition. A second group of motifs has different
motif frequencies before normalization, but is similar after correcting
for the nucleotide background. Examples are the xt20 and SP1 motifs
shown in Figs. 10B and C. These motifs seem to have changed their fre-
quencies along with the nucleotide composition. Such a change in motif
frequency could be adaptive as their relative, normalized enrichment
is similar between species, even though the nucleotide background is
widely different. Finally, the last group is comprised of motifs which
are selectively enriched in one of the species both before and after
normalization and represents truly species-specific motif enrichment
independent of nucleotide composition trends.
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class distribution distribution examples
before after
normalization normalization
Conserved Similar Similar or
Different
Ets, NF-Y
Adaptive Different Similar SP1, TATA
box
Species-
specific
Different Different xt15, xt19
Table 4: Motif classes. Motifs can be divided in different classes according to their
distributions in Xenopus and human promoters before and after normalization
with the background nucleotide composition.
3.2.6 Comparison of Xenopus and human promoter elements
To extend this analysis we implemented the nucleotide frequency nor-
malization in a comprehensive comparison to identify the elements
preferentially enriched in either Xenopus or human core promoters. We
combined 1,794 human promoter sequence motifs predicted in several
promoter studies (FitzGerald et al., 2004; Xie et al., 2005; Vardhanabhuti
et al., 2007; Tharakaraman et al., 2008; Yokoyama et al., 2009) with the
Xenopus motifs predicted in this study and selected all positionally
enriched motifs.
For a robust comparison between species, we also checked the posi-
tional enrichment of these motifs in completely independent validation
datasets for Xenopus and human to ensure that the analysis is not bi-
ased towards TSS-seq or CAGE. For this purpose we predicted TSSs
based on a strict selection of spliced expressed sequence tags (ESTs) that
overlap with the 5’ exons of known genes and share the same orienta-
tion relative to genomic sequence (Ohler et al., 2002, see Supplemental
Methods and Supplemental Fig. S9 for details). Using this approach we
obtained 3,867 Xenopus tropicalis TSSs (Supplemental Table S7A), and a
set of 6,761 human TSSs (Supplemental Table S7B). These TSSs cluster
just upstream of the 5’ end of annotated genes (Supplemental Fig. S9B)
and are generally positioned within 20bp of the actual start sites as
determined by primer extension and analysis of the nearest TSS-seq
read in 1,997 promoters that are present in both promoter collections
(Supplemental Fig. S9).
We selected all motifs with a positional bias in either TSS-seq (Xeno-
pus) or CAGE (human) data, with a consistent positional bias in the
corresponding EST TSS dataset. For all positionally enriched elements
3.2 results 51
identified in the first step, the frequency in the core promoters was de-
termined (Supplemental Table S8). We then selected the motifs that were
more abundant (at least 2-fold difference) in either Xenopus or human,
resulting in a set of 898 differential motifs (adaptive or species-specific,
cf. Table 4) versus 966 conserved motifs with a comparable promoter
distribution between species (difference < 2-fold). The differential mo-
tifs were clustered to obtain a set of non-redundant motifs. Finally,
we normalized the motif frequencies of all clustered non-redundant
motifs on the basis of the single nucleotide frequencies in the core pro-
moter, and checked for preferential enrichment using the normalized
frequency (Supplemental Table S9). This resulted in a set of 12 non-
redundant motifs, preferentially enriched in either Xenopus or human
core promoters (Fig. 11A-C).
Eight motifs are preferentially enriched in Xenopus, showing rela-
tively low enrichment in human promoters, independent of nucleotide
composition bias (Fig. 11A). These include the Clus1 motif (xt7) and the
two novel motifs xt15 and xt19 identified in this study. The CRE motif
does also show positional enrichment in human promoters, but oc-
curs with higher frequency in Xenopus promoters. This group includes
four motifs predicted in human promoter studies (Average_140, Aver-
age_171, Average_203, xie_149), which, however, show much stronger
enrichment in Xenopus promoters.
One motif appears to be preferentially enriched in human promot-
ers independent of nucleotide composition bias (Fig. 11B): Motif 74
predicted by Xie et al. (Xie et al., 2005).
The Nrf-1 and xt8 (a SP1 reverse complement) motifs and the TATA
box (Fig. 11C) are special cases as they are partially conserved and
partially adapative with regard to nucleotide bias. Nrf-1 and xt8 are
more prevalent in human promoters, but are more enriched in Xenopus
promoters after normalization. For the TATA box the opposite differ-
ential enrichment before and after normalization is observed; this core
promoter motif is more abundant in Xenopus promoters. For all three
motifs the Xenopus-human frequency differences are inverted after nor-
malization, which is observed in both the TSS-seq/CAGE and the EST
TSS data sets (cf. Figs. 11C and S10). This shows that their frequency
has changed significantly along with the nucleotide background, but
also that this change would have been larger had these motifs not
been partially retained against the nucleotide composition trends. The
frequency of the TATA box is higher in the more AT-rich Xenopus pro-
moters, while the SP1 frequency is higher in human promoters, which
have a higher GC content (Figs. 10A and 11C). These results show a
remarkable degree of plasticity in well-known promoter motifs between
vertebrates.
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Figure 11: Comparison of Xenopus and human promoter elements (A) Distribu-
tion of motifs specifically enriched in Xenopus promoters relative to human
promoters. The distribution of the positions of the motifs within a region
from -400 to +100 relative to the TSS was determined by binning these posi-
tions at 20 bp resolution in Xenopus (blue) and human (orange) promoters.
The top panel for each motif shows the frequency per bin, the bottom panel
shows the normalized frequency, based on the motif consensus, using the
nucleotide frequencies in that bin. (B) Distribution of motifs specifically
enriched in human promoters relative to Xenopus promoters. (C) Distribu-
tion of motifs that have a different species-preferential enrichment before
and after nucleotide frequency normalization.
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3.3 discussion
In this study we have analyzed the genome-wide core promoter archi-
tecture of Xenopus based on a set of approximately 4,000 transcription
start sites, which were obtained by oligo capping in combination with
high-throughput sequencing. We defined a high-confidence set of TSSs
by combining this dataset with an experimental ChIP-seq dataset of the
transcription initiation factor TBP. To be able to systematically predict
eukaryotic motifs we developed a motif prediction pipeline (Fig. 7). This
pipeline uses an ensemble of different complementary motif prediction
tools, to avoid being dependent on a single computational approach
(Tompa et al., 2005). To compare and cluster motifs we developed a
motif similarity metric based on the Information Content, the WIC
score. This similarity metric compared favorably to current similarity
metrics and performs well in an iterative motif clustering approach
(Supplemental Figs. S2 and S3).
A search for motifs enriched in the sequence surrounding the TSSs
in Xenopus led to the identification of 24 significantly enriched motifs
(Table 3 and Supplemental Table S2). Though most of these are also
present in human promoters, there are some that are specific to Xenopus,
indicative of both similarities and differences between the two species.
Some of the known core promoter motifs and the known CRE, Ets,
Nrf-1, YY1 and NF-Y promoter motifs are also found in this study. All
these positionally enriched elements are shared with mammals but not
flies, most likely reflecting similarities in mechanisms of transcriptional
regulation in vertebrates. The YY1 element plays a dual regulatory role
in promoters (Xi et al., 2007). It can function in transcriptional regulation
by recruiting YY1, but, if present in the plus-orientation downstream
of the transcription start site it can act either as a Kozak consensus
site in the transcribed mRNA for translation or as a binding site for
YY1 (Xi et al., 2007). The Clus1 element, xt7, identified previously
(FitzGerald et al., 2004; Yamashita et al., 2007; Wyrwicz et al., 2007;
Guo et al., 2008; Mikula et al., 2010) is one of the most well positioned
motifs identified in Xenopus promoters. The exact identity of this motif
remains unclear, but the highly specific positioning relative to the TBP
binding peak could indicate that it is bound by an important element
in the core transcriptional machinery, warranting further investigation.
The mammalian Inr (consensus YYAnWYY, Smale and Baltimore, 1989)
is enriched in Xenopus promoters, however the more strict Drosophila
Inr (consensus TCAGTY, Ohler et al., 2002) shows a much stronger
positional enrichment in Xenopus promoters.
It is known that CpG and non-CpG island promoters are structurally
and functionally different from each other. CpG island promoters are
associated with house-keeping genes, show a broad distribution of
54 vertebrate core promoter motif analysis
start sites, and seem to be particularly rapidly evolving in mammals
(Carninci et al., 2006). There is also evidence for functional differences
in the requirements of basal transcription factors between CpG and
non-CpG island promoters (Denissov et al., 2007). Although the CpG
dinucleotide content of Xenopus promoters, and of the whole genome
in general, is lower than that of homeothermic vertebrates (Costantini
et al., 2009), we find that promoter elements are differentially enriched
in these two classes of promoters. The C- and A-rich motifs are specific
to non-CpG promoters, whereas all predicted motifs with a CpG are
enriched in CpG island-containing promoters..
The single nucleotide frequencies are markedly different between
Xenopus and human promoters (Fig. 10A). The Xenopus promoter region
is relatively AT-rich, whereas human promoters are more GC-rich. In
Xenopus, at and around the TSS, only G is enriched relative to the other
nucleotides. The nucleotide composition has a significant impact on the
distribution of some motifs. The TATA box has a higher frequency in
Xenopus as compared to human promoters. However, when normalized,
it shows significantly higher enrichment in human promoters (Fig. 11C).
The opposite is true for the SP1 motif. The strong positional enrichment
around the TSS in human promoters seems to be mostly a product of
the nucleotide background, as the normalized motif frequency shows
no such peak. This motif is bound by the transcriptional activator
Sp1 (Zhao and Meng, 2005). Sp1 has been shown to interact directly
with several TFIID components, including TBP, and is essential for
TFIID-recruitment in absence of a TATA box (Emili et al., 1994; Gill
et al., 1994; Chiang and Roeder, 1995; Kaufmann and Smale, 1994). In
addition, SP1 motifs do not only recruit TBP via Sp1, but also keep CpG
islands methylation-free (Brandeis et al., 1994; Macleod et al., 1994).
Non-methylated CpG islands recruit Cfp1, which allows H3K4me3
deposition and promoter activity (Thomson et al., 2010). This raises
the interesting possibility that the evolution of GC-rich promoters in
some vertebrates, which seems to be particularly rapid in mammals
(Carninci et al., 2006), may have driven the increased use of functional
GC-rich motifs, such as SP1, to recruit the transcription machinery to
these promoters, accompanied by a correspondingly reduced usage of
the TATA box to recruit TFIID.
We identified two Xenopus specific motifs (xt15, consensus GCGW-
GATGAGACT and xt19, consensus TGAGACTTG) in this study. These
novel motifs match no known TF binding sites. Further investigation
should clarify the role of these motifs, and if they can function as bona
fide core promoter elements. In addition, two motifs were identified
(xt7/Clus1 and CREB) that show a stronger enrichment in Xenopus
promoters compared to human promoters.
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In conclusion, this report represents the first analysis of a large set
of amphibian core promoters and a first comparison with human core
promoter elements. Although Xenopus promoters differ in nucleotide
composition compared to human promoters, most of the known core
promoter motifs are shared, indicating a similar vertebrate core pro-
moter architecture. However, the distribution of some motifs is different.
Motifs such as SP1 and the TATA box, seem to be adapted to the local
nucleotide background, whereas other motifs are strongly conserved,
despite different nucleotide background frequencies. This may indi-
cate that, while there is a functionally conserved set of essential core
transcription factors, the motif frequencies reflect adaptive changes in
factor usage in response to a changing nucleotide composition. This
allows for extensive cis-regulatory plasticity in the presence of a highly
conserved transcription machinery.
3.4 methods
3.4.1 Animal procedures
X. tropicalis embryos were obtained by natural mating, dejellied in 3%
cysteine, and collected at the indicated Nieuwkoop-Faber stages.
3.4.2 RNA isolation and TSS-seq
X. tropicalis oocytes and embryos of stage 10-12 were collected and
total RNA was isolated using Trizol and the QIAGEN RNeasy Kit.
The oligo-capping and sequencing was performed as has been previ-
ously described (Tsuchihara et al., 2009). Shortly, 50 µg of purified total
RNA was dephosphorylated with Bacterial Alkaline Phosphatase, lig-
ated with oligo-RNA (5’-AAUGAUACGGCGACCACCGAGAUCUA-
CACUCUUUCCCUACACGACGCUCUUCCGAUCUGG-3’) using T4
RNA ligase, and cDNA was then synthesized using a random hexamer
primer (5’-CAAGCAGAAGACGGCATACGANNNNNNC-3’) with Su-
per Script II (Invitrogen). The cDNA was amplified by 20 cycles of
PCR, and massive parallel sequencing was executed with Illumina GA
sequencer (Illumina) to obtain reads with 36 nt length. All reads were
mapped to the X. tropicalis genome (Joint Genome Institute (JGI), as-
sembly version 4.1 (Hellsten et al., 2010)) using ELAND. All unmapped
reads, or reads mapping to multiple positions were discarded. To call
transcription start sites, all positions with at least 20 overlapping reads
were filtered to overlap with either a TBP peak or a H3K4me3 peak
(Akkers et al., 2009).
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3.4.3 TBP ChIP-sequencing
Embryos were collected at stage 12. Chromatin harvesting and ChIP
using the α-TBP antibody (SL33) was performed as described previ-
ously (Jallow et al., 2004) with minor modifications: 12.5 µl Prot A/G
beads (Santa Cruz) were used, and during reversal of cross-linking,
proteinase K was omitted from the buffer. Sequencing samples were
prepared according to the manufacturer’s protocol (Illumina). Shortly,
adapter sequences were linked to the generated ChIP sample, the li-
brary was size selected (300 bp), and amplified by PCR. The subsequent
sequencing was carried out on a Genome Analyzer (Illumina). All 35-
basepair reads were mapped to the X. tropicalis genome, JGI, assembly
version 4.1 Hellsten et al., 2010 using ELAND (GAPipeline version 1.4,
Illumina) allowing 1 mismatch. Peaks were called using MACS (Zhang
et al., 2008) with a p-value cutoff of 1e-7.
3.4.4 Data availability
The TSS-seq and ChIP-seq data have been deposited in NCBI’s Gene
Expression Omnibus (GEO) (Edgar and Barrett, 2006) and are accessible
through GEO Series accession number GSE21482 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE21482). Visualization tracks
are available at http://www.ncmls.nl/gertjanveenstra.
3.4.5 WIC motif similarity score
The WIC score reflects the comparison of two motif columns and is
based on two terms. The first term is an indication of how informative
the motif positions are, the second is a measure of their difference. A
position with a strong preference for a specific nucleotide, will likely
be more important for binding of the transcription factor to the DNA,
and therefore be more informative. The score can be summarized as
follows: WIC = Information−Difference. The WIC score will be
higher for more informative positions, compared to positions that are
not informative. Similarly, the WIC score will be lower for different
positions, and higher for more similar positions. The first term is based
on the Information Content (IC), while the second term expresses the
differences between two positions similar to the IC, as detailed in the
formulas below.
The Information Content (IC) of a specific motif position is defined
as:
IC(Xi) =
∑
n∈{A,C,G,T}
fxi,n · log2(
fxi,n
fbg
) (3.1)
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where IC(Xi) is the IC of position i of motif X, fxi,n is the frequency of
nucleotide n at position i and fbg is the background frequency (0.25).
The WIC score of position i in motif X compared to position j of
motif Y is defined as:
WIC(Xi, Yj) =
√
IC(Xi) · IC(Yj) − c ·DIC(Xi, Yj) (3.2)
where c is a scaling constant, andDIC(Xi, Yj) is a differential IC defined
in equation 3.3. The constant c is set to 2.5. This value was based on
optimal performance in benchmarks of JASPAR data (Supplemental
Fig. S3B), and was confirmed using other benchmarks (Supplemental
Figs. S3C and D).
The differential IC (DIC) of position i in motif X and position j in
motif Y is defined as:
DIC(Xi, Yj) =
∑
n∈{A,C,G,T}
|fxi,n · log2(
fxi,n
fbg
) − fyj,n · log2(
f
y
j,n
fbg
)| (3.3)
The WIC score of all individual positions in the alignment is summed
to determine the total WIC score of two aligned motifs. To calculate the
maximum WIC score of two motifs, all possible scores of all alignments
were calculated, and the maximum scoring alignment was kept. Op-
tionally an empirical p-value can be calculated based on the maximum
WIC score and the length of the motif. This was done according to
the method of Sandelin and Wasserman, based on simulated PFMs
(Sandelin and Wasserman, 2004). 10,000 random PFMs were generated
using the JASPAR website (http://jaspar.cgb.ki.se/).
3.4.6 Motif clustering
Similar motifs were clustered using an iterative procedure. Pairwise
comparisons were performed for all motifs using the WIC score. The
two most similar motifs were merged, and an average motif was com-
puted, weighted using the column frequencies of the PFMs. The pair-
wise scores of this new average motif to all other motifs were calculated,
and the two most similar motifs are again merged. This procedure was
repeated until the best scoring alignment did not reach a predefined
threshold (WIC p-value 6 0.05).
3.4.7 Motif prediction on Xenopus TSS dataset
Motifs were predicted separately for CpG and non-CpG promoters
and subsequently combined. The CpG and non-CpG sets of Xenopus
promoters (-60 to +40 around the TSS) were split randomly in a pre-
diction and a validation subset (each containing 50% of the sequences).
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The former subset was used to predict motifs using four de novo mo-
tif prediction tools: MEME (Bailey et al., 2009), MotifSampler (Thijs
et al., 2001), Weeder (Pavesi et al., 2004) and MDmodule (Liu et al.,
2002). Weeder performed generally well in a benchmark study (Tompa
et al., 2005), while MEME and MotifSampler showed complementary
behaviour (Tompa et al., 2005). MEME, MDmodule and MotifSampler
were each used to predict 10 motifs for each of the widths between 5
and 12. We used the “medium” analysis setting for Weeder and the
“zoops” distribution for MEME. Where possible we specified strand-
specific motif prediction using only the + strand relative to the promoter
orientation. All other parameters were according to the default settings.
The significance of the predicted motifs was determined by scanning
the validation set, the remaining 50% of the promoter sequences not
used for motif prediction, and a background set of random sequences
generated according to a 1st order Markov model, matching the dinu-
cleotide frequency of the promoter sequences. P-values were calculated
using the hypergeometric distribution with the Benjamini-Hochberg
multiple testing correction (Benjamini and Hochberg, 1995). Motifs with
a p-value 6 0.001 and an absolute enrichment of at least > 1.5-fold
compared to background were determined as significant. All significant
motifs were passed through another level of filtering by looking at
their enrichment as compared to the surrounding sequences. To this
end the positions of these motifs were determined in the complete TSS
promoter data set from -400 to +100 relative to the TSS. To determine if
sequence motifs peak in the promoter region, a clustering factor (CF),
similar to ref. FitzGerald et al., 2006, was calculated. A local background
mean (xmean) and standard deviation (σ) was calculated for the bins of
length 20 between positions -400 and -250 relative to the TSS. The CF
is calculated using the maximum bin value (xmax) between positions
-250 and +50: CF = (xmax - xmean) / σ. The CF values were used to
determine if a sequence motif is clustering in the promoter-proximal
region. Only motifs with CF > 4 were kept for further analysis. This
whole prediction pipeline was repeated 10 times, and only motifs which
were identified at least 5 times were kept.
3.4.8 Frequency of known motifs
The consensus sequences for known promoter elements were obtained
for the human and Drosophila Inr (Juven-Gershon and Kadonaga, 2010),
BREu and BREd (Deng and Roberts, 2006), DPE (Burke and Kadonaga,
1996), XCPE1 (Tokusumi et al., 2007), XCPE2 (Anish et al., 2009) and
MTE (Lim et al., 2004). These consensus sequences were converted to
weight matrices and the frequency was determined by scanning the
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whole set of core promoters (-60 to +40 around the TSS) with a strict
cutoff of 0.95 of the score of the best possible match.
3.4.9 Nucleotide frequency normalization
First, the frequency of each motif was determined from -400 to +100
relative to the TSS, and binned at 20 bp resolution. For each of these
20 bp bins the mean single nucleotide frequency was calculated. Subse-
quently, the motif frequency per bin was normalized depending on the
motif consensus.
fnorm = fmotif ·
fx[1]
0.25
· fx[2]
0.25
· ... · fx[k]
0.25
(3.4)
where fmotif is the motif frequency for a specific bin, fx[1] is the nu-
cleotide frequency (in that specific bin) of the nucleotide in position 1 of
the motif consensus, fx[2] is the nucleotide frequency of the nucleotide
in position 2 of the motif consensus, etc. and k is the motif length. If
the consensus was a degenerate symbol, the sum of the frequencies of
the individual nucleotides were used. For instance the frequency of S
(the IUPAC symbol for either a G or a C) is the frequency of G plus the
frequency of C.
3.4.10 Comparison of human and Xenopus promoters
All human promoter motifs predicted in five studies (FitzGerald et al.,
2004; Xie et al., 2005; Vardhanabhuti et al., 2007; Tharakaraman et al.,
2008; Yokoyama et al., 2009) were retrieved and combined with the 24
Xenopus motifs determined in this study. The Clustering Factor (CF) for
each of these motifs was calculated for human and Xenopus promoters,
both in the predicted TSS set, as well as the validation set. All motifs
with a consistent CF > 4 in two independent TSS collections (Xenopus:
TSS-seq and EST, human: CAGE and EST) were kept for further analysis.
For each positionally enriched motif, the motif frequency was calculated
for human and Xenopus promoters in the region between -150 and +50
relative to the TSS (Supplemental Table S7). All motifs with a frequency
of at least 1% in either Xenopus or human promoters, and at least a
2-fold difference in frequency between Xenopus and human promoters
were clustered. For all the clustered motifs we determined the frequency,
the nucleotide normalized frequency and the CF (Supplemental Table
S8).
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Epigenetic mechanisms set apart the active and inactive regions in the genome
of multicellular organisms to produce distinct cell fates during embryogenesis.
Here, we report on the epigenetic and transcriptome genome-wide maps of
gastrula-stage Xenopus tropicalis embryos using massive parallel sequencing
of cDNA (RNA-seq) and DNA obtained by chromatin immunoprecipitation
(ChIP-seq) of histone H3 K4 and K27 trimethylation and RNA Polymerase
II (RNAPII). These maps identify promoters and transcribed regions. Strik-
ingly, genomic regions featuring opposing histone modifications are mostly
transcribed, reflecting spatially regulated expression rather than bivalency as
determined by expression profile analyses, sequential ChIP, and ChIP-seq on
dissected embryos. Spatial differences in H3K27me3 deposition are predictive
of localized gene expression. Moreover, the appearance of H3K4me3 coincides
with zygotic gene activation, whereas H3K27me3 is predominantly deposited
upon subsequent spatial restriction or repression of transcriptional regulators.
These results reveal a hierarchy in the spatial control of zygotic gene activation.
Supplemental material is available online at http://www.cell.com.
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4.1 introduction
Changes in the chromatin state play an important role in develop-
mental gene regulation; covalent posttranslational modifications of the
N-terminal tails of histone proteins affect chromatin accessibility and
serve to recruit effector molecules to mediate this regulation (reviewed
in Strahl and Allis, 2000; Bhaumik et al., 2007; Taverna et al., 2007).
Deposition of three methyl groups on lysine 4 of histone H3 (H3K4me3)
generally occurs at the promoters of transcribed genes (Santos-Rosa
et al., 2002). During Drosophila embryogenesis Trithorax group pro-
teins (trxG) deposit this mark and positively regulate the expression of
homeotic genes (Breen and Harte, 1993). In embryonic stem (ES) cells
H3K4me3 was identified at active promoters including genes without
elongation of transcription (Guenther et al., 2007). The H3K4me3 mark
can directly interact with for example TAF3, a subunit of the general
transcription initiation factor TFIID (Vermeulen et al., 2007), but it
also recruits the chromatin-remodeling complex NURF (Wysocka et al.,
2006) and CHD1, a protein involved in transcription elongation and
pre-mRNA splicing (Sims III et al., 2007).
Polycomb group (PcG) proteins, a well conserved group of transcrip-
tional repressors, are required during the development of multicellular
organisms (Schuettengruber et al., 2007). The methyl groups of lysine
27 of histone H3 (H3K27me3) are respectively deposited and bound by
Polycomb repressor complexes PRC2 and PRC1 (Cao et al., 2002; Schuet-
tengruber et al., 2007). In cultured embryonic stem cells H3K4me3 and
H3K27me3 can co-occupy a subset of promoters (Azuara et al., 2006;
Bernstein et al., 2006; Mikkelsen et al., 2007). This “bivalent“ configura-
tion results in gene repression but may poise developmental regulator
genes for later transcriptional activation. During differentiation of the
stem cells one of the two marks is lost at most loci, leading to either
activation or stable repression, but the co-occurrence of H3K4me3 and
H3K27me3 does not exclusively arise in pluripotent cells (Barski et al.,
2007; Mikkelsen et al., 2007; Pan et al., 2007; Cui et al., 2009). Bivalency
is infrequent in Drosophila embryos (Schuettengruber et al., 2009). The
Drosophila trxG and PcG proteins act as antagonistic regulators at the
Drosophila Hox gene Ultrabithorax where the H3K4 methyl transferase
Ash1 selectively prevents lysine 27 methylation at the promoter (Papp
and Müller, 2006). Antagonism of the two histone H3 modifications in
mammalian cells is mediated by Rbp2 (Jarid1a), a histone H3 lysine
4 demethylase that interacts with PRC2, and UTX, a histone H3 ly-
sine 27 demethylase that interacts with MLL H3K4 methyl transferase
complexes (Lee et al., 2007b; Pasini et al., 2008).
Characterizing epigenetic control in vertebrate embryos could shed
more light on early events such as zygotic gene activation and the
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spatial control of chromatin states underlying germ layer specification,
patterning and morphogenesis in vertebrates. In Xenopus, the onset of
embryonic transcription takes place at the mid-blastula transition (MBT;
Newport and Kirschner, 1982a,b). Global gene repression is relieved by
a change in the cytoplasm-to-nucleus ratio during the blastula stages
(Newport and Kirschner, 1982a,b) which, at least in part, is mediated
by the competing effects of repressive chromatin and the transcription
machinery (Prioleau et al., 1994; Almouzni and Wolffe, 1995; Veenstra
et al., 1999). Knockdown of DNA methyltransferase 1 (DNMT1) led to
precocious transcription, revealing a role in maintaining transcriptional
repression before the MBT (Stancheva and Meehan, 2000; Dunican et al.,
2008). During gastrulation histone B4 is replaced by histone H1 (Smith
et al., 1988; Dimitrov et al., 1993), which causes selective repression of
oocyte but not somatic 5S transcription, as well as a loss of mesoderm
competence (Wolffe, 1989; Bouvet et al., 1994; Steinbach et al., 1997).
Global assessment of histone modifications by western blotting and
mass spectrometry in oocytes, sperm, sperm nuclei incubated in egg
extract, cell lines and erythrocytes revealed that the differentiation
status is correlated with histone modification signatures (Nicklay et al.,
2009; Shechter et al., 2009).
These observations suggest that chromatin plays an important role
during early development, however chromatin state maps and the dy-
namics of epigenetic control in early vertebrate embryos are unknown.
Here we report on genome-wide profiles of H3K4me3, H3K27me3,
RNA polymerase II (RNAPII) and the transcriptome of Xenopus trop-
icalis gastrula embryos using chromatin immunoprecipitation (ChIP)
experiments and massive parallel sequencing. The H3K27me3 mark cor-
relates with spatial regulation of expressed transcription factor genes.
The bivalent configuration is not predominant, and chromatin-bound
H3K4me3 and H3K27me3 emerge after the MBT, coincidental with zy-
gotic transcription activation and transcriptional repression respectively.
The analyses reveal a hierarchy in activating the embryonic genome
by activating and repressive histone marks and spatially restricted
transcriptional regulators.
4.2 results
4.2.1 Histone Methylation Profiles and the Transcriptome of X. tropicalis
Gastrula Embryos
To generate epigenetic profiles, ChIP was performed using specific
antibodies against trimethylated H3K4 and H3K27 in Xenopus gastrula-
stage embryos (Nieuwkoop-Faber stage 11-12), followed by deep se-
quencing (ChIP-seq). In addition, polyA-selected RNA (stages 10-13)
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was reverse-transcribed and sequenced (RNA-seq). We also carried out
a RNAPII ChIP-seq. The reads were mapped to the X. tropicalis genome,
Joint Genome Institute version 4.1 (Klein et al., 2002, 2006). For details
see experimental procedures and supplementary information (Table
S1).
The high resolution profiles show that H3K4me3 is enriched at the 5’
end of genes (shown for a number of representative loci; Figure 12A).
The H3K4me3 signals coincide with transcribed loci as is shown by a
strong RNAPII signal throughout the gene body as well as RNA-seq
evidence. H3K27me3 is enriched in broad domains as is illustrated for
example by the HoxD cluster (Figure 12B). The hoxd1 gene is marked
with H3K4me3 and shows expression, whereas a widespread presence
of repressive H3K27me3 decorates the other HoxD genes at this stage.
To determine the extent of genome-wide H3K4me3- and H3K27me3-
enrichment, peaks were identified with a sliding window approach
(see experimental procedures). A total of 12,281 and 3,599 regions were
found enriched for H3K4me3 and H3K27me3 respectively. These num-
bers are comparable to those previously found (Zhao et al., 2007) for the
same modifications in human ES cells (17,167 and 4,392 regions). To vali-
date these sets, randomly chosen regions were experimentally validated
and a false discovery rate of <0.06 was found (Figure S1). In addition,
EZH2, the catalytic PRC2 subunit responsible for H3K27 methylation,
was detected solely at genes that are enriched for H3K27me3 (Figure S2).
In conclusion, robust epigenetic profiles and a sensitive transcriptome
profile were obtained using deep sequencing of gastrula X. tropicalis
embryos.
4.2.2 Genes with Both H3K4me3 and H3K27me3 Are Expressed in Gastrula
Embryos
The Joint Genome Institute generated a collection of gene models based
on gene prediction algorithms (FilteredModels genes v1, JGI FM). We
compared the distribution of both chromatin modifications and RNAPII
around the transcription start site (TSS) of JGI FM genes (Figure 13A).
H3K4me3- and H3K27me3-enriched regions are strongly associated
with the 5’ ends of genes; H3K27me3 however is distributed more
broadly compared to H3K4me3. RNAPII enrichment also peaks at the
TSS but is also detected in the gene body, as expected. To determine
the number of peaks that associate with JGI FM genes, the peaks were
correlated to annotation within 1kb of the transcription start site. A
considerable number of H3K4me3 peaks cannot be correlated to the
present annotation (Figure 13B). These H3K4me3-enriched regions that
show no overlap with JGI FM genes likely represent upstream pro-
moters of suboptimal annotated regions and novel transcribed regions.
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Figure 12: Histone methylation profiles and the transcriptome of the Xenopus
tropicalis gastrula embryo. Profiles of H3K4me3 (green), H3K27me3 (red),
RNAPII (purple), and RNA-seq (blue) are visualized using the UCSC
Genome Browser for two genomic regions. (A) The upper panel shows a
region on scaffold_8 with three expressed genes (ppp3r1, pno1, and wdr92).
(B) The lower panel shows the HoxD cluster on scaffold_163.
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We also determined the overlap with other gene collection databases.
The Xenopus model organism database (Xenbase) contains gene an-
notations based on a subset of JGI FM genes, improved by manual
curation (Bowes et al., 2008). In addition, we include Ensembl genes,
RefSeq genes and human genes mapped to X. tropicalis. To compare
these gene collections the occurrence of H3K4me3 peaks within 1kb of
the annotated 5’ ends was determined (Figure S3). The JGI FM genes
(of 27,916 gene models), represented the most inclusive Xenopus gene
set and overlapped with the most H3K4me3-enriched regions. However,
all these databases contained a unique set of genes overlapping with
H3K4me3 peaks that were not present in any other collection of genes
(Figure S3), showing that the current annotation is not optimal yet.
We used the RNA-seq expression and splice junction information in
combination with H3K4me3 and RNAPII ChIP-seq data to combine
the (unique) models of different gene databases and improve the cur-
rent gene annotation based on experimental evidence. Gene models
from Xenbase, JGI, Ensembl and Refseq were combined and updated
with EST (Gilchrist et al., 2004) and RNA-seq data, and H3K4me3 and
RNAPII data were used to validate or update the 5’ ends of the gene
models (for details see Figures S4 and S5). This annotation pipeline
resulted in a collection of 14,253 Xenopus tropicalis experimentally vali-
dated gene models (Xtev genes; Tables S2 and S3). A comparison of the
overlap between H3K4me3- and H3K27me3-enriched regions at both
JGI FM genes and Xtev genes is shown in Figures 13B and 13C. Out of
the 14,253 Xtev genes 10,055 (71%) have a H3K4me3-enriched region
within 1kb of the 5’ end of the gene, which is a marked improvement
over 7,291 JGI FM genes (26%) associated with a H3K4me3-enriched
region. For further analyses the Xtev genes have been used, except
when a genome-wide coverage including non-expressed genes was
appropriate.
H3K4me3- and H3K27me3-enriched regions are associated with
10,055 and 1,672 Xtev genes respectively (Figure 13C). Gene Ontology
analysis of genes marked by H3K27me3 showed that this epigenetic
modification decorates many genes with a function in development
and transcriptional regulation (Figure S6 and Table S4). For example,
as many as 46 out of 50 top ranking H3K27me3-enriched genes encode
transcription factors (Table S5), many of which are known to play impor-
tant roles during embryonic development. Genes with H3K27me3 in ES
cells are also tied to roles in transcriptional regulation and development
(Boyer et al., 2006).
The correlation of H3K4me3 with transcriptional activation and that
of H3K27me3 with repression has not yet been studied in vertebrate
embryos. Therefore, the presence of H3K4me3 and H3K27me3 at the
promoter was compared with expression levels as determined by their
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Figure 13: Primary data analysis and comparison to gene models (A) Profiles
of H3K4me3, H3K27me3, and RNAPII at annotated genes. The average
H3K4me3 read coverage for genes with a H3K4me3-enriched region within
1kb of the JGI FM genes annotated 5’ end is shown in the left panel (mean
number of reads per 500 bp, green). The middle panel shows the equivalent
for H3K27me3 (red) and the right panel for RNAPII (purple). (B) Overlap
of H3K4me3- and H3K27me3-enriched regions with JGI FM genes (within
1kb of the annotated 5’ end). (C) Overlap of H3K4me3- and H3K27me3-
enriched regions with X. tropicalis experimentally validated genes (within
1 kb of the annotated 5’ end). (D) H3K4me3 and H3K27me3 correlate
with gene expression levels. JGI FM genes were divided in equal-sized
groups based on normalized RNA-seq expression level (no, low, medium,
and high expression). For these groups, H3K4me3 (green) and H3K27me3
(red-dotted) occupancy profiles (mean number of reads per 500bp) are
shown.
68 epigenetic control in xenopus embryos
RNA-seq levels (Figure 13D). For this purpose the RNA-seq reads were
mapped to JGI FM genes and normalized expression levels were calcu-
lated. The balance between H3K4me3 and H3K27me3 correlates well
with gene expression levels and association of RNAPII (Figures 13D
and S7A, R2 of H3K4me3 ~RNAPII = 0.58). On silent genes H3K27me3
dominates, whereas highly expressed genes show a strong enrichment
for H3K4me3. Genes with a low expression level show both marks,
and conversely, genes with both marks recruit RNAPII (Figures 13D
and S7B, Table S6). In total 72% of the JGI FM genes marked with
both H3K4me3 and H3K27me3 are expressed in Xenopus embryos. At
face value this is in contrast to studies in ES cells in which bivalent,
co-occurring H3K4me3 and H3K27me3 histone modifications repress
developmental regulators (Azuara et al., 2006; Bernstein et al., 2006;
Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). To explore this
issue we compared the double-marked genes in Xenopus to bivalent
genes in mouse and human ES cells. Among orthologs of human and
mouse bivalent genes, on average 18% is marked by both H3K4me3
and H3K27me3 in Xenopus (p<10E-69), a majority of which is expressed
(64%; Table 5). It has been reported that genes that are bivalent in mouse
ES cells frequently have a paused RNAPII (Stock et al., 2007). In Xeno-
pus gastrula embryos however, the RNAPII pausing index (Welboren
et al., 2009) of genes with both histone modifications was not higher
than that of genes enriched for H3K4me3 only (Figure S8). All these
observations raise the question whether the two marks co-occupy the
same nucleosomal DNA or occupy the locus in different cells of the
embryo.
4.2.3 H3K4me3 and H3K27me3 Decorate Different Nucleosomal DNA Pop-
ulations
Gata3 is an example of a bivalent gene in ES cells which in embryos
displays enrichment for both H3K4me3 and H3K27me3 and is robustly
expressed, as indicated by the abundant presence of RNAPII and RNA-
seq reads (Figure 14A). To directly examine the bivalent chromatin state
of genes in the embryo sequential ChIP was performed. In these experi-
ments the material obtained after the first round of ChIP is subjected
to a second immunoprecipitation with a different antibody (reChIP).
Positive signals in the reChIP would allow the conclusion that histones
with the two different modifications co-occupy the same nucleosomal
DNA. Either an H3K4me3 or an H3K27me3 antibody was used in the
first ChIP, followed by a reChIP with either the same antibody (positive
control) or the antibody for the other histone modification. To account
for the signal generated by residual antibody of the first IP, an essential
beads-only negative control was also included in the reChIP. The gata3
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mikkelsen pan zhao
et al . et al . et al.
Organism mouse human human
Bivalent Genes 2.632 3.244 1.766
X. trop. Orthologs of Bivalent
Genes (Ensembl)
2.090 2.432 1.361
Double-Marked X. trop. Orthologs
(Ensembl)
388 390 283
% 18.6 16.0 20.8
Double-Marked JGI FM Genes 334 334 249
Expressed Genes 213 209 160
% 63.8 62.6 64.3
Table 5: Overlap Double-Marked Regions in Xenopus Compared to Mouse and
Human ES Cells. Orthology mapping was based on Ensembl gene IDs.
~20% of double-marked genes in X. tropicalis are registered as bivalent genes
in either mouse or human ES cells. In general, these genes are expressed
in Xenopus embryos (~64%), whereas these genes are repressed in the ES
cells. 72.0% of all JGI FM genes that have double markings are expressed in
Xenopus embryos.
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gene is enriched for H3K4me3 and H3K27me3 in the first round of
ChIP (Figure 14B, left panel). In the reChIP with different antibodies
(K4-K27 and K27-K4), the signals are comparable to the beads-only
control, whereas the positive control reactions (K4-K4 and K27-K27)
yielded significantly more chromatin, establishing a functional reChIP
(Figure 14B, right panel). In total we tested 21 double-marked genes in
the reChIP, including 9 genes identified as bivalent in previous studies
(Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007) which are not
expressed in Xenopus embryos. This revealed that most of the genes
that have both marks show enrichment of less than two-fold when the
opposite antibody is used in the reChIP (Figure 14C). The same results
are obtained when the order of the antibodies is reversed. We did not
observe any difference between expressed and silent double-marked
genes. A relatively minor K27-K4 enrichment was observed for 6 out
of 21 genes, but this effect is only observed when the sequential ChIP
is started with the H3K27me3 antibody and not when the order is
reversed (Figure S9). Therefore bivalent marking of genes is not a preva-
lent configuration in Xenopus embryos. It appears that K4me3- and
K27me3-modified histone H3 mark different DNA fragments, presum-
ably derived from different cells in gastrula-stage embryos. This raises
the possibility that the two marks decorate loci in a spatially regulated
fashion, contributing to the regulation of localized gene expression.
4.2.4 H3K27me3 Is Associated with Spatially Regulated Genes
To study the spatial epigenetic markup of the embryo, genes with dif-
ferential spatial expression in the embryo along either the dorso-ventral
or the animal-vegetal axis (Zhao et al., 2008) were investigated for the
H3K4me3 and H3K27me3 occupancy of their promoters (Figure 15).
Genes that are preferentially expressed in the animal or the vegetal
pole are both enriched with H3K4me3 at their promoters. However,
H3K27me3 is mainly detected at promoters of genes that are preferen-
tially expressed at the vegetal pole. Likewise, genes that show either
dorsal- or ventral-specific expression are mostly trimethylated at H3K27.
This is in contrast to genes which show no clear differential expression
along either axis, where H3K27me3 is hardly observed at the 5’ end
(Figure 15). Similarly, genes with preferential expression in anterior
mesoderm, posterior mesoderm or notochord (Tanegashima et al., 2008)
are also enriched for H3K27me3, in contrast to genes lacking a localized
expression (Figure S10). Transcripts that are enriched in the animal pole
represent the only group of genes with localized expression that lack
H3K27me3; these transcripts are also expressed albeit at lower levels at
the vegetal pole. In general however, double-marked loci correspond to
spatially regulated genes (Figures 15 and S10).
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Figure 14: Sequential ChIP experiments for genes enriched for H3K4me3 and
H3K27me3 (A) The gata3 locus is visualized using the UCSC Genome
Browser; H3K4me3 (green), H3K27me3 (red), RNAPII (purple), and RNA-
seq (blue). (B) Enrichment of H3K4me3 and H3K27me3 in the first round
of ChIP (left panel), calculated as the fold over the background of a negative
locus. Sequential ChIP enables to examine the presence of two histone
modifications at the same chromatin fragment. The eluted chromatin fraction
of the first ChIP was used as the starting material for a second round of
ChIP (reChIP). In the reChIP (right panel), enrichment was calculated
relative to a beads-only (no antibody) control. This is the most relevant
control to determine enrichment due to the relatively high background
generated by residual antibody of the first ChIP reaction. Enrichment in the
reChIP (K4-K27 and K27-K4, gray bars) was less than two-fold. ReChIP
with the same antibody shows strong signals (K4-K4, green bars, and K27-
K27, red bars). Enrichment values are presented as the mean + SEM of five
independent experiments. Asterisks indicate p value < 0.05 (t-test). (C)
ReChIP results for 21 double-marked genes visualized in a boxplot. Double
asterisks indicate p value < 0.001 (t-test).
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Figure 15: H3K27me3 is linked to localized repression patterns H3K27me3 marks
genes spatially regulated along the dorso-ventral and animal-vegetal axis.
Xenopus embryo explant microarray data (animal and vegetal cap, dorsal
and ventral marginal zone) was compared to H3K4me3 and H3K27me3
occupancy at promoters of differentially regulated genes. H3K27me3 is
enriched at the 5’ ends of genes that are at least 2-fold higher expressed
in the vegetal side of the embryo compared to the animal cap. Genes that
are either preferentially expressed (2-fold difference) at the dorsal or at the
ventral side of the embryo are also enriched for H3K27me3 at their 5’ ends.
Number of genes in these groups: animal, 211; vegetal, 201; dorsal, 33;
ventral, 22; no differential expression, 2955.
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To experimentally validate these findings and test the predictive
power of spatially deposited histone marks, gastrula-stage embryos
(stage 10-12) were dissected in animal and vegetal halves, and animal
and vegetal H3K27me3 ChIP-seq profiles were generated. The profiles
observed for the vegt gene, which is decorated with both histone modi-
fications (Figure 16A) and is expressed at the vegetal pole (Zhang and
King, 1996), show that H3K27me3 is enriched in the animal hemisphere
at this locus (Figure 16B). To assess this relationship in a genome-wide
fashion, the reads obtained for the two samples were normalized and
we calculated the animal/vegetal H3K27me3 ratio for all genes. Genes
with more than two-fold difference in H3K27me3 between animal and
vegetal hemispheres (Table S7) displayed localized expression patterns
(Figure 16C and S11). Interestingly, the genes with animal hemisphere
H3K27me3 include genes that are regulated by vegt like xbra, gsc and
sox17a (Engleka et al., 2001; Vonica and Gumbiner, 2002; Messenger
et al., 2005). Conversely, genes with higher expression in the animal
or vegetal hemisphere according to microarray data (Zhao et al., 2008)
have different animal/vegetal H3K27me3 ChIP-seq ratios. Genes that
are preferentially expressed in the vegetal half have a significantly
higher (p<0.01) animal/vegetal H3K27me3 ratio compared to genes
that are not differentially expressed (Figure 16D). Reciprocally, genes
with higher expression in the animal hemisphere have a lower ani-
mal/vegetal H3K27me3 ratio. In conclusion, these results indicate that
the H3K27me3 histone modification is spatially deposited, which is
predictive of expression patterns within the embryo.
4.2.5 Temporal Delay of H3K27me3 Deposition after the Mid-Blastula Tran-
sition
To determine the temporal aspect of epigenetic regulation, the interplay
of H3K4me3, H3K27me3 and gene expression levels between blastula
and larval stages was explored (st. 7-34). ChIP-qPCR and qRT-PCR
was performed with material obtained from different stages of devel-
opment, including pre-mid-blastula transition stages (pre-MBT; stage
7-8), before the onset of embryonic transcription. Genes known to play
important roles in development were selected for this analysis and
ChIP values relative to RNA levels were hierarchically clustered and
visualized in a heat map (Figures 17 and S12). The clusters found in this
analysis differ in both the kinetics and the extent of transcriptional acti-
vation during early development. For all tested genes chromatin-bound
H3K4me3 and H3K27me3 signals emerge after the MBT, whereas hi-
stone H3 is detected before this stage with an H3-core antibody. No
substantial trimethylation of H3K27 is observed on genes before the
mid-gastrula stage (stage 11), whereas H3K4me3 is observed between
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Figure 16: Spatial deposition of H3K27me3 is predictive of localized expres-
sion (A) The vegt locus is visualized using the UCSC Genome browser;
H3K4me3 (green), H3K27me3 (red), RNAPII (purple), and RNA-seq (blue).
(B) H3K27me3 ChIP-seq of animal and vegetal halves (stage 10-12). The
vegt gene is most enriched for H3K27me3 in the animal hemisphere. (C)
qRT-PCR expression ratio (animal/vegetal) of genes with animal-high (n =
4) or vegetal-high (n = 25) H3K27me3 (normalized H3K27me3 ChIP-seq
ratio, 2Log > 1). Double asterisks indicate p value < 0.0001 (t-test). (D)
Normalized H3K27me3 ChIP-seq ratio (2Log animal/vegetal) of genes with
expression differences: nondifferential (n = 195), animal preferential (n = 9),
and vegetal preferential genes (n = 35). Numbers refer to genes that are both
enriched for H3K27me3 in whole embryos and included in the microarray
data (Zhao et al., 2008). Asterisks indicate p value < 0.01 (t-test).
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the MBT and the start of gastrulation. For most genes transcription
activation coincides with or follows the appearance of H3K4me3, and
reduced mRNA levels correlate with increasing levels of H3K27me3
and a drop in H3K4me3 (Figure 17 and S12). GS17, one of the early
genes that is actively transcribed after the MBT (cluster 1), is an ex-
ception showing no deposition of H3K27me3 upon downregulation.
Deposition of H3K4me3 precedes accumulation of transcript in the
second cluster of genes, with expression peaking toward the end of
gastrulation (stage 12.5). These genes are generally robustly expressed
during gastrulation, which distinguishes this cluster from the third
cluster that is characterized by low H3K4me3; these genes are also
expressed at relatively low levels. For example, the neuro2d promoter is
only enriched for H3K27me3 in the absence of expression, whereas Lbx1
and dlx1 are low for H3K4me3 and transcription levels fluctuate over
time with increasing H3K27me3. Some of these transcripts likely origi-
nate from maternal RNA since RNA is detected before the MBT. The
fourth cluster consists of genes that have high levels of H3K4me3 and
are robustly expressed at the end of gastrulation, whereas H3K27me
shows relatively little enrichment, with the exception of myoD which
shows an increase in H3K27me3 levels at larval stages. To visualize the
ChIP signals appearing at a gene locus, several primers set were devel-
oped for the xbra locus and tested in ChIP-qPCR. H3K27me3 appears at
the promoter concomitantly with repression and subsequently spreads
within the locus (Figure S13). Most of the genes analyzed here show
deposition of H3K4me3 prior to or concomitant with transcriptional
activation, without significant prior enrichment for H3K27me3 (p<0.001
for difference at stage 9-10).
4.3 discussion
This study uncovers a key feature of epigenetic regulation in vertebrate
embryos. H3K4me3 and H3K27me3 modifications strongly correlate
with expression levels but these epigenetic marks do not represent the
bivalent configuration as they by and large do not co-occur on the same
nucleosomal DNA. Gene loci with both modifications have RNAPII in
the gene body and 72% are expressed. Correlation of the epigenetic pro-
files with spatially regulated genes identified by microarray expression
analysis (Tanegashima et al., 2008; Zhao et al., 2008) reveals that the
H3K27me3 mark is associated with genes that display spatial regulation
of expression. ChIP-sequencing for H3K27me3 in animal and vegetal
halves shows that spatial differences in deposition of the Polycomb
mark are predictive of spatially regulated expression in the embryo.
Concordantly, paused RNAPII was not observed at the double-marked
genes in Xenopus embryos, whereas RNAPII elongation is impaired at
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Figure 17: Dynamic regulation of epigenetic marks and gene expression during
development (A) Hierarchical clustering results of relative ChIP recov-
eries for H3K4me3 (green) and H3K27me3 (red) and RT-PCR for stages
7-34 of developmentally regulated genes (blue). Intensities of the signal
show high or low ChIP enrichment and expression. (B) The panels show the
average relative ChIP recoveries for H3K4me3 (green), H3K27me3 (red),
and expression values (qRT-PCR in blue) of the corresponding stages 7-34
for the four clusters. ChIP signals represent the average of a biological
duplicate experiment.
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bivalent genes (Stock et al., 2007). The number of targets of double-
marked regions in Xenopus embryos is comparable to the number of
regions with bivalent status in mouse and human ES cells (2,000-3,000
promoters; Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007.
There is a considerable overlap of H3K4me3- and H3K27me3-modified
genes between ES cells and Xenopus embryos (~18%). However, two
thirds of these double-marked regions in Xenopus embryos correspond
to expressed genes, rather than genes that are poised for activation
upon differentiation. H3K4me3 and H3K27me3 tend to be separated in
embryonic space and time. It is possible that the two marks co-occur
on the same nucleosomal DNA with low frequency in Xenopus em-
bryos. We suggest that true bivalency may result from the co-occurring
antagonistic forces of activation and repression in a given cell rather
than representing a special mechanism of gene activation. It is pos-
sible that the key to bivalency is in the dynamics of differentiation.
Cells differentiating from a progenitor into different lineages tend to
be spatially separated in the embryo but do still express competing
activities for alternative transcription programs. Therefore bivalency
may particularly be prevalent in situations in which differentiation is
inhibited, representing a ”holding pattern”. The antagonism between
the marks is likely mediated by complexes harboring both histone
methyltransferase and demethylase activities (Lee et al., 2007b; Pasini
et al., 2008), a conserved feature of developmental gene regulation,
whereas the extent to which bivalency is observed may depend on the
dynamics of differentiation, which is variable between systems.
The data reported here reveal a hierarchy in epigenetic and tran-
scriptional regulation that exhibits both spatial and temporal aspects.
In most cases H3K4me3 precedes or coincides with transcriptional
activation after the mid-blastula stage. Well after the deposition of
H3K4me3 and the onset of embryonic transcription, H3K27me3 accu-
mulates and is deposited on many transcription factor genes, coinciding
with repression or spatial restriction of gene expression. These spatially
regulated transcription factors in turn activate or repress their cognate
downstream targets within their expression domains as is seen for the
vegt gene regulatory network. The relatively late role for H3K27me3
is concordant with an earlier observation that the RNA of the Xenopus
Polycomb homolog, a subunit of the PRC1 complex, is only translated
after the MBT (Strouboulis et al., 1999). Consistent with a role well after
the onset of transcription, YY1, a homolog of Drosophila Pho, interacts
with the PRC2 subunit EED and both proteins are involved in neural
induction in Xenopus (Satijn et al., 2001). Experimental validation of the
PRC2 subunit EZH2 revealed that this subunit was only detected on
gene loci that are enriched for H3K27me3.
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The epigenetic hierarchy of activation and repression is likely to
extend to other epigenetic marks and to involve other factors, such as
maternal activators and induced repressors. For example, activation of
mesoderm gene expression is observed in embryos in which protein
synthesis is inhibited, however proper spatial restriction of expression
requires induced repressors (Latinkic´ et al., 1997; Lerchner et al., 2000;
Kurth et al., 2005). DNA methylation has been implicated in gene
activation at the MBT at specific gene loci (Stancheva et al., 2002). Other
epigenetic cross-talk likely includes histone acetylation and methylation
at different residues, for example H3K9me3, which like H3K4me3 and
H3K27me3 is much more abundant in somatic cells when compared
to sperm and pronuclei (Shechter et al., 2009). In embryos, stored
diacetylated histone H4 becomes incorporated at cleavages stages, but
is deacetylated between cleavage stages and gastrulation Dimitrov et al.
(1993). During later development WDR5 is essential for deposition
of H3K4me3 and spatial regulation of Hox genes (Wysocka et al.,
2005). These and other studies show that epigenetic regulation is highly
dynamic and interconnected during development.
Additional genome-wide localization and functional studies will
provide important new insights in the role of other epigenetic marks,
chromatin modifying enzymes and chromatin remodelers, and how
they control spatio-temporal patterns of gene expression during devel-
opment, which will enhance our current knowledge in transcription
regulation and the complex interplay between different cells and tissues
in the embryo.
4.4 experimental procedures
4.4.1 Animal procedures
Xenopus tropicalis embryos were obtained by natural mating, dejellied
in 3% cysteine and collected at the indicated stage. Dissections were
performed on in vitro fertilized embryos using a Gastromaster micro-
surgery apparatus (Xenotek Engineering) equipped with white tips.
4.4.2 Chromatin immunoprecipitation and antibodies
Chromatin harvesting and ChIP was performed as described (Jallow
et al., 2004) with minor modifications: 12.5µl of Prot A/G beads (Santa
Cruz) were used and during reversal of crosslinking proteinase K
was omitted from the buffer. The following antibodies were used: α-
H3K4me3 (Abcam, ab8580), α-H3K27me3 (a kind gift from J. Martens
and T. Jenuwein; Peters et al., 2003), RNAPII (Diagenode AC-055-100),
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EZH2 (Active Motif, 39103). For sequential ChIP, chromatin of the first
ChIP was eluted from the beads in 100 µl elution buffer (100 mM
NaHCO3 pH 8.8; 1% SDS), diluted 10 times in incubation buffer (50
mM Tris pH 8.0; 100 mM NaCl; 2 mM EDTA; 1 mM DTT; 1% NP40;
protease inhibitor cocktail, Roche) and a second round of ChIP was
performed.
4.4.3 RNA preparation for RNA-Seq
X. tropicalis embryos of stage 10-13 were collected and total RNA was iso-
lated using Trizol and the Qiagen RNeasy Kit. Subsequently, polyadeny-
lated RNA was selected twice with the Oligotex mRNA kit (Qiagen)
to remove rRNA. cDNA was prepared with random hexamer primers
using Superscript III (Invitrogen) and the second strand was made with
DNA polymerase I, DNA ligase and T4 DNA polymerase. The purified
double-stranded cDNA was used for Illumina sample preparation.
4.4.4 Quantitative (RT-) PCR
PCR reactions were performed on a MyIQ single color real-time PCR
detection system (BioRad) using iQ SYBR Green Supermix (BioRad).
Primer sequences are available upon request.
4.4.5 Sample preparation and sequencing
Sequencing samples were prepared according to the manufacturer’s
protocol (Illumina). Shortly, adapter sequences were linked to the gener-
ated ChIP and cDNA samples, the library was size selected (200-250bp)
and amplified by PCR. The subsequent sequencing was carried out on
a Genome Analyzer (Illumina).
4.4.6 Alignment of reads
We used ELAND (GAPipeline version 1.0, Illumina) to map sequence
reads to the Xenopus tropicalis genome, Joint Genome Institute, assembly
version 4.1 (Klein et al., 2002, 2006). All unfiltered (Illumina Chastity
Filter) 32-mer reads were aligned allowing up to two mismatches. For
the histone modifications all mapped reads were extended to 133 bp
(estimated fragment length). See table S1 for statistics.
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4.4.7 Data availability
The data have been deposited in NCBI’s Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through GEO Series accession
number GSE14025 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE14025). Visualization tracks are available at the authors’ web
site (http://www.ncmls.nl/gertjanveenstra) and at Xenbase (http:
//www.xenbase.org).
4.4.8 Detection of enriched H3K4me3 and H3K27me3 regions
Enriched regions were defined using a read count threshold with a
sliding window approach (window of 500bp, threshold of 9 and 12
reads for H3K4me3 and H3K27me3 respectively). These thresholds
were chosen on basis of a Monte-Carlo simulation where we randomly
placed reads on the mappable part of scaffold_1 (ELAND) and called
the number of enriched regions in this simulated dataset. This proce-
dure was repeated 1,000 times, and a False Discovery Rate (FDR) was
calculated for each threshold. We chose the threshold corresponding
to the same theoretical FDR (<0.001) for both samples, and validated
randomly chosen regions by ChIP-qPCR.
4.4.9 Generation of distribution profiles
The mean number of mapped reads per 500bp was computed for 20kb
around the annotated 5’ end of genes with an enriched region for
H3K4me3, H3K27me3 and RNAPII within 1kb.
4.4.10 Gene Ontology analysis
Gene Ontology annotations for JGI FilteredModels genes v1 were ob-
tained from Xenbase (http://www.xenbase.org), and the analysis was
carried out using Ontologizer (Grossmann et al., 2007). We used the
Parent-Child method with Westfall-Young-Single-Step multiple testing
correction and set a corrected p-value threshold of 0.01.
4.4.11 Normalized expression level and detection call of expressed genes
Using an approach similar to (Sultan et al., 2008), the normalized
expression level was calculated as the number of reads mapped to a
gene divided by the total number of unique 32-mers in a gene:
NEL = Nmapped/Nunique (4.1)
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Nunique was determined by generating all possible 32-mers for each
gene and mapping these to the Xenopus tropicalis genome and the JGI
FM genes using ELAND. All 32-mers that mapped uniquely to the
JGI FM genes and did not map to multiple sites in the genome were
counted as unique.
4.4.12 Comparison with explant microarray data
Xenopus laevis explant microarray data were downloaded from the
Gene Expression Omnibus (accession GSE8990) and ArrayExpress (ac-
cession E-MEXP-717). We used RMA normalization (limma package,
Bioconductor; Gentleman et al., 2004) on the raw expression values as
provided by the submitter. All probe sequences from the microarray
design were retrieved from Affymetrix (http://www.affymetrix.com)
and were mapped to the JGI FM genes with blat (Kent, 2002). Hits were
filtered based on the following criteria: 30% of the probe matches, at
least 50% similarity, no more than 4 matches. Using the microarray
data we compared the expression in different explants, and selected
JGI FM genes with a 2-fold or higher difference in expression. Histone
modification profiles were computed as described above.
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The tumor suppressor p53 is a sequence-specific transcription factor, which
regulates the expression of target genes involved in different stress responses.
To understand p53’s essential transcriptional functions, unbiased analysis of
its DNA-binding repertoire is pivotal. In a genome-wide tiling ChIP-on-chip
approach, we have identified and characterized 1,546 binding sites of p53
upon Actinomycin D treatment. Among those binding sites were known as
well as novel p53 target sites, which included regulatory regions of poten-
tially novel transcripts. Using this collection of genome-wide binding sites, a
new high-confidence algorithm was developed, p53scan, to identify the p53
consensus-binding motif. Strikingly, this motif was present in the majority of
all bound sequences with 83% of all binding sites containing the motif. In
the surrounding sequences of the binding sites, several motifs for potential
regulatory cobinders were identified. Finally, we show that the majority of the
genome-wide p53 target sites can also be bound by overexpressed p63 and p73
in vivo, suggesting that they can possibly play an important role at p53 binding
sites. This emphasizes the possible interplay of p53 and its family members
in the context of target gene binding. Our study greatly expands the known,
experimentally validated p53 binding site repertoire and serves as a valuable
knowledgebase for future research.
Supplemental material is available online at http://nar.oxfordjournals.org/.
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5.1 introduction
The tumor suppressor gene p53 is the most frequently mutated gene
in human cancers (Hollstein et al., 1991). It can be activated by a large
number of stress signals. The p53 protein is able to function as a
sequence-specific transcription factor (Kern et al., 1991) and it regulates
the expression of target genes involved in growth arrest, apoptosis,
DNA repair, senescence, differentiation and other responses (Vogelstein
et al., 2000). Substantial evidence indicates that the transcriptional
functions of p53 are necessary for p53-mediated tumor suppression
(Laptenko and Prives, 2006), although it has also been reported that
p53 can induce apoptosis without a functional transactivation domain
(Erster and Moll, 2005).
The tumor suppressor p53 binds in a sequence-dependent manner to
a so-called p53 consensus-binding motif. This motif is found in many
identified binding sites of, mostly upregulated, p53 target genes and
consists of two copies of the palindromic consensus half-site RRRCWW-
GYYY separated by a spacer of 0-13 bp, in which R =purine, W = A or
T and Y = pyrimidine (el-Deiry et al., 1992). The p53 binding ability and
its transcriptional activity might be influenced by the sequence of the
two half-sites as well as their mutual orientation (Zhao et al., 2000). Up
to now it was thought that this p53 response element is mostly found
within a few thousand base pairs of the transcriptional start site (TSS)
(Laptenko and Prives, 2006). In addition, binding sites which differ
from the classical p53 binding motif have been reported (Inga et al.,
2002; Contente et al., 2002). It has been suggested that the deviations
from the consensus sequence hint at the possibility that DNA topology
also determines p53 binding (Göhler et al., 2002) and that even the
DNA structure might totally replace the consensus sequence (Jett et al.,
2000). However, these findings are largely based on single target genes;
a genome-wide analysis of binding sequences for common motifs will
be very informative.
The transcriptional activity of p53 can be regulated by posttransla-
tional modifications (Bode and Dong, 2004; Brooks and Gu, 2003) as
well as transcriptional cofactors and p53-binding proteins (Laptenko
and Prives, 2006; Aylon and Oren, 2007). p300 acts as an p53-dependent
coactivator for p53 target genes by acetylating p53 (Avantaggiati et al.,
1997; Gu and Roeder, 1997) and it binds to various corecruited factors
that enhance the p53 response (Coutts and Thangue, 2005). Two of
those have recently been identified, JMY and Strap, and both factors
are required for p53 activity (Shikama et al., 1999; Demonacos et al.,
2001). Recent studies have also provided evidence that the selection
of p53 target genes can be modulated by p53 interacting proteins. The
ASPP (apoptosis-stimulating protein of p53) proteins have been shown
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to interact with p53 and to specifically modulate p53-induced apoptosis
but not cell cycle arrest (Sullivan and Lu, 2007). Interestingly, the hCAS
(human cellular apoptosis susceptibility) protein has been reported to
be part of a distinct macromolecular complex of p53 at specific sub-
sets of p53 target genes, e.g. Pig3 and p53AIP1 and its knockdown
attenuates the p53-dependent apoptosis (Tanaka et al., 2007). Other
transcription factors that might be involved in the target gene selec-
tion of p53 are the Brn3 family of POU domain transcription factors
(Budhram-Mahadeo et al., 2006), the YB1 protein (Homer et al., 2005),
NF-kappaB and IKKalpha (Huang et al., 2007; Schumm et al., 2006)
as well as the hematopoietic zinc-finger cofactor (HZF) protein (Das
et al., 2007). In addition to transcriptional factors that influence the
p53-target gene binding, there is also evidence that the p53 family
members p63 and p73 can contribute to the p53-recruitment at specific
target genes. Both p63 and p73 were reported to be required for the
p53 binding to the p53 response elements of the target genes Perp, Bax
and Noxa, but not to those of p21 or Mdm2 (Flores et al., 2002). A
’priming model’ was suggested, in which p63 and p73 can bind to a
specific chromatin-embedded response element not accessible for p53,
and subsequently modify the context of the response element in such a
way that it becomes available for p53 binding (Espinosa, 2008). So far,
a systematic analysis of the capability of p63 and p73 to play a role in
vivo at p53-target sites has not been performed.
Many p53 target genes are currently known, e.g. identified with
microarray expression profiling (Sbisà et al., 2007; el-Deiry, 1998), and
at the moment it is intensively studied how p53 determines which
target genes to activate or repress in a certain stress response (Laptenko
and Prives, 2006; Horn and Vousden, 2007). In addition to the exper-
imentally identified p53 target genes, there are also computationally
predicted binding sites (Veprintsev and Fersht, 2008; Hoh et al., 2002).
These predictions do not necessarily reflect the actual target sites bound
in vivo by p53. For the selection of functional binding sites, the involve-
ment of other cellular factors, chromatin accessibility, DNA sequences
surrounding the potential binding site and DNA topology have to be
taken into consideration, in addition to the consensus-binding sequence
itself. These factors can not yet be accurately modeled. It is estimated
that there are between 300 and 3,000 binding sites for p53 in the human
genome, based on studies from Hoh et al. (Hoh et al., 2002), ChIP-on-
chip (chromatin immunoprecipitated DNA hybridized on DNA arrays)
data extrapolated from chromosome 21 & 22 (Cawley et al., 2004) and
ChIP-on-chip data derived from ENCODE regions (Kaneshiro et al.,
2007). Since there are only about 180 experimentally confirmed target
genes (Sbisà et al., 2007), and 542 high-probability binding sites (Wei
et al., 2006), it is expected that there are still many unidentified binding
86 the genome-wide p53 binding repertoire
sites and target genes, notwithstanding several studies that have re-
ported binding sites for p53 (Cawley et al., 2004; Kaneshiro et al., 2007;
Wei et al., 2006; Krieg et al., 2006; Ceribelli et al., 2006; Jen and Cheung,
2005; Hearnes et al., 2005; Zeng et al., 2008) . Furthermore, it remains to
be seen how a comprehensive set of p53-DNA binding sites in vivo can
be used to give more insight into the different transcriptional functions
of p53.
Here, we report a genome-wide ChIP-on-chip study of p53 employing
high-resolution tiling arrays with an average probe spacing of 100 bp.
We have identified 1,546 high-confidence sites and performed extensive
analysis of the in vivo binding sites with respect to their sequence as
well as surroundings and nearby genes. We report the development of a
new publicly available algorithm, p53scan, to identify the p53 consensus
binding motif with high specificity. The motif is present in 83% of all the
p53-bound sequences and in almost all highly enriched binding sites.
Potential novel functions of p53 derived from the global binding sites
were investigated and validated. To obtain a more complete picture of
the in vivo bound target genes of p53, we have also performed ChIP-
on-chip analyses with two of its family members, p63 and p73. We
show that a large fraction of these newly identified binding sites for
p53 could also be bound by p63 and p73 in vivo.
5.2 results
5.2.1 Genome-wide identification of p53-binding sites using ChIP-on-chip
In order to detect in vivo binding sites for p53 on a genome-wide scale,
we applied the ChIP-on-chip approach to endogenous p53 express-
ing U2OS osteosarcoma cells. In unstressed cells, endogenous p53 is
maintained at low levels. To activate p53, cells were treated with 5 nM
Actinomycin D for 24 h (Ashcroft et al., 2000). Upon Actinomycin D
treatment, p53 is stabilized and growth arrest is induced (Figure 18A
and B). ChIP was performed upon this treatment. To assess the speci-
ficity of our ChIP-results, p53 binding to exon 2 of the myoglobin
gene was determined as background signal and enrichment was cal-
culated as fold binding over background signal (Figure 18C). For the
p21-promoter, an enrichment of p53 binding of almost 600-fold was
attained showing that the immunoprecipitation was highly specific. For
the global binding site analysis, the enriched (ChIP) sample and the
nonenriched (Total) DNA sample were amplified, differentially labeled
and cohybridized to 38 DNA arrays covering the whole human genome
(repeat masked) with a probe spacing of 100 bp and a probe length of
50 bp (NimbleGen Systems, Inc.).
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Figure 18: Genome-wide identification of p53-binding sites using ChIP-on-chip.
(A) Representative cell cycle profile of U2OS cells untreated or treated for
24 h with 5 nM Actinomycin D. (B) Western blot showing p53 expression
levels of U2OS cells, untreated or treated for 24 h with 5 nM Actinomycin
D. (C) ChIP enrichment (fold over negative control, myoglobin) of p53 at
the p21 promoter and the intronic binding site of GADD45A. (D) ChIP-
on-chip profile of p53 binding to chromosome 6 visualized using Signalmap
(NimbleGen Inc.). Shown are the log2 ratio of ChIP/Total signal derived
from the genome-wide tiling data and a zoomed-in view of binding to the
p21 promoter for all three biological replicates. Genes are represented by
thick horizontal bars (plus-strand positive, minus-strand negative). (E)
Overlap of the ChIP-on-chip derived p53-binding sites with PET5+ data
from Wei et al.
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We called putative p53-binding sites combining three different peak
extraction algorithms to maximize the number of potential peaks. The
genomic loci of the combined peaks were combined to generate a so-
called dedicated array (Kim et al., 2005), which was used to hybridize
two further biological replicate experiments (Figure 18D). If a peak was
identified in all three biological replicates, it was considered as a high-
confidence p53-binding site. This way, we identified in total 1,546 high-
confidence binding sites for p53. Verification of the identified binding
sites was performed by quantitative PCR with three independent ChIP
experiments. In total, 50 potential binding sites were randomly selected
and tested. This resulted in a confirmation of 48 out of 50 sites. We
conclude that we identified 1,546 genome-wide p53-binding sites with
a false positive rate of ~4%.
Since several studies, using different ChIP-based techniques, have
identified binding sites for p53 in various cell systems (Cawley et al.,
2004; Kaneshiro et al., 2007; Wei et al., 2006; Krieg et al., 2006; Yang
et al., 2006), we compared these to the collection of our binding sites
(Table 6). The overlap between our data set and the PET5 cluster in
the ChIP-PET data set for p53 by Wei et al. (Wei et al., 2006) was 69%,
even though different cell lines and treatments were used (Figure 18E).
The extensive overlap with the highest ranked targets of the ChIP-PET
data (69%) and lower overlap (17%) in the low ranked targets with
ChIP-PET data is in concordance with the study of Euskirchen et al.
(Euskirchen et al., 2007), where they compared ChIP-sequencing with
ChIP-on-chip under the same conditions for STAT1 and also found the
most overlap in the highest ranked regions. From the genes that were
identified by a ChIP-based screen in yeast (Hearnes et al., 2005), 50% are
found in our study. Thus, even when using different cellular systems
and physiological conditions as well as various ChIP-based techniques,
half or more of the p53-binding sites appear to be overlapping with our
global ChIP-on-chip approach, showing we created a high-confidence
p53-binding dataset.
5.2.2 Characterization of identified p53-binding sites
To annotate the identified p53 binding sites, their locations were ana-
lyzed with respect to annotated Ensembl genes. We found that 21% of
all p53-binding sites mapped to TSS flanking regions (5 kb upstream,
first exon and intron), 28% were within a gene (excluding first exon and
intron), 3% within 5 kb downstream, 16% within 5-25 kb upstream or
downstream and 32% in intergenic regions (Figure 19A). We compared
the frequency of p53 binding in specific genomic regions to the distribu-
tion of these genomic regions over the whole genome (using Ensembl
gene annotations) and found that p53-binding sites are significantly
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published study total num-
ber of bind-
ing sites
overlap
with p53
of this
study (1,546
total)
Yang et al. 5,807 383
Wei et al. PET2+ 1,773 301
PET2+ with
p53PET motif
542 262
PET3+ 327 170
PET4+ 169 111
PET5+ 106 73
Krieg et al. Low 113 3
Mid 34 1
High 8 1
Cawley et al. 48 15
Kaneshiro et al. 37 16
Hearnes et al. 38 26
Table 6: Overlap with published data sets
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enriched in TSS flanking regions and within 5-25 kb upstream or down-
stream of a gene (P = 1.49E-009 and 0.0094, respectively) (Figure 19A).
To study if binding of p53 in TSS flanking regions can regulate the
transcription of the corresponding gene products, we randomly selected
11 genes in this group to test their changes of expression upon p53
activation (Figure 19B). Four of these genes were indeed more than
2-fold upregulated, two were >2-fold downregulated, and five did not
change >2-fold. Thus, upon p53 binding in TSS flanking regions, genes
can get activated or repressed by p53, which is in accordance with the
described function of p53 as transcriptional activator and repressor.
While the biological function of p53 binding to promoter regions is
well established, we wanted to study the functional potential of intronic
as well as intergenic p53 binding. We first tested nine of the intronic and
intergenic binding sites (randomly chosen) in transactivation assays
cloning them into a pGL3-promoter-luciferase vector, which can be
used to test enhancer functions. U2OS cells were transiently transfected
with these luciferase constructs and treated with Actinomycin D to
activate p53. For each of the selected binding sites, the luciferase ac-
tivity increased two to nine times compared to the pGL3prom control
vector (Figure 19C). This indicates that p53-binding sites in introns and
intergenic regions can play a role as transcriptional enhancers.
To test whether the p53 binding in intergenic regions could also
regulate the transcription of novel gene products, we mapped the
intergenic binding sites to human expressed sequence tags (ESTs). This
revealed that 67% of intergenic p53-binding sites are located within 5
kb up- or down-stream of an EST. This is a significant enrichment (P
= 1.50E-4) compared to the proportion of the complete genome that
falls within this category. From these binding sites close to an EST,
we chose four sites for further analysis (Figure 19D, upper panel). We
validated binding of p53 to these sites in targeted ChIP experiments
(Figure 19D, lower left panel) and tested changes of expression of
these novel transcripts upon p53 activation. The four chosen transcripts
showed a 2- to 15-fold induction (Figure 19D, lower right panel) upon
p53 activation. This indicates that many novel, currently unannotated
transcripts may be regulated by p53.
5.2.3 Functional annotation of the p53-binding sites
Since we found well-known p53 target genes involved in pathways
such as DNA repair (GADD45A, DDB2), cell cycle regulation (MDM2,
p21) and apoptosis (BAX, DR5) (Table S1), we wanted to analyze the
possible biological roles of all the p53-binding sites in our dataset. When
we grouped our p53 targets, which have a binding site within 5 kb,
according to function in GO using Ontologizer (Grossmann et al., 2007;
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Figure 19: Characterization of identified p53 binding sites. (A) Distribution of the
p53-binding site location relative to Ensembl genes (upper panel) compared
to the genome-wide distribution (lower panel). Locations of binding sites
are divided in TSS flanking region (5 kb upstream of TSS + first exon +
first intron), intragenic region (all introns and exons except first), 5 kb
downstream (5 kb downstream of last exon), 5-25 kb up- or down-stream
or intergenic regions (everything else). The asterisk represents significant
enrichment. (B) Expression change of genes which have a p53 binding site
in the TSS flanking region. The expression change is shown after 24 h of
5 nM Actinomycin D treatment in fold over untreated U2OS cells. Error
bars represent standard deviation of three independent experiments. (C)
Transactivation assay of intronic (yellow) and intergenic (blue) p53-binding
sites. The relative luciferase activity is plotted in fold over empty vector.
Error bars represent standard deviations of three independent biological
replicates. (D) Binding profile and expression change of four ESTs bound
by p53. In the upper panel, the ChIP-on-chip data is visualized. In the
lower left panel, these binding sites are confirmed by targeted ChIP for p53.
Shown is the enrichment in fold over negative control (myoglobin). In the
lower right panel, the expression change of the EST is shown after 24 h of
5 nM Actinomycin D treatment in fold over untreated U2OS cells. Error
bars represent standard deviation of three independent experiments.
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Robinson et al., 2004), we found several new groups of target genes
that have not been linked to p53 function before or that expand p53’s
functions such as the phosphorus and biopolymer metabolism group
(Figure 20A). Metabolic changes occur in many cancers and recently
p53 has been linked to changes in metabolism (Bensaad et al., 2006).
The fact that we find metabolism-related genes significantly enriched
in our binding site list could well indicate that p53 plays an even wider
role in metabolic changes besides the so far described function of p53 in
glucose metabolism and oxidative stress (Bensaad and Vousden, 2007).
To study the involvement of our identified p53-target genes in en-
tire biological pathways, we classified them according to the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) using FatiGO+ (Al-
Shahrour et al., 2004). Axon guidance and calcium-signaling pathways
(Figure 20B) are significantly overrepresented in our dataset, suggesting
a hitherto undescribed role for p53 in these biological processes. To
study the axon guidance target gene group further, we randomly chose
three genes from this group for our analysis: SEMA3C, SEMA6A and
SEMA3A (Figure 20C, upper panel). We validated the ChIP-on-chip
data (Figure 20C, upper panel) by targeted ChIP and found a significant
enrichment of p53 binding upon Actinomycin D treatment of U2OS
cells to all tested sites (Figure 20C, lower panel). Thus, it remains to be
elucidated which role the target genes from the axon guidance group
could play during the p53-mediated stress response.
5.2.4 Development of p53scan, a novel p53-motif finding algorithm
The p53 DNA binding site has been characterized and is consistently
described as two copies of the half-site RRRCWWGYYY separated by a
spacer of 0-13 bp, where R = purine, W = A or T and Y = pyrimidine.
Although this may be the most optimal sequence for p53 binding, only
52 out of the 1,546 binding targets in this study contain a perfect match
to this sequence. Thus, the p53 motif shows a high degree of degener-
acy, which could create the versatility of different p53-mediated stress
responses in vivo. Different approaches for identifying the degenerate
p53-consensus binding motif have been described. Most are based on
a PWM scoring method although recently an algorithm based on ex-
perimentally measured binding affinity was shown to give interesting
results (Veprintsev and Fersht, 2008).
An accurate PWM which correctly reflects the binding preference of
a transcription factor is a crucial parameter for identifying binding sites
with PWM algorithms. The different PWMs that have been described
for p53 until now were constructed based on only 17 (TRANSFAC) to
39 (Wei et al., 2006) binding sequences. Consequently, these PWMs only
reflect the information present in those few sequences. Therefore, not
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Figure 20: Functional annotation of identified p53-binding sites. (A) All Ensembl
genes within 5 kb of an identified p53-binding site were annotated according
to the Gene Ontology (GO) using Ontologizer. Significantly enriched
groups (P < 0.05) are indicated with an asterisk. Shown is a selection of
GO categories. (B) All Ensembl genes within 5 kb of an identified p53-
binding site were annotated according to Kyoto Encyclopedia of Genes
and Genomes (KEGG) using FatiGO+. Significantly enriched pathways
(P < 0.05) are indicated with an asterisk. Shown are the five pathways
with the highest number of p53-bound genes. (C) Binding profile of p53
target genes involved in the axon guidance pathway. In the upper panel the
ChIP-on-chip data is visualized. In the lower panel these binding sites are
confirmed by targeted ChIP for p53. Shown is the enrichment in fold over
negative control (myoglobin).
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Figure 21: Development of p53scan, a p53-motif finding algorithm. (A) p53
motif identified de novo with MDmodule, visualized using WebLogo. (B)
ROC curve comparing p53scan, p53MH and Match. The FPR used to
characterize the p53-binding sites (~7%) is marked. (C) Distribution of
spacer length in the p53 consensus sites based on the p53scan algorithm.
surprisingly, using p53MH (which uses a PWM based on 37 sequences)
with a cutoff of 90 as suggested by the authors (Hoh et al., 2002), we find
that only 33% of our high-confidence binding sequences contain a motif.
Having identified a set of genome-wide binding sites, we wondered
if we could use the information encompassed in a wide variety of
p53-binding sites to develop a more sensitive algorithm. We randomly
selected 773 sequences (one half of our identified binding targets) and
ordered these based on the ChIP/Total ratio of the highest probe in
the peak. We used the de novo motif prediction program MDmodule
(Liu et al., 2002) on the ordered sequences to predict the p53 motif
(Figure 21A). The PWM was constructed from these results (matrix
shown in Table S2) and combined with a scoring scheme adapted from
the p53MH model. This approach enabled us to greatly increase the
amount of binding sequences with an identified p53 motif up to 83%
(FPR ~7%).
The performance of our algorithm, p53scan, was benchmarked on
the binding sites identified in this study (the ones not used for training)
and the human p53-binding sites identified previously by ChIP in
combination with paired end tag sequencing (ChIP-PET 3+, Wei et al.,
2006). We compared the performance to p53MH and to the Match
algorithm (Kel et al., 2003) with the p53 PWM from TRANSFAC, using
three different metrics: ROC AUC, MNCP (Clarke and Granek, 2003)
and the harmonic mean of precision and recall (F-measure). The training
and benchmarking process was repeated in ten independent runs and
the average results are shown in Table 7. We implemented the best
performing PWM in p53scan, and compared the performance on all
binding targets to p53MH and Match (Figure 21B). We also compared
p53scan to the ChIP-PET algorithm described by Wei et al. (Wei et al.,
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p53 chip-on-chip p53 chip-pet 3+
mncp auc f-measure mncp auc f-measure
p53scan 8.67 0.90 0.86 3.97 0.93 0.91
p53MH 5.62 0.83 0.76 3.37 0.86 0.81
Match 7.35 0.82 0.82 3.49 0.87 0.81
Table 7: The performance of p53scan
2006) using the ChIP-PET 3+ sequences. The authors identified 72%
of these sequences as having a motif using p53PET with an estimated
FPR of 0.68%. Using p53scan on their sequence set with the same
estimated FPR, we find a p53-binding motif in 82% of the binding sites.
These results clearly show that p53scan can identify more p53 motifs
in the evaluated sequence sets than the currently described algorithms,
without lowering specificity.
The possibility of a spacer within the p53 motif deserves special
consideration. If all spacer lengths from 1 to 13 are considered without
specifying additional constraints the false positive rate of a PWM al-
gorithm like p53scan greatly increases, due to the greater number of
possible motifs that is evaluated. As can be seen in Figure 21C most of
our p53-binding motifs actually do not have a spacer between the two
half sites. Therefore by default p53scan employs a strict score threshold
for all spacer lengths other than 0. The score threshold for each individ-
ual spacer length was selected by scanning a background sequence set
(random nonbound sequences of equal length) for each spacer length
and selecting the cutoff that resulted in no hits. Thus, we have developed
a highly specific and inclusive algorithm to identify p53-binding motifs,
which is freely available at: http://www.ncmls.nl/bioinfo/p53scan.
5.2.5 Characterization of the p53-binding motif
The p53scan cutoff resulting in the highest F-measure (FPR ~7%, as
marked in Figure 21B) represents a balance between retrieving false
positives and missing false negatives. We have used this setting to
analyze and further characterize the bound target sites identified in this
study. We found the p53 motif in 1,281 out of 1,546 (83%) binding sites.
We determined the location of the consensus motif with respect to the
ChIP-on-chip data and found it to be located mainly in the centre of the
peaks (Figure 22A). To study whether there is a correlation between the
ChIP/Total binding ratio of p53 and the occurrence of the p53-binding
motif, we ranked the identified p53-binding sites according to their
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Figure 22: Characterization of the p53-binding motif. (A) Histogram of the dis-
tance of the p53 consensus site to the probe with the highest mean ratio
within a binding site, based on the p53scan algorithm. (B) Percentage of
binding sites containing a motif relative to binding ratio. The identified p53-
binding sites were ranked according to their binding ratio (log2 ChIP/Total)
and divided into three groups ranging from low to high ratios. Shown for
each group is the percentage of sequences containing a motif, based on the
p53scan algorithm. (C) Average binding ratio (log2 of ChIP/Total) relative
to the number of mismatches to the p53 consensus site visualized in a
boxplot. Data based on p53scan results
relative binding enrichment (log2 ChIP/Total) and divided them into
three subgroups of low, medium and high ratios. The percentage of
binding sites, which contain the p53-binding motif increased slightly
with the binding ratio of the peaks. In the high-enrichment subgroup
(468 sites with a log2 ChIP/Total ratio of at least 3.17), almost 90% of
the p53-binding sites contain a p53-binding motif (Figure 22B).
Next, we analyzed the binding enrichment as measured by ChIP/Total
signal ratio in relation to the exact composition of the consensus site.
We averaged the binding ratio as a function of the number of mis-
matches to the consensus motif (Figure 22C). This shows that there is a
correlation between enrichment in vivo as measured by ChIP-on-chip
and the nucleotide composition of the p53-binding motif.
Since 52 (~11%) of the sequences in the high subgroup, consisting
of the most highly enriched targets (Figure 22B), do not contain a p53-
binding motif as identified by p53scan, we tried to further characterize
the motifs in these sequences. When we expand the peak area to 1.5 kb,
p53scan can find a binding motif in 43 out of the 52 sequences, using
settings that result in only 15 motifs found in 1,500 random coding
sequences of equal length (FPR ~1%). In these cases, the actual calling
of the peak area could have been imprecise, most likely due to the
binding site being located in repeat-masked areas. Remarkably, when
we take these matches into account, in total 98% of the sequences in the
high subgroup contain a p53 motif.
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5.2.6 Transcription factor binding motifs in the vicinity of the identified
p53-binding sites
Corecruited DNA-binding factors (Coutts and Thangue, 2005) have
been invoked to play a role in the flexible response of p53 to various
stress signals. We therefore analyzed the vicinity of the p53 sites (500
bp centered on the peak of the p53 binding) for the potential presence
of other known transcription factor binding sites, using TAMO (Gordon
et al., 2005) with the TRANSFAC database (Matys et al., 2003). Predicted
binding sites of eight different motifs of transcription factors were found
to be significantly overrepresented in the surrounding sequences of
the p53-binding sites (Figure 23). Among those were potential binding
sites for Krüppel-like factors (KLF), Sp1/Sp3, the group of basic helix-
loop-helix (bHLH) proteins, AP1, AP2, MZF1, CP2 and ETS2. Many
of these factors that we have found to be statistically enriched in our
genome-wide collection of p53-binding sites have been experimentally
shown to influence p53-dependent transcriptional activity for single
target genes. The most overrepresented motif in our dataset are the
motifs for KLF; it has been suggested that KLF4 is a mediator of p53 in
controlling progression of the cell cycle following DNA damage (Yoon
et al., 2003). Interestingly, p53 has been reported to require cooperation
of Sp1 or a Sp1-like factor for the transcriptional activation of the human
BAX promoter (Thornborrow and Manfredi, 2001) as well as for p21
(Koutsodontis et al., 2001). To find out if the potentially cobinding tran-
scription factors might influence p53-transcriptional activity towards a
specific direction of the response pathway, we looked at the different
subsets of the p53-binding sites containing a specific motif. We analyzed
the potential biological significance of the genes, which are within 5
kb of these binding sites using GO annotations, as described above.
Three significantly enriched GO categories were found for the cobind-
ing factors: developmental, metabolic and cell-cell signaling pathways
(Table 8). In all three pathways p53 has been reported to play a role.
Our data thus supports the notion that the response pathways of p53
might be influenced by the identified potential cobinding transcription
factors.
5.2.7 p63 and p73 binding to p53 targets
The p53 family members p63 and p73 have been reported to contribute
to the p53 stress response in certain tissues in vivo (Flores et al., 2002,
2005). They might play a role in the regulation of transcriptional ac-
tivities of p53 as well as potential cobinding transcription factors as
evidenced by their influence on p53’s ability to bind to various apop-
totic promoters in vivo (Flores et al., 2002, 2005). Furthermore, Yang et
98 the genome-wide p53 binding repertoire
KLF/PAX4/
Sp1
576 2.11e-21 19.77
0
1
2
bi
ts
1 2 3 4 5 6 7
Sp1 96 5.34e-20 18.37
0
1
2
bi
ts
1 2 3 4 5 6 7 8 9
bHLH 681 5.78e-09 7.34
0
1
2
bi
ts
1 2 3 4 5 6
AP2 14 2.31e-06 4.73
0
1
2
bi
ts
1 2 3 4 5 6 7 8 9 10 11 12
MZF1 576 3.32e-05 3.58
0
1
2
bi
ts
1 2 3 4 5 6 7
CP2 72 1.09e-04 3.06
0
1
2
bi
ts
1 2 3 4 5 6 7 8 9 10 11
ETS2 33 2.38e-04 2.72
0
1
2
bi
ts
1 2 3 4 5 6 7 8 9 10 11 12 13 14
AP1 269 1.74e-02 0.86
0
1
2
bi
ts
1
C
2 3 4 5 6 7
Factor Number
of
sequences
Significance MotifP-value
Figure 23: Overrepresented transcription factor binding motifs in the vicinity
of identified p53-binding sites. Known transcription factors motifs
identified in the 500 bp region centered around p53-binding sites based on
TRANSFAC 6 database. Statistical significance (P < 0.05) was calculated
using TAMO. Motifs were visualized using WebLogo.
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transfac go term go description p-value
MZF1 GO:0007275 Multicellular organismal de-
velopment
0.03
bHLH GO:0007275 Multicellular organismal de-
velopment
0.04
bHLH GO:0019219 Regulation of nucleobase,
nucleoside, nucleotide and
nucleic acid metabolic pro-
cess
0.04
CP2 GO:0007267 Cell-cell signaling 0.04
AP1 GO:0007275 Multicellular organismal de-
velopment
0.05
Table 8: Enriched TRANSFAC motifs involved in a biological function
al. (Yang et al., 2006) studied the genome wide binding of p63 and iden-
tified a p63-specific motif. Since this motif strongly resembles the motif
to which p53 binds, we were interested if and to what extent p63, and
the other p53 family member p73, can bind to our identified p53 global
binding sites. Because of possible cell-type specific differences in the
transcriptional response pathways of the p53-family, a cellular system
was needed that would allow a direct comparison between p53, p73 and
p63. We generated Saos-2 cell lines expressing TAp63α, TAp73α or p53
under a tetracycline-inducible promoter. We performed ChIP-on-chip
analysis for p63 and p73 as well as overexpressed p53 on the dedicated
array. Comparing the binding sites identified for endogenous p53 in
U2OS cells to those identified for exogenous p53 in the Saos-2 p53 cell
line, we found that 1,112 of the endogenous binding sites (72%) are
bound by exogenous p53 as well. Very interestingly, if we compare these
1,112 p53 exogenous-binding sites, which overlap with the binding sites
occupied by wt endogenous p53, 72% of those p53-binding sites could
also be bound by p73 and/or p63 in vivo (Figure 24). With the majority
of the p53-binding sites also being bound by p73 and p63, there seems
to be good evidence that p63 and p73 could play an important role in
the p53 transcriptional response pathways.
To investigate whether binding sites that can be bound only by
p53 or also by p73 and p63 show sequence differences, we compared
the p53 motif based on p53scan in shared binding sites (Figure 24B,
upper panel) and binding sites which are not bound by p63 and p73
(Figure 24B lower panel). These motifs very much resemble each other,
independently of whether they are bound by p53 only or by all three
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Figure 24: p63 and p73 binding to p53 targets. (A) Overlap of p53-binding sites
also bound by p63 and p73 in Saos2 inducible cell lines as determined by
ChIP-on-chip on the dedicated p53 array. (B) p53 motif identified with
p53scan, visualized using WebLogo for p53-binding sites also bound by p63
or p73 (upper panel) and binding sites only bound by p53 (lower panel).
family members. Accordingly, p63 and p73 are actually able to bind
sequences containing this p53-binding motif on a global scale. The
p53-binding motif was identified in 86% of the shared binding sites
and in 76% of the binding sites for p53 only. It remains to be elucidated
which other parameters of a p53-binding site determine whether it
can be bound by p53 only or also by the family members. It has been
shown in vitro that five specific bases in the p53 consensus sequence are
important for stable binding of p73 to DNA (Lokshin et al., 2006). These
specific nucleotides are present in 9.6% of the motifs found by p53scan
in the shared binding sites, and in 10.8% of the motifs in p53-only
binding sites. Therefore, according to our observations this specific
characteristic of the p53 consensus motif cannot explain the difference
between p53 only and shared binding site of our genome-wide in vivo
binding data.
Besides differences in the p53 motif, we also analyzed the p53 only
versus the shared binding sites in respect to their genomic location, GO
annotation, and the potential presence of other known transcription fac-
tor binding sites, as described above, but could not observe significant
differences (data not shown). Thus, we found that the DNA binding
characteristics of the p53-binding sites which were bound by its family
members closely resemble those that were bound by p53 only.
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5.3 discussion
5.3.1 Genome-wide identification of p53-binding sites
To characterize the transcriptional mechanisms of the p53-mediated
stress response, we analyzed p53 binding to chromatin on a genome-
wide scale using the ChIP-on-chip approach and identified 1,546 high-
confidence binding sites.
While these binding sites were significantly enriched in TSS flanking
regions, encompassing possible promoters, a large fraction was located
in intragenic or intergenic regions, as also observed in other studies
(Wei et al., 2006; Hearnes et al., 2005). We and others have provided
evidence for functionality of these intergenic binding sites. In our
reporter assays, we could show that the intergenic and intragenic p53-
binding sites can function as enhancers. Likely, the interaction between
enhancer and target gene is mediated via loop formation, as shown
for example for the Hoxd gene cluster and the β-globin locus (Li et al.,
2006). Furthermore, the intergenic-binding sites could be involved in
regulation of nonprotein coding genes as well as other novel transcripts,
as has been suggested by smaller scale ChIP-on-chip analyses (Cawley
et al., 2004). In our study, we discovered that unannotated transcripts
located near intergenic p53-binding sites can be upregulated upon p53
activation.
5.3.2 Motifs in the p53-binding site
We have developed a new algorithm, p53scan, which incorporates the
motif derived de novo from the genome-wide binding sites identified
in this study as shown in Figure 21A. Although this motif resembles
the different versions of the p53-binding motif described up to now, it
more accurately reflects the in vivo binding preference of p53, as this
new motif is based on information from hundreds of binding sites.
Indeed, comparisons of p53scan to other publicly available algorithms,
including p53MH, which has been most widely used, show that it
produces markedly better results in the metrics that were tested in this
study. In addition, we compared p53scan to the algorithm developed
by Wei et al. (Wei et al., 2006), called p53PET model, with the sequences
identified in their study as input. We found more sequences containing
a motif with p53scan than with p53PET model (82% versus 72%) at
the same specificity level. This confirms that the sensitivity of p53scan
is not limited to the binding sites of our ChIP-on-chip dataset, but
that it can also be used for future analysis of other binding data. As
a publicly accessible, intuitive and above all sensitive and specific
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algorithm, p53scan is a useful addition to the available tools that will
help characterize the widely diverse binding preference of p53.
When analyzing our p53-binding sites with p53scan, 83% of the
identified binding sites contained a motif that is reminiscent of the
p53-binding motif. The predominant motif has no spacer in between
the two half-sites, although there is a small fraction with a spacer of
one nucleotide. This is in agreement with the genome-wide spacer
distribution found previously (Wei et al., 2006). In the most highly
enriched group of target sites, nearly all bound sequences contain our
p53-consensus motif. This suggests that almost all highly enriched p53-
binding sites are bound in a direct sequence-specific manner dependent
on the consensus motif. Of all the identified binding sites, in 17%
p53scan cannot detect the p53 consensus motif. Although previous
studies have also found p53-binding sites without a detectable p53-
consensus motif (Kaneshiro et al., 2007; Wei et al., 2006), we find less of
those binding sites in our study using the more inclusive identification
of the motif by p53scan. The fact that no p53 motif can be identified in
a small subset of binding sites can have several reasons: either p53 is
also able to bind purely on the basis of DNA topology independent of
the sequence (Göhler et al., 2002), or it might bind to a different motif
like microsatellites for the PIG3 target gene (Contente et al., 2002). The
remaining sites without a common motif could of course also be bound
due to indirect binding of p53 to chromatin.
By grouping the binding sites according to their ChIP/Total ratio,
we found a positive correlation with both the percentage of binding
sites containing a p53-binding motif, as well as the degree of similarity
of the identified motifs with the p53 consensus motif. Thus, the more
the binding sequence resembled the p53 consensus motif, the higher
the ChIP/Total ratio. This is in accordance with the structural data of
DNA-bound p53 that showed that protein-DNA interfaces vary as a
function of the specific base sequence of the DNA (Kitayner et al., 2006).
From this structural data, it was also concluded that the differential
binding affinity is correlated with sequence-specific variations, which
have a direct influence on the protein-DNA contact geometry.
The binding of p53 to DNA occurs in the context of other transcrip-
tion factors and cofactors. It has been shown for individual target genes
that other transcriptional activators or repressors can act together with
p53 and can have differential effects on the transcription of target genes.
Therefore, we analyzed common cis-elements among the genome-wide
set of p53-binding sites. We find potential SP1-binding sequences to
be highly enriched in the vicinity of p53-binding sites in our global
approach; p53 has been reported to require the cooperation of Sp1 or a
Sp1-like factor for transcriptional activation of the human BAX and p21
promoter (Thornborrow and Manfredi, 2001; Koutsodontis et al., 2005).
5.3 discussion 103
For bHLH motifs, which we found to be enriched in our set of target
sites, it is known that the p53 promoter itself contains a functional
consensus sequence for bHLH proteins. In the murine p53 promoter,
this element has been shown to be required for full promoter activity
(Demonacos et al., 2001). The fact that we find bHLH motifs enriched
in the vicinity of p53-binding sites, shows that these factors might be
involved in a positive feedforward regulation of p53 pathways. Thus,
our findings extend the analysis of the transcriptional environment of
single targets to a larger subset of target genes derived from a global
screen. In the future, we will need to elucidate what biological conse-
quences might result from certain combinatorial interplay between p53
and other cobinding factors. Therefore, an interesting challenge will lie
in the elucidation of which transcription factor complexes can be found
at which p53-target genes and whether certain biological responses
appear to be dependent on the macro-molecular transcription factor
complexes at p53-binding sites. A first interesting approach to purify
macromolecular complexes at different subsets of p53-target genes was
done by Tanaka et al. (Tanaka et al., 2007) by fractionating cross-linked
p53-associated chromatin and identifying the human cellular apoptosis
susceptibility protein (hCAS/CSE1L) in the one fraction of a subset of
p53 target promoters, including PIG3, in a p53-autonomous manner.
Thus, it remains to be seen whether also for other cellular response
pathways specific combinations of cobinding factors can be isolated at
p53-target genes.
5.3.3 Global binding of p73 and p63 to p53-binding sites
For the first time, we investigated on a global scale to which extent
p53-binding sites can be occupied by p73 and p63 upon a specific stress
signal in vivo. We found that 72% of the p53-binding sites can also be
bound by p73 and/or p63. Some groups have postulated differences
in binding motif for the p53 family members, but this is mostly based
on individual targets or in vitro derived data. Lokshin et al. (Lokshin
et al., 2006) showed the importance of five bases in the p53 consensus
sequence for stable binding of in vitro p73 to DNA. In our global binding
site set, we cannot differentiate between the sets of shared and p53-only
binding sites on the basis of this sequence difference. The fraction of
motifs containing these five bases was comparable in both sets. We
could also not identify a significant difference between the motif for
p53 in shared binding sides or sites exclusively bound by p53. The
fact that we did not find specific motif variation, is in agreement with
the genome-wide screen for p63-binding sites by Yang et al. (Yang
et al., 2006) and in vitro studies from Perez et al. (Perez et al., 2007),
which showed with a SELEX approach that p63 binds principally to
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the p53-consensus motif, preferentially to a slightly more degenerate
form of it. Therefore, we conclude that p63 and p73 can bind to p53-
binding sites on a large scale, which may imply that the stress response
is mediated in part by either competitive or cooperative binding of
p53 family members to target genes. Alternatively, this could hint at
the possibility that p63 and p73 are capable of taking over part of the
function of p53 if needed.
This study provides a global set of high-confidence p53-binding
sites, which greatly expands the known, experimentally validated p53
binding repertoire and gives a global insight into their characteristics.
These data can serve as a valuable knowledgebase for further research,
in which new functional studies will help to further clarify the complex
role of p53 and its family members.
5.4 materials and methods
5.4.1 Cell culture and drug treatment
The human osteosarcoma cell lines U2OS expressing endogenous wild-
type p53, and Saos-2, which are p53 null (Kubbutat et al., 1998), were
maintained in Dulbecco’s modified Eagle medium supplemented with
10% fetal calf serum at 37°C. The Tet-on inducible expression system
(BD Biosciences, Breda, The Netherlands) was used in Saos-2 cells to
generate cell lines that conditionally express FLp53, TAp63α or TAp73α.
cDNA of the gene of interest was cloned into the pTRE vector and
cotransfected with the pZoneXN, which has a puromycin selection
marker, into Saos-2 cells. Transfections were performed by the cal-
cium phosphate precipitation method. Stable clones were selected with
1µg/ml puromycin (Sigma, Zwijndrecht, The Netherlands). To induce
the expression of FLp53, TAp63alpha or TAp73alpha, 2 µg/ml doxycy-
clin (Sigma), a Tetracyclin homologue, was added to the medium. The
inducible Saos-2 cell lines were first induced with doxycyclin for 24 h
and then treated with 5 nM Actinomycin D (Sigma) for another 24 h.
The U2OS cells were treated with 5 nM Actinomycin D for 24 h.
5.4.2 Cell cycle analysis
Cells were induced and treated as described above. The cells were fixed
with 96% ethanol and stained with propidium iodide (Sigma). DNA
content was analyzed by flow cytometry (Becton Dickinson FACScan)
and analyzed using CellQuest Pro software.
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5.4.3 Immunoblotting
To assess protein levels, proteins from whole-cell extracts were har-
vested, lyzed and separated by SDS-PAGE and analyzed by western
blotting with α-p53 (DO1, BD PharMingen, Breda, The Netherlands).
5.4.4 Transactivation assays
The selected binding sites were amplified from genomic U2OS DNA
and cloned behind the luciferase gene into the pGL3-promoter vec-
tor (Invitrogen, Breda, The Netherlands), which contains a luciferase
reporter gene behind a SV40 promoter. U2OS cells were transiently
transfected with pGL3 constructs and a pRL-TK reporter (Promega,
Leiden, The Netherlands), constitutively expressing Renilla as a normal-
ization control, by calcium phosphate transfection. Cells were lyzed and
luciferase activity was measured using the Dual-Luciferase Reporter
Assay System (Promega).
5.4.5 RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini kit according to
protocol (Qiagen, Venlo, The Netherlands). For cDNA synthesis, reverse
transcription was performed with 1 µg of the total RNA, oligodT
anchor primers, dNTPS, DTT, buffer and Superscript Retrotranscriptase
(Invitrogen). cDNA was analyzed by qPCR using a MyIQ machine
(Biorad, Veenendaal, The Netherlands). Primers used for real-time PCR
are available upon request.
5.4.6 ChIP and ChIP-on-chip
Chromatin immunoprecipitation (ChIP) was essentially performed as
described by Denissov et al. (Denissov et al., 2007). The cells were
sonicated using a Bioruptor sonicator (Diagenode, Liege, Belgium) for
15 min at high power, 30 s ON, 30 s OFF. Antibody incubation with
chromatin from U2OS cells treated with Actinomycin D was performed
overnight at 4°Cwith 2 µg of DO1 antibody (BD PharMingen). For ChIP
experiments in Saos-2 inducible cell lines DO1 (BD PharMingen), 4A4
(Abcam, Cambridge, UK) and BL906 (Abcam) were used for p53, p63
and p73, respectively. Real-time PCR was performed using the SYBR
Green mix (Biorad) with the MyIQ machine (Biorad). Primers used for
real-time PCR are available upon request. To produce more material
for a ChIP-on-chip, the total DNA and ChIP DNA needed to be ampli-
fied. For genome-wide hybridization, the material was amplified using
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LM-PCR amplification (Ren et al., 2000). The T7-based amplification
procedure (Liu et al., 2003) was used for the hybridizations on the dedi-
cated arrays. The total DNA and ChIP DNA were hybridized to whole
genome tiling arrays (HG17Tiling Set) or custom designed microarrays
manufactured by NimbleGen Systems, Inc., Madison, WI, USA. Raw
data for all microarray hybridizations are available at ArrayExpress
(http://www.ebi.ac.uk/arrayexpress) under accession E-TABM-442.
5.4.7 Custom microarray design
Peak detection (see below) was performed on the genome-wide dataset
and all probes within the positive regions recognized by the peak de-
tection procedure, extended equally up- and downstream to a total of 2
kb, were spotted on a custom design array (NimbleGen Systems), here-
after referred to as dedicated design. All the probes from a continuous
region of chromosome 21 (from 28,692,406 to 41,270,931) on the hg17
array were included in the dedicated design to provide a baseline for
normalization purposes. This region is hereafter referred to as tilepath.
5.4.8 Data normalization
The probe sequences from both the whole genome and the dedicated
design were compared to the human genomic sequence with BLAT
(Kent, 2002). Probes with 10 or more matches were discarded for use in
the subsequent analysis. The raw probe ratios were normalized within
arrays using Tukey’s biweight. For all hybridizations performed on the
dedicated array, the ratios were normalized against the tilepath region.
5.4.9 Peak detection
The microarray data were analyzed using three different peak detection
programs to identify putative targets with a high degree of confidence.
Default parameters were used except where noted. The proprietary
program provided by NimbleGen was run with a 1% false positive rate.
For Tilemap (Ji and Wong, 2005), hybridization length was set to 50
and maximal gap size to 100. All probes with posterior probability of
at least 0.9 were defined as peaks. For Mpeak (Zheng et al., 2007), the
maximum gap was set to 300, and a minimum log2 ChIP/Total ratio of
at least 2.5 SD was used as a threshold. All positive regions or peaks
< 1 kb in length were extended equally up- and down-stream to cover
1 kb. Per biological replicate all regions determined to be positive by
one of the programs were combined. Finally, a peak was defined as a
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binding target if positive regions shared any overlap in each biological
replicate.
5.4.10 Mapping binding sites to genes
Target locations were mapped to NCBI 36 coordinates using the Batch
Coordinate Conversion (liftOver) utility provided by the UCSC Genome
Bioinformatics group. Gene locations of all genes were downloaded
from Ensembl (release 43, February 2007, Hubbard et al., 2007). To map
a target to a gene, the distance from the middle of the target to the
Ensembl gene start was used.
5.4.11 Annotation of genes
For annotation of genes, only target genes with a binding site within
5 kb of the gene were used. Overrepresented Gene Ontology (GO)
(Ashburner et al., 2000) categories within annotation of the target genes
were determined with Ontologizer using the parent-child method,
which takes into account the parent-child relationships of the GO
hierarchy (Grossmann et al., 2007). The P-values were adjusted using
Westfall-Young single-step multiple testing correction and a corrected
P-value threshold of 0.05 was used as a cut-off for reporting significant
matches. Genes were annotated with KEGG pathways (Kanehisa, 2006)
using Fatigo+ (Al-Shahrour et al., 2004). Overrepresented pathways
were determined according to the hypergeometric distribution with a
P-value threshold of 0.05.
5.4.12 The p53scan algorithm and motif analysis
Sequences of equal length were selected for all targets by determining
the probe with the highest mean ratio value within each peak and
selecting a 500 bp region centered on this probe. All probes within
regions on the slide of at least 10 consecutive probes, or 1 kb, with a
maximum mean log2 ChIP/Total ratio of 0.5 were selected as back-
ground sequences. These sequences were divided in 500 bp regions to
create sequences of the same length as the target sequences.
To determine the optimal positional weight matrix (PWM) for p53scan,
the de novo motif discovery program MDmodule (Liu et al., 2002) was
applied to half of the 500 bp target sequences, 773 in total. Sequences
were ordered based on the ChIP/Total ratio of the highest probe in the
peak. MDmodule was run with a width of 20 and the number of top
sequences to look for motifs was set to 200. Default parameters were
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used for all other options. The MDmodule output was subsequently
converted to a PWM.
In p53scan, the score of a subsequence x of length L is calculated as
follows:
L∑
i=1
ln(
fi,b
g
+ z) (5.1)
where fi,b is the fraction of each nucleotide at position i, g is 0.25 and
z is 0.01.
To incorporate a variable spacer length, the two half-sites are scanned
separately and the scores for each half-site are combined. Cutoffs for
spacer lengths greater than 0 were determined by scanning 10 times as
many random nonbound sequences and choosing the threshold that
result in no hits. This enables p53scan to take high-scoring motifs with
spacer lengths other than 0 into account without drastically changing
the false positive rate (FPR).
To test the performance of the algorithm and to compare it to other
available algorithms, the 773 sequences not used for training were
compared to a background set of five times as many random nonbound
sequences. Three different metrics were used for comparison:
1. The area under the receiver operator curve (ROC AUC), which
reflects the balance between the false positive rate and the true
positive rate.
2. The mean normalized conditional probability (MNCP) as de-
scribed by Clarke and Granek (Clarke and Granek, 2003).
3. The maximum F-measure or weighted harmonic mean of preci-
sion and recall.
Recall =
True Positives
True Positives+ FalseNegatives
(5.2)
Precision =
True Positives
True Positives+ False Positives
(5.3)
F−measure =
2 · Precision · Recall
Precision+ Recall
(5.4)
The process of randomly selecting training, test and background
sequences and subsequent performance comparison was repeated in
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10 independent runs. In all cases the performance was comparable.
The best scoring PWM was kept and implemented. All 1,546 targets
were compared to five times as many randomly selected noncoding
sequences of equal length to produce Figure 21B. Subsequently, p53scan
was used to analyze the complete set of target sequences with a score
cutoff of 4.393 for spacer length 0 resulting in the highest F-measure,
corresponding to an estimated FPR of ~7%.
For de novo motif prediction of possible cofactor motifs, the motif
discovery program MDmodule was applied to the 500 bp target se-
quences. The same procedure as described for the p53scan PWM was
followed. The number of top sequences to look for motifs was set to
100, all widths from 6 to 16 were considered, and the number of motifs
to report was set to 10. To calculate the significance of the discovered
motifs, the number of sequences with at least one motif instance with
0.8 x maximum possible score was determined in both the sample and
the background sequences using TAMO (Tools for Analysis of Motifs)
(Gordon et al., 2005). For each motif a P-value was calculated using the
hypergeometric distribution. The corresponding significance value was
calculated as Significance(S) = −log10(P− value).
As selection criteria, we used a significance cut-off of 1.3 correspond-
ing to a P-value of 0.05 with a minimum of occurrence of at least
10 times. All significantly enriched motifs were clustered using a k-
medoids clustering algorithm as described in (Harbison et al., 2004).
Clustered and aligned motifs were averaged to produce consensus
motifs. The significance of the resulting motifs was determined as
described in the previous paragraph.
To analyze target sequences for known motifs, the sequences were
scanned with all the position weight matrices from the TRANSFAC
database (public release version 6.0) (Matys et al., 2003) and further
analyzed as described in the previous de novo motif prediction section.
Similar motifs were grouped and averaged.
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6C R O S S TA L K B E T W E E N C - J U N A N D TA P73α/β
C O N T R I B U T E S T O T H E A P O P T O S I S - S U RV I VA L
B A L A N C E
Max Koeppel, Simon J. van Heeringen, Daniela Kramer, Leonie
Smeenk, Eva Janssen-Megens, Marianne Hartmann, Hendrik G.
Stunnenberg, Marion Lohrum
The p53-family member p73 plays a role in various cellular signaling pathways
during development and growth control and it can have tumor suppressor
properties. Several isoforms of p73 exist with considerable differences in their
function. Whereas the functions of the N-terminal isoforms (TA and δNp73)
and their opposing pro- and anti-apoptotic roles have become evident, the
functional differences of the distinct C-terminal spliceforms of TAp73 have
remained unclear. Here, we characterized the global genomic binding sites
for TAp73α and TAp73β by ChIP-sequencing as well as the transcriptional
responses by performing RNA-sequencing. We identified a specific p73 con-
sensus binding-motif and found a strong enrichment of AP1 motifs in close
proximity to binding sites for TAp73α. These AP1 motif-containing target genes
are selectively upregulated by TAp73α, while their mRNA expression is re-
pressed upon TAp73β induction. We show that their expression is dependent
on endogenous c-Jun and that recruitment of c-Jun to the respective AP1 sites
was impaired upon TAp73β expression, in part due to downregulation of
c-Jun. Several of these AP1-site containing TAp73α-induced genes impinge on
apoptosis-induction suggesting an underlying molecular mechanism for the
observed functional differences between TAp73α and TAp73β.
Supplemental material is available online at http://nar.oxfordjournals.org/.
Published in Nucleic Acids Research, 2011.
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6.1 introduction
The transcription factors of the p53-family, p53, p63 and p73, maintain
the balance between cell survival and induction of apoptosis during
development, growth, differentiation and cellular stress. The members
of the p53-family thereby display common as well as specific functions
(DeYoung and Ellisen, 2007). They determine the cellular fate dependent
on the family member and isoform expressed in a specific tissue. The
p73 protein exists in multiple isoforms due to different promoter usage
at the N-terminus and to C-terminal splice events. The δNp73-isoforms
that are derived from an internal promoter antagonize the growth
suppressing, pro-apoptotic functions of p53 and of the full length
TAp73-isoforms in a dominant negative way by competing for the
respective binding sites (Moll and Slade, 2004). Overexpression of
δNp73-isoforms is found in several tumors (Zaika et al., 2002; Concin
et al., 2004) whereas mutations in the p73 gene are rarely found in
human cancers (Melino et al., 2002).
Under certain conditions, p53 is unable to induce apoptosis in the ab-
sence of p73 or p63 (Flores et al., 2002). Furthermore, mice heterozygous
for p53/p73 show a higher tumor burden compared to p53 heterozy-
gous mice (Flores et al., 2005). Although complete knockout of the
p73 gene in mice mainly leads to developmental defects (Yang et al.,
2000), the knockdown of only the TA-isoforms induces genomic insta-
bility, thus showing tumor suppressor activities of TAp73 (Tomasini
et al., 2008). TAp73 isoforms have been reported to play a role in DNA
damage pathways, since p73 is activated by ionizing irradiation and
cisplatin through c-Abl, thereby inducing apoptosis (Agami et al., 1999;
Yuan et al., 1999; Gong et al., 1999). Furthermore, TAp73-isoforms are
upregulated by different mechanisms through chemotherapeutic drug
induced DNA damage (Pediconi et al., 2003; Irwin et al., 2003).
The transcriptional function of p73 is complex because of the plethora
of p73-isoforms, which have varying transcriptional activity towards
target genes. In addition to shared target sites, the p53-family members
differ in their ability to transactivate common target genes like p21
(Laurenzi et al., 1998) or Bax (Melino et al., 2004; Flinterman et al.,
2005). Some genes are only induced by specific isoforms, like p57/kip2
by p73β but not by p73α or by p53 (Bálint et al., 2002).
Besides its function as a pro-apoptotic protein, several reports have
also described an inhibition of apoptosis or a support of growth by
TAp73 in certain cell lines under specific conditions (Toh et al., 2008;
Nyman et al., 2005). It has been shown, that a crosstalk between the
transcription factor c-Jun and p73 regulates growth and that c-Jun
enhances the function of p73 (Vikhanskaya et al., 2007; Toh et al., 2004).
6.2 results 113
However, the exact molecular mechanism of this crosstalk remains
unknown.
c-Jun is a member of the AP1 family of heterodimeric transcription
factors, regulating growth and apoptosis depending on the cellular
environment and on the composition of the respective dimer (Shaulian
and Karin, 2002). Dimers containing c-Jun mainly promote growth via
G1-progression through the transactivation of Cyclin D1 (Wisdom et al.,
1999). The fact that a c-Jun null mutation is embryonically lethal and
causes retarded growth of cultured cells underscores the importance
of c-Jun for cellular growth (Johnson et al., 1993). AP1 dimers can also
protect cells from UV-mediated apoptosis by negatively regulating p53
(Schreiber et al., 1999) and c-Jun is also required for re-entry of cells
into cell cycle after UV-induced p53 mediated growth arrest (Shaulian
et al., 2000). Due to the complexity of the many p73-isoforms and the
varying composition of the Jun/Fos dimers several different interactions
between p73 and Jun/Fos might be possible, probably with different
consequences for the cellular fate.
To gain insight into the molecular basis for the different physio-
logical function of TAp73α and TAp73β, we identified their bind-
ing sites by chromatin-immunoprecipitations (ChIPs) coupled with
deep-sequencing (ChIP-seq) and global expression analysis using RNA-
sequencing (RNA-seq). This revealed that the two TAp73-isoforms bind
to both shared and isoform-specific target sites and distinctly transacti-
vate target genes. We uncovered a p73-consensus motif that is present
in a large fraction of the p73 binding sites. The binding sites of TAp73α
but not those of TAp73β showed an overrepresentation of AP1 binding
sites to which c-Jun can bind simultaneously with TAp73α. The binding
of c-Jun to DNA is decreased upon TAp73β expression, which reduces
the mRNA and protein levels of c-Jun. The expression of distinct tar-
get genes with an AP1 site close to TAp73α binding sites depends on
c-Jun and they can influence apoptosis induction by TAp73α, possi-
bly explaining the different physiological responses mediated by the
respective TAp73-isoforms.
6.2 results
6.2.1 Physiological and molecular differences in the cellular responses to
TAp73α and TAp73β
The domain organization of the predominant TAp73α- and TAp73β-
isoforms shows some similarity with the related tumor suppressor p53,
but the three proteins differ completely in their C-terminus (Figure
25A). To characterize their common and distinct functions, we used
isogenic Saos cell lines (Smeenk et al., 2008) to express TAp73α and
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Figure 25: Differential physiological and molecular effects of TAp73α and
TAp73β (A) Domain structure of the p53-family members TAp73α,
TAp73β and p53. TA: transactivation domain; DBD: DNA binding do-
main; OD: oligomerization domain; SAM: sterile alpha motif; ID: inhibitory
domain. (B) Expression of TAp73α, TAp73β and p53 in Saos inducible
cell lines. Whole cell extracts or chromatin was harvested after 24 hr of
induction and protein levels were analyzed by western blot. (C) Induction
of apoptosis. Saos cells expressing the indicated member of the p53-family
were induced for 24 hr or 48 hr, before the amount of cells in sub-G1 phase,
as a measure for apoptotic induction, was counted using FACS. Error bars
indicate standard deviation (SD) derived from three independent exper-
iments, asterisks indicate statistical significance as shown by Student’s
T-test (p < 0.05). (D) Differential binding of TAp73α and TAp73β to
target genes, using p53 as a positive control. Saos TAp73 or p53 inducible
cells were induced for 24 hr before chromatin was isolated. Complexes of
TAp73 or p53 and chromatin were precipitated and qPCR analysis was
performed with primers for the putative binding sites and enrichment is
shown in fold over an unspecific control (myoglobin). SD results from
three independent experiments. (E) Expression changes upon induction
of p53-family isoforms. RNA from Saos cells was harvested 24 hr after
induction of the respective family-member. After cDNA synthesis qPCR
was performed with the indicated primers and results were normalized
against GAPDH expression. The induction was calculated as fold over the
normalized expression values from Saos2 parental cells. SD was calculated
from three independent experiments.
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TAp73β at comparable protein-levels as detected in whole cell lysates as
well as in the chromatin bound fraction (Figure 25B). As a comparison
the effect of p53 on apoptosis induction was included. To quantify the
degree of cell death after induction of TAp73α, TAp73β or p53, FACS
analysis was performed and apoptosis was measured as the sub-G1
cell population (Figure 25C). Whereas in the parental Saos2 cells only a
small proportion of cells undergo programmed cell death, the induc-
tion of TAp73α, TAp73β or p53 leads to an increase in the apoptotic
population. The levels of apoptosis after TAp73α induction are rather
modest. Upon TAp73β induction on the other hand, apoptosis lev-
els are three to eight times higher than in parental Saos2 cells, thus
comparable to p53 induced cell death. Since the different p53-family
members displayed distinct effects on the level of apoptosis induction,
we examined possible molecular causes for these differences. To ana-
lyze the DNA-binding capacities of the two p73-isoforms and p53 we
used chromatin-immunoprecipitation followed by qPCR (ChIP-qPCR).
As shown in Figure 25D binding of p53 and both TAp73-isoforms is
observed to the p21 and Mdm2 genes. It is higher for TAp73β at the p21
and Mdm2 binding sites than for TAp73α. Examining the transactivat-
ing potential of these p73-isoforms and p53 shows that both isoforms
increase the level of p21 mRNA, with a much stronger increase medi-
ated by TAp73β (Figure 25E). The mRNA level of Mdm2 is increased
upon TAp73β and p53 expression, but not upon TAp73α expression in
this cell system (Figure 25E). Thus, induction of TAp73α and TAp73β
had different effects on the transcriptional activation of target genes as
well as on the cellular apoptotic response.
6.2.2 Global binding profiles reveal common as well as distinct binding sites
for TAp73α and TAp73β
To shed light on the molecular mechanisms for the differential cellular
responses induced by the two TAp73-isoforms we compared their DNA-
binding site repertoire at a genome wide scale, performing ChIP-seq of
the TAp73-isoforms as well as of p53 (two biological replicates each). To
validate the reproducibility of the data-sets we compared the number
of reads per peak between two biological replicates and found a high
correlation (Supplemental Figure 1). Identifying binding sites by peak
calling on the combined data using MACS (Zhang et al., 2008), with
an input DNA sample as background control, resulted in 15,293 peaks
for TAp73α, 23,505 peaks for TAp73β and 9,878 peaks for p53 (Table 9).
We identified genome-wide binding sites that are shared by both p73
isoforms (10,319 sites) or are preferential for either TAp73α (4,196 sites)
or TAp73β (11,849 sites) exemplified by the Mdm2, IL1RAP and APOD
gene, respectively (Figure 26A-C).
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repl. uniquely reads number genes
no. mapped after of peaks with a
reads norm. peak
(million) (million) within 25kb
Saos control 1 14.82 14.82
Saos TAp73α 1 12.52 7.41
15,293 5,405
Saos TAp73α 2 13.77 7.41
Saos TAp73β 1 12.10 7.41
23,505 6,932
Saos TAp73β 2 13.08 7.41
Saos p53 1 5.53 3.00
9,878 5,665
Saos p53 2 14.71 3.00
Table 9: ChIP-seq results
Comparing the binding sites of TAp73α, TAp73β and p53, we found
that a large portion of binding sites is bound by all three proteins, but
also that a considerable number is preferably bound by only one of
the three proteins (Figure 26D). We found that 44% of the TAp73β
binding sites and 46% of the p53 binding sites, respectively, overlap
with TAp73α (Figure 26D). Thus, while there are many target genes
common between TAp73α, TAp73β and p53, there are also isoform and
family-member specific binding sites, possibly mediating the differen-
tial functions of TAp73α, TAp73β and p53. To gain further insight into
the characteristics of the DNA-binding sites we analyzed their genomic
distribution (Figure 26E). Both TAp73-isoforms show almost the same
genomic binding distribution being significantly enriched in promoter
regions, compared to genomic background, but not as pronounced as
the p53-binding sites from which almost one third are found close to
transcriptional start sites.
Since we have identified global binding profiles for TAp73α, TAp73β
and p53 expressed in isogenic Saos cell lines we wanted to verify that
these binding sites could be physiological target sites of endogenous
p73 and p53. Therefore, we have analyzed MDA-MB231-, HEK293-,
and HCT116- cell lines, which express p53 and p73 (Figure 27A, left),
for p73- and p53-DNA binding and compared it to the binding-events
in the different Saos cells used before. Binding to the positive control
p21 occurred in all cases (Figure 27A, right), while some binding sites
can be bound by p73 as well as p53 in several different cell lines, e.g.
binding sites close to the FAS, DCP1B and GDF15 gene (Figure 27B).
Furthermore we also identified target sites that are selectively bound
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by p73 only in specific cell lines, such as the METT10D, NDUFS2 and
DEDD gene (Figure 27C). Thus, binding sites originally identified in
Saos cell lines can also be found in cell lines expressing endogenously
p73 or p53. The isoform-specific occupancy appears to be cell-type
dependent.
6.2.3 Isoform-specific transcriptional responses
Having identified genome-wide binding sites for TAp73α, TAp73β and
p53, we were interested in the transcriptional consequences of the in-
duction of the three proteins and to which extent the DNA-binding and
transcriptional changes could be correlated. Therefore, we performed
global transcriptome analysis of TAp73α, TAp73β and p53 expressing
Saos cells using RNA-seq. Two biological replicates were sequenced
per cell line and the fold change relative to the Saos2 parental control
was calculated using DEGseq (Wang et al., 2010). The two p73 isoforms
show distinct expression signatures, with genes specifically regulated
after induction of TAp73α (485 genes) or TAp73β (575 genes), as well
as genes regulated in both cases (338 genes) (Figure 28A and B). The
previously reported, TAp73β-specific target gene p57/Kip2/CDKN1C
is also in our genome-wide RNA-seq data clearly induced only upon
TAp73β expression (Supplemental Figure 2A). Two newly identified
examples of isoform-specific regulation are shown in Figure 28C and
D: the SFN gene, specifically activated by TAp73α and the BGN gene,
specifically activated by TAp73β. Both genes are also differentially
bound by one of the p73-isoforms as seen in the ChIP-seq data being in
good agreement with the RNA-seq data. The GHRL3 gene on the other
hand showed binding and activation by both isoforms (Figure 28E). The
differential transcriptional response observed was further validated by
RT-qPCR proving good agreement with the RNA-seq results (Figure
28C-E, right).
The overlap between regulated genes and p73 binding sites is highly
significant. Of the TAp73α upregulated genes 49% have a TAp73α
binding site within 25 kb (p = 3.08E-19), and 50% of the TAp73β upreg-
ulated genes have a TAp73β binding site (p = 3.56E-7) (Table 10 and
Supplemental Table SI). The relation between binding and expression is
visualized in Figure 28F, which illustrates that differentially regulated
genes have a significantly higher association strength (Ouyang et al.,
2009) than unregulated genes (TAp73α p<2.2e-16, TAp73β p<2.2e-16).
Analyzing the functional annotation of bound and regulated TAp73α
and TAp73β target genes by GO analysis using DAVID (Dennis et al.,
2003; Huang et al., 2009) we uncovered a plethora of different physi-
ological aspects that appear to be regulated by TAp73α and TAp73β
(Supplemental Table SII). Most strikingly, both isoforms regulate the
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Figure 26: Global binding site analysis of p53-family members (A) Common
binding site for TAp73α and TAp73β. The lower track displays the location
of the Mdm2 proto-oncogene in the UCSC genome browser. The upper
track shows the binding site for TAp73α and the middle one the site for
TAp73β as determined by ChIP-seq using the Genome analyzer (Illumina)
and visualized with the UCSC genome browser. (B) Preferential binding
site for TAp73α. The lower track displays the location of the IL1RAP gene,
the other tracks as described in A). (C) Preferential binding site for TAp73β.
The lower track displays the location of the APOD gene, the other tracks
as described in A). (D) Overlap of target genes that were determined by
ChIP-seq for TAp73α, TAp73β and p53. (E) The genomic distribution of
binding sites for TAp73α, TAp73β and p53 after ChIP-seq is compared to
the respective categories within the human genome. Locations of binding
sites are divided in transcriptional start site (TSS) flanking region (5 kb
upstream of TSS + first exon + first intron), intragenic region (all exons
and introns except first), < 25 kb (peaks within 25 kb of the next annotated
gene) and intergenic region (peaks > 25 kb away from any annotated gene).
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Figure 27: Validation of binding sites in other cell lines (A) Expression of en-
dogenous p73 and p53 in several human cell lines. Protein samples were
harvested from the different cell lines and stained against p73 or p53 as
indicated (left). As a positive control for ChIP-qPCR in the respective cell
line, binding to the p21-promoter was examined (right). Error bars were
derived from two independent experiments. (B) Binding of p73 and p53
to target genes in several cell lines. ChIP-qPCR with a p73-antibody was
performed in MDA-MB231, HEK293 and HCT116 cells or against p53 in
HCT116 and HEK293 cells. As a comparison, binding to the sites in the
different Saos cells is shown. The indicated primers were used to calculate
the respective enrichment. Error bars were derived from two independent
experiments. (C) Cell line specific binding to target genes. ChIP-qPCR was
performed as in B).
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total genes with a p-value
number binding site of overlap
of genes within 25kb
Induced by TAp73α 344 170 3,08E-019
Repressed by TAp73α 477 100 9,99E-001
Induced by TAp73β 260 129 3,56E-007
Repressed by TAp73β 653 193 9,97E-001
Induced by p53 350 152 6,53E-010
Repressed by p53 305 66 9,97E-001
Table 10: Expression changes upon TAp73 induction
expression of genes involved in different developmental processes such
as tissue development, cell differentiation and development of specific
anatomical structures. Interestingly, in a KEGG pathway analysis (Kane-
hisa, 2006) of regulated target genes, the two p73 isoforms appear to
regulate different functional subgroups of genes, highlighting that the
function of TAp73α and TAp73β are not merely overlapping, but also
distinct (Supplemental Table SII). The most prominent functional link
of this KEGG pathway analysis can be seen for TAp73α for metastasis
involved processes: TAp73α seems to induce target genes that fall into
several functional categories linked to metastasis, such as focal adhe-
sion, ECM-receptor interaction, cell communication and regulation of
actin cytoskeleton. For TAp73β on the other hand the p53-signalling
pathway is the first functional category that appears in the KEGG path-
way analysis. Thus, the functional annotation analysis hints at common
as well as distinct functions of TAp73α and TAp73β during cellular
growth and development.
6.2.4 Characteristics of TAp73α and TAp73β binding sites
The distinct binding patterns of TAp73α and TAp73β as well as their
different transactivating potential led us to analyze the binding sites
with respect to their sequence contents and properties. We used a
comprehensive discovery approach to predict motifs for the TAp73α
as well as the TAp73β binding sites. Three different motif prediction
tools (MDmodule, MotifSampler and Weeder) were applied to the
binding sites and resulting motifs were tested for their significance
compared to a set of background sequences (see Materials & Methods
for details). After inspection of the significant motifs using STAMP
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Figure 28: Analysis of expression changes induced by TAp73 by RNA-Seq
(A) Differential transcriptional responses upon induction of TAp73α or
TAp73β. Upon 24 hr induction of TAp73α or TAp73β global expression
profiles were obtained in duplicates using RNA-seq. The fold change relative
to Saos2 parental control was calculated using DEGseq (Wang et al., 2010)
and differential gene expression of the two p73-isoforms was plotted. (B)
Overlap of expression-changing genes after induction of TAp73α, TAp73β
or p53 as analyzed by RNA-seq. (C) Preferential binding of TAp73α results
in specific transcriptional induction of the SFN gene by TAp73α. The two
upper tracks display the ChIP-seq-data from TAp73α or TAp73β, respec-
tively. The three lower tracks show the signals from RNA-seq for Saos2
parental cells or upon induction of either TAp73α or TAp73β. Below the
tracks the respective gene is displayed. On the right the expression change
of the respective gene upon TAp73α or TAp73β induction is validated
by RT-qPCR. SD was derived from three independent experiments. (D)
Preferential binding of TAp73β results in specific transcriptional induction
of the BGN-gene by TAp73β. (E) The GRHL3-gene was bound by TAp73α
and TAp73β and changes its expression upon induction of both isoforms.
(F) Correlation between association strength of TAp73α and TAp73β and
expression changes. Non-regulated genes and genes regulated with an
absolute log2 > 1 are shown.
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(Mahony and Benos, 2007) we found the prevalent motif in both TAp73
sets to be a p53-like motif, hereafter referred to as the p73 consensus-
binding motif (Figure 29A; Supplemental Table SIII). We tested the
performance of the discovered motifs by comparing the Area Under
Curve (AUC) of the Receiver Operator Curve (ROC), which summarizes
the tradeoff between sensitivity and specificity when varying the motif
score threshold. There was no clear difference in the Positional Weight
Matrices (PWM) of the best performing TAp73α and TAp73β motif,
but slight differences when comparing it to the PWM we published
earlier for p53 (Supplemental Table SIV) (Smeenk et al., 2008). The
best performing p73 consensus motif based on the ROC AUC, is more
degenerate than the previously identified p53 motif and clearly shows
a better performance for the p73 sequences (Supplemental Figure 3).
We used the algorithm p53scan (Smeenk et al., 2008) with this PWM to
scan all identified binding sites for the new p73 consensus motif. For
this purpose, we grouped all binding sites into seven different groups,
according to which combinations of p53-family proteins were recruited
(Table 11). Subsequently, we determined the fraction of sequences
containing a p73 motif for each group (Figure 29B). In the p73 groups we
find that at least 70% of the sequences contain the p73 consensus motif.
In contrast, the group of sequences bound only by p53 has a low number
of p73 consensus motifs (20%). The score of the p73scan algorithm
depends on the conformity of the identified motif in a specific sequence
to the ideal consensus motif, the p73 motif in this case. Interestingly,
the median motif score for TAp73α and p53 groups of binding sites
is lower compared to groups containing TAp73β binding sites (Figure
29C). The group with the highest score, i.e. with the highest similarity
to the ideal consensus p73 motif, is the group of target sites bound by
both p53 and TAp73β. We conclude that the p53-family members have
distinct requirements towards their binding sites resulting in specific
motifs and that a p73 specific binding motif can be extracted from our
global analysis.
Besides the p73 motif itself, the AP1 motif (Figure 29D) which can
be bound by heterodimers of the Jun/Fos family (Nakabeppu et al.,
1988) is significantly overrepresented in the sequences occupied by
TAp73α (8.2 times, p<1e-10) and in the TAp73α and p53 group (11.8
times, p<1e-10) compared to a random set of background sequences
(Figure 29E). Strikingly, whereas this motif is found in 24-35% of the
sequences in sites bound by TAp73α or TAp73α and p53, it is not
enriched in the TAp73β or the p53 and TAp73β sites. The location of
the AP1 motif is plotted relative to the TAp73α peak summit in Figure
29F. The distinct centered distribution indicates that the AP1 motif is
located in very close proximity to the actual TAp73α binding site. A
similar distribution is also seen for the distance between TAp73β or
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genes bound by different family members number of
binding sites
TAp73α only 4,196
TAp73β only 11,849
p53 only 4,009
p53 + TAp73α 4,532
p53 + TAp73β 5,091
TAp73α + TAp73β 10,319
p53 + TAp73α + TAp73β 3,754
Table 11: Groups of p53-family specific genes
p53 peak summits and occurring AP1-motifs, although the frequencies
of AP1 motif occurrences are lower (Supplemental Figure 4A). While
the AP1 and p73 motifs occur close together, there does not seem to
be a specific fixed distance (Supplemental Figure 4B). The relationship
between TAp73α and transcription factors binding to AP1-sites was
further strengthened when we assessed putative AP1 target genes.
Recently, a group of genes predicted to be controlled by c-Jun/NF-κB
was identified (Barenco et al., 2009). Of those genes, 20% overlap with
the genes differentially regulated by TAp73α and TAp73β (p < 0.0001).
Strikingly, the median log2 fold expression change for these genes in
TAp73α cells is 0.36, while these genes have a median log2 fold change
of -0.41 (p < 0.001) in TAp73β cells (Figure 29G). In TAp73α expressing
cells genes with an AP1 motif are more often upregulated compared
to genes lacking this motif (Supplemental Figure 5). This correlation is
not observed for TAp73β.
In conclusion, the sequences of the identified p73 binding sites show
clear isoform-specific characteristics. In particular, the overrepresen-
tation of the AP1 motif distinguishes the TAp73α from the TAp73β
binding sites.
TAp73α activates genes containing an AP1 motif close to a p73 binding site
The transcription factors of the AP1 family regulate many growth
related functions, therefore we wondered whether genes assigned to
p73 binding sites co-occurring with AP1 motifs could contribute to the
physiological differences we observed between TAp73α and TAp73β.
We chose five genes in which an AP1 motif is also present and detected
strong enrichment of TAp73α at all tested binding sites, while the
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Figure 29: Characteristics of TAp73α and TAp73β binding sites (A) The newly
identified TAp73 binding motif visualized by WebLogo (Crooks et al., 2004).
(B) The percentage of binding sites containing the p73 motif as determined
by p73scan. Binding sites are divided in seven different groups based on
detected binding of TAp73α, TAp73β and/or p53: 1)-3) bound by only one
family member, 4) and 5) by p53 and either TAp73-isoform, 6) by both
TAp73-isoforms and 7) by both TAp73-isoforms and p53. (C) Boxplot of
the TAp73 motif scores, as determined by p73scan, of the groups described
in B). (D) The AP1 sequence motif identified in the TAp73α binding sites
visualized by WebLogo. (E) The percentage of binding sites containing the
AP1 motif of the groups described in B). (F) The location of the AP1 motif in
TAp73α binding sites, relative to the peak summit. (G) Boxplot of the log2
fold expression change (Saos cells expressing TAp73α or TAp73β versus
Saos2 parental control) of the genes identified in Barenco et al. (Barenco
et al., 2009) to be c-Jun/NF-kB dependent. Expression of TAp73α cells is
shown in green, TAp73β is shown in blue. The difference in the median fold
change between TAp73α and TAp73β is significant (p<0.001, Wilcoxon
Rank Sum test).
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binding of TAp73β is not significantly enriched (Figure 30A). Next,
we assessed whether c-Jun is differentially recruited in the presence
or absence of either TAp73α or TAp73β. ChIP-qPCR of c-Jun revealed
clear binding of c-Jun to target sites in parental Saos2 and in TAp73α
expressing cells (Figure 30B). In the cases of NEDD4L and RNF43
the expression of TAp73α increases the binding of c-Jun, compared
to parental Saos2 cells. Importantly, in TAp73β expressing cells c-Jun
binding to the respective target sites is reduced compared to parental
Saos2 cells. We also analyzed whether p53 was bound to these AP1-
motif containing sites and whether it could change the recruitment of
c-Jun. While strong binding of p53 was not observed, the binding of c-
Jun to these sites appears to remain unchanged in p53- expressing cells
compared to parental Saos2 cells (Supplemental Figure 6). To validate
that TAp73α and c-Jun are actually bound simultaneously to the same
binding regions, we performed ChIP-reChIP analysis. For all tested
target genes we could reChIP c-Jun at the TAp73α-bound target sites
and vice versa, showing that TAp73α and c-Jun can indeed be found on
the same binding regions at the same time (Figure 30C, Supplemental
Figure 7).
In concordance with the binding data, TAp73α induces the mRNA
expression of all five genes (Figure 30D). Surprisingly, we found a
repression of the level of mRNA of the same genes upon TAp73β
induction, in the case of RNF43 or IL1RAP a substantial decrease to
5-10% of the level of expression in the parental Saos2 cells. To show the
dependence of these target genes from endogenous p73 and c-Jun we
silenced the expression of p73 and c-Jun in HCT116 and MDA-MB231
cells, respectively and analyzed the expression NEDD4L, IL1RAP and
CDK6 (Figure 30E,F). The reduction of p73-levels leads to a small
decrease of NEDD4L- and CDK6-mRNA and a strong reduction of the
IL1RAP-expression (Figure 30E). After the reduction of c-Jun expression,
the mRNA levels of all three tested genes were reduced more than 30%
(Figure 30F). To further explore the relationship between c-Jun and
p73, we analyzed the levels of c-Jun mRNA in TAp73β expressing cells
(Figure 30G, left). Strikingly, upon TAp73β induction the c-Jun mRNA
level is strongly reduced, an effect also seen in our RNA-seq data
(Supplemental Figure 2C). The protein level of c-Jun is also reduced
specifically upon TAp73β induction, while neither TAp73α nor p53
exert a similar effect (Figure 30G, right).
Thus, we have identified a specific set of TAp73α target sites that
also contain an AP1 site and that are bound by c-Jun. Very interestingly,
these AP1 motif containing target sites are not bound by TAp73β.
Furthermore, while the endogenous expression of these genes seems
to depend on p73 and c-Jun, a repression of the associated genes
specifically upon TAp73β induction is observed, at least partly due to a
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negative regulation of c-Jun by TAp73β. Thus, the interplay between
c-Jun and TAp73 is isoform dependent, leading to differential binding
of c-Jun to its target genes and to a differential transcriptional outcome.
6.2.5 The TAp73α target genes IL1RAP and NEDD4L can influence apopto-
sis
Several of the genes that are in close proximity to combined TAp73α/AP1
binding sites are linked to tumorigenesis or malignant growth (Table
12). Because TAp73α can induce these genes, we assessed whether
these target genes impede on the induction of programmed cell death.
To this end we overexpressed two of these gene products, NEDD4L
and IL1RAP, in Saos cells inducible for TAp73α. The effect of the over-
expressed proteins on the TAp73α induced apoptosis was monitored
by staining for active Caspase3. TAp73α induces the cleavage of Cas-
pase3 mainly after 48 hr (Figure 31A). Upon transfection of IL1RAP, the
amount of activated Caspase3 is markedly decreased, especially after
48 hr of TAp73α induction. NEDD4L impedes on the accumulation
of active Caspase3 in a similar way, mainly after 48 hr of TAp73α in-
duction. To examine the physiological role of IL1RAP and NEDD4L in
the TAp73α signaling pathway, we transfected siRNAs directed against
IL1RAP and NEDD4L into TAp73α expressing cells. Analysis of the
mRNA after transfection of the respective siRNA and induction of
TAp73α for 24 hr shows that the knockdown of IL1RAP and NEDD4L
has an efficiency of at least 80% (Figure 31B). Strikingly, the knockdown
of IL1RAP and NEDD4L increases the induction of active Caspase3
after 24 and 48 hr of TAp73α induction (Figure 31C, left). Analyzing the
population of cells in sub-G1, we found that the knockdowns lead to a
statistically significant increase of TAp73α induced apoptosis (Figure
31C, right). Thus, we have identified two target genes of TAp73α that
seem to impede on the apoptosis induction capability of TAp73α, most
likely via a pathway involving c-Jun.
We propose that the differences in apoptosis induction by TAp73α
and TAp73β are mediated at least partly by the differential collaboration
with c-Jun: in the case of TAp73α AP1 binding sites are bound by c-
Jun and the respective proliferation related target genes are induced
leading to a weaker apoptotic response of TAp73α. On the other hand
the TAp73β binding sites are not only devoid of AP1 sites, but TAp73β
negatively regulates the c-Jun levels leading to much less c-Jun being
bound at the respective AP1 sites which ultimately results in much
higher levels of apoptosis.
6.2 results 127
TAp73
p53
c-Jun
TBP
S
ao
s2
p5
3
TA
p7
3α
TA
p7
3β
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p5
3
TA
p7
3α
TA
p7
3β
fo
ld
 in
du
ct
io
n
0.0
0.2
0.4
0.6
0.8
1.0
TBP
siRNA: control
c-Jun
c-Jun
R
el
at
iv
e 
to
 c
on
tro
l s
iR
N
A
NE
DD
4L
IL1
RA
P
CD
K6
NEDD4L IL1RAP PAI-1 CDK6 RNF43
35
25
15
5
0
10
20
30
TAp73α
TAp73β
fo
ld
 e
nr
ic
hm
en
t
NE
DD
4L
IL1
RA
P
CD
K6
p73
TBP
siRNA: control p73
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
to
 c
on
tro
l s
iR
N
A
G
Saos
TAp73α
TAp73β
fo
ld
 e
nr
ic
hm
en
t
NEDD4L IL1RAP PAI-1 CDK6 RNF43
12
8
4
0
D p73-induced expression changes
TAp73α
TAp73β
100
10
1
0.1
0.01ra
tio
 c
om
pa
re
d 
to
 S
ao
s2
 c
el
ls
NEDD4L IL1RAP PAI-1 CDK6 RNF43
C
fo
ld
 o
ve
r a
ct
in
 c
on
tro
l
reChIP in Saos TAp73α cells
First ChIP: anti-p73
anti-p73 reChIP
anti-c-Jun reChIP
165
NEDD4L IL1RAP
100
10
0
c-Jun mRNA
expression
A Bp73 ChIP of AP1 sites c-Jun ChIP
PAI-1CDK6 RNF43
E Effect of p73-knockdown on 
target genes in HCT116 cells
F Effect of c-Jun-knockdown on
target genes in MDA-MB231cells
Figure 30: Opposite effects of TAp73α and TAp73β on target genes close to an
AP1 motif. A-D,G: SD was derived from three independent experiments. E-
F: Error bars were derived from two independent experiments. (A) TAp73α
but not TAp73β binds to AP1 motif containing binding sites. ChIP-qPCR
was performed in Saos cells expressing TAp73α or TAp73β for 24 hr,
with primers covering putative AP1 binding sites. (B) Binding of c-Jun to
putative target genes is reduced in TAp73β expressing cells. ChIP-qPCR
of c-Jun was performed in parental Saos2 cells, or Saos2 cells expressing
TAp73α or TAp73β for 24 hr. Same primers as in A) were used. (C) ChIP-
reChIP shows binding of TAp73α and c-Jun to the same sites on DNA.
After induction of TAp73α chromatin-complexes were precipitated first
with a p73-antibody. After elution a second round of IP was performed
with a c-Jun- or again with a p73-antibody. The second ChIP included an
unspecific antibody-control to calculate enrichment. (D) Opposite regulation
of AP1 motif containing target genes by TAp73α and TAp73β. Changes in
expression of mRNA of the target genes from A), upon induction of TAp73α
or TAp73β for 24 hr. (E) Expression of AP1-motif containing target genes
is reduced after knockdown of p73. After knockdown of p73 in HCT116
cells, protein levels of p73 (left) or transcriptional levels of the respective
target genes (right) were analyzed. (F) Knockdown of c-Jun reduces the
expression of AP1-motif containing target genes. After knockdown of c-
Jun in MDA-MB231 cells, protein levels of c-Jun (left) or transcriptional
levels of the respective target genes (right) were analyzed. (G) The c-Jun
expression levels are downregulated by TAp73β Expression of c-Jun mRNA
upon induction of TAp73α, TAp73β or p53 for 24 hr (left). Protein-levels
of c-Jun were analyzed in Saos cells after induction of TAp73α, TAp73β
or p53 for 24 hr before whole cell extract was isolated and the indicated
proteins were stained by western blot (right).
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gene known function
name
RNF43 upregulated in colorectal cancers; growth promoting if
exogenously expressed (Sugiura et al., 2008; Arévalo et al.,
2006)
NEDD4L Na+ channel regulation/ tumor associated via Wnt-
signaling in liver cancer/ neuronal survival via Trk neu-
rotrophin receptors (Arévalo et al., 2006; Lee et al., 2007a)
CDK6 catalytic subunit for G1/S transition/ stimulates growth
in prostate cancer/ overexpressed in medullablastoma;
poor prognosis marker (Lim et al., 2005; Mendrzyk et al.,
2005)
IL1RAP involved in IL1 action during inflammation/ activation of
NFkB-pathway (Cullinan et al., 1998; Towne et al., 2004)
PAI-1 promoter of tumor progression/ poor prognosis marker
(Bajou et al., 1998; Gutierrez et al., 2000; Kortlever and
Bernards, 2006; Nekarda et al., 1994)
RIPK4 can activate NFkappaB/ processed during apoptosis/
involved in differentiation(Adams et al., 2007; Meylan
et al., 2002)
GAP43 growth associated protein 43/ highly expressed during
neuronal development and axonal regeneration/neurite
outgrowth/ AP1 TrkA associated (Diolaiti et al., 2007)
SDC1 participates in cell proliferation, cell migration and cell-
matrix interactions/ Altered (higher) syndecan-1 expres-
sion has been detected in several different tumor types
(Choi et al., 2007; Maeda et al., 2006)
NGFR tumor suppressor in retinoblastoma/ necessary for cell
survival in ESCC/ Inducer of apoptosis in absence of lig-
and/ Interaction with TrkA/ critical regulator of glioma
invasion (Dimaras and Gallie, 2008; Johnston et al., 2007;
Khwaja et al., 2006; Okumura et al., 2006)
Table 12: Known function of TAp73α target genes with an AP1 motif
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Figure 31: Target genes of TAp73α and c-Jun impede on apoptosis induction
(A) Overexpression of IL1RAP, NEDD4L or an empty vector in Saos cells
expressing TAp73α. After induction for 24 hr or 48 hr whole cell extracts
were analyzed by western blot. (B) Knockdown of IL1RAP and NEDD4L.
TAp73α expressing Saos cells were transfected twice with a pool of four
different siRNAs against each gene or a non-targeting siRNA-pool. After
induction for 24 hr mRNA was harvested and the efficiency of knockdown
was monitored setting the non-targeting sample to 100%. Error bars result
from two biological replicas. (C) Knockdown of IL1RAP and NEDD4L
increases apoptosis. TAp73α expressing Saos cells were transfected as in
B), prior to isolation of whole cell extract and western blot analysis (left
panel) or preparation for FACS-analysis to determine the amount of cells in
sub-G1 phase as a measure for apoptotic induction (right). * indicates p <
0.05. SD was derived from three independent experiments.
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6.3 discussion
A marked physiological difference between the two most commonly
expressed TAp73-isoforms, TAp73α and TAp73β has been reported
(Melino et al., 2004; Klanrit et al., 2008), but the molecular mechanism
for the observed different cellular response upon TAp73α and TAp73β
activation has remained elusive. Here, we analyze the differences of
TAp73α and TAp73β target gene-binding and -regulation and propose
that the balance between survival and apoptosis induction by TAp73α
and TAp73β is mediated at least partly by the differential interplay
with c-Jun. In our global binding site analysis we identified a consensus
binding motif for TAp73α and TAp73β. Although this motif resembles
the previously described p53 consensus motif (Smeenk et al., 2008), it
has several distinct features, e.g. the bases outside the four nucleotide
core are less preserved and it is thereby closer related to the binding
motif described for p63 (Ortt and Sinha, 2006). Assessing the molecular
differences between TAp73α and TAp73β, we found that an AP1 motif
is strongly enriched in the region surrounding many binding sites
of TAp73α, but not in TAp73β binding sites. We observed a striking
difference in the expression of the target genes with an AP1 motif in
the TAp73α- versus TAp73β-expressing cells. While these target genes
are selectively bound by TAp73α together with c-Jun and subsequently
upregulated, TAp73β represses their mRNA expression. In line with
these findings, we observed that the recruitment of c-Jun to the AP1 sites
of these genes is impaired upon TAp73β induction probably caused by
a downregulation of c-Jun mRNA and protein by TAp73β. Several of
the assigned target genes are related to malignant growth, like CDK6
and RNF43 (Lim et al., 2005; Sugiura et al., 2008). We show that two
genes specifically upregulated in TAp73α expressing cells, NEDD4L
and IL1RAP, are able to influence the induction of apoptosis upon their
overexpression or siRNA-mediated downregulation, thereby showing
that TAp73α indeed induces anti-apoptotic factors.
6.3.1 Analysis of TAp73α and TAp73β transcriptional activities
It has been reported previously, that TAp73β can induce the expression
of p53-target genes like p21 or Mdm2 to a higher extent than TAp73α
(Laurenzi et al., 1998; Lee and Thangue, 1999; Ueda et al., 1999), while
also TAp73α-specific target genes have been reported (Fontemaggi et al.,
2002). Furthermore, TAp73β has been described to be a much stronger
inducer of apoptosis (Oshima et al., 2007; Gonzalez et al., 2005). In
line with this, our data shows that known target genes like Mdm2
and p21 are bound with higher affinity and induced to higher levels
through TAp73β and that the induction of apoptosis by TAp73β is
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much stronger. Nevertheless, our study now extends previous analy-
sis by combining ChIP-seq and RNA-seq to compare these two most
prevalent TAp73 isoforms with each other as well as with p53 with
respect to global target gene binding and expression. Strikingly, be-
sides common target genes bound and regulated by TAp73α, TAp73β
and p53 we found target genes that were regulated in an isoform-
specific manner. In summary, our data provide genome-wide analysis
of TAp73α, TAp73β and p53 chromatin occupancy and the correlation
thereof with transcriptional changes upon TAp73α, TAp73β and p53
induction. This enables a careful examination of the isoform-specific
as well as overlapping target genes and provides a basis for further
functional characterization.
6.3.2 Isoform-specific functional interplay of TAp73 with c-Jun
Our data shows that the cellular outcome of the interplay between c-
Jun and p73 depends on the presence of the respective TAp73-isoform.
First, our motif analysis of genome wide data showed a striking co-
occurrence of c-Jun binding motifs with TAp73α-binding sites, to which
both proteins bind simultaneously. Second, induction of TAp73β re-
sulted in a reduction of c-Jun mRNA and protein levels and hence
to a lack of recruitment of c-Jun. Third, there is a positive correlation
between TAp73α-induced genes and c-Jun target genes, while this corre-
lation is inversed for TAp73β-regulated genes. Thus, the poor induction
of cell death by TAp73α could be due to activation of anti-apoptotic
target genes along with c-Jun, while the stronger apoptosis induced
by TAp73β is caused at least partly by a reduction of cellular c-Jun
levels and subsequent reduced recruitment of c-Jun to DNA resulting in
repression of these target genes. Several of these target genes are linked
to malignant growth and their mRNA levels were induced by TAp73α
but repressed by TAp73β. The negative regulation of genes related to
proliferation by TAp73β and p53 that was reported earlier (Scian et al.,
2008) might therefore also be extended to these AP1 motif containing
genes. This AP1 motif can be bound by c-Jun, which has been reported
to stabilize p73 and thereby to enhance its function, although no di-
rect interaction was observed (Toh et al., 2004). More recently it was
reported, that c-Jun plays an important role in apoptosis induced by
chemotherapeutic treatments mediated by YAP1, a critical regulator of
p73 (Danovi et al., 2008; Strano et al., 2005). On the other hand, c-Jun
and p73 have also been shown to co-operate during growth promotion
and to synergistically induce transcription from c-Jun response element
containing promoter constructs in the absence of additional apoptosis-
inducing treatments (Vikhanskaya et al., 2007). Based on our findings,
we speculate that the differences in cellular outcome are due to the pres-
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ence of the particular TAp73 isoform and its respective interplay with
c-Jun. The weaker induction of cell death by TAp73α that we observed
might be mediated by the activation of anti-apoptotic target genes to-
gether with c-Jun, while the stronger apoptosis induced by TAp73β
might be due to the repression of these target genes and a reduction of
c-Jun levels. The treatment- and isoform-specific differences influencing
the cellular fate hint towards several layers of regulation between p73
and c-Jun and might be a very important molecular explanation for the
different observed phenotypes induced by the TAp73 isoforms.
6.4 material and methods
6.4.1 Cell culture conditions
The human MDA-MB231, HCT116, HEK293 cell lines and the osteosar-
coma cell line Saos2 (parental cells or cell lines with inducible p53,
TAp73α or TAp73β) (Smeenk et al., 2008) were maintained in Dulbecco
modified Eagle medium supplemented with 10% fetal calf serum at
37°C. Expression of p53, TAp73α or TAp73β in stably transfected cells
was induced with 0.5 µg doxycyclin (for TAp73α) or 2.0 µg doxycyclin
(for TAp73β and p53). Transfections were performed using the calcium
phosphate precipitation method (BES). Transient knockdown of IL1RAP
and NEDD4L was achieved by using Dharmacon ON-TARGETplus
siRNAs, according to manufacturers manual. Lentiviral transduction
was used to deliver pLKO-siRNA constructs for the knockdown of c-Jun
(a kind gift from F. Galvagni) and p73 (Sigma), while pLKO-siRNA
targeting Luciferase served as a control.
6.4.2 Cell cycle analysis
Saos2 parental cells and Saos cell lines inducible for TAp73α, TAp73β
or p53 were induced for 24 hr or 48 hr, prior to harvest. All cells
were collected, resuspended in PBS containing 1% FCS and fixed in
ethanol overnight at 4°C. DNA content was stained with propidium
iodide (Sigma) for 30 min at room temperature and analyzed by flow
cytometry (Becton Dickinson FACScan). The data was analyzed using
CellQuest Pro software.
6.4.3 Western Blot analysis
Whole cell extract was harvested in 2x SDS-sample buffer, 4x sample
buffer was added to aliquots of chromatin samples (see below for prepa-
ration of chromatin), both types of samples were boiled and proteins
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were separated by SDS-page. After blotting the following antibodies
were used to detect proteins: BL609 (anti-p73; Abcam), DO1 (anti-p53;
BD PharMingen), ab13487 (anti-active Caspase3; Abcam), SC45-X (anti-
cJun; SantaCruz Biotechnology), SL30 (anti-TATA-box Binding Protein;
anti-TBP), M2 (anti-FLAG; Sigma). Secondary antibodies used were
either rabbit-anti-mouse or swine-anti-rabbit conjugated to HRP (Dako).
6.4.4 Chromatin immunoprecipitation (ChIP)
The chromatin immunoprecipitation (ChIP) was basically done as de-
scribed by Denissov et al. (Denissov et al., 2007). To immunoprecipitate
p53, DO1 antibody (BD PharMingen) was used and BL906 (Abcam) was
used for p73. Immunoprecipitation of c-Jun was done with an anti-c-Jun
antibody (Upstate). Real-time qPCR was performed using the SYBR
Green mix (Biorad) with the MyIQ machine (Biorad). Primers are listed
in Supplemental Table SV. Prior to the reChIP, p73-antibody (BL609) or
c-Jun-antibody (Upstate) was cross-linked to protein-A/G-beads (San-
taCruz) using 20 mM dimethylpimelimidate (pH: 8,5). The chromatin-
complexes from the first ChIP were eluted in 50 µL of elution-buffer
and the SDS-concentration was adjusted with 5x incubation buffer with-
out SDS to 0.15% in the second ChIP-reaction. The reChIP included an
unspecific or a beads only control, respectively, to allow an estimation
of leakage and antibody-carryover from the first ChIP.
6.4.5 RNA isolation and RT-PCR
Total RNA was extracted using the RNeasy Mini Kit according to pro-
tocol (Qiagen). For cDNA synthesis retrotranscription was performed
using 1 µg of RNA with random hexamer primers, dNTPS, DTT, buffer
and Superscript Retrotranscriptase (Invitrogen). The cDNA was ana-
lyzed by real-time qPCR using a MyIQ machine (Biorad). Primers are
listed in Supplemental Table SV.
6.4.6 RNA-sequencing
To prepare samples for RNA-seq 100 µg of total RNA were subjected to
polyA-selection with Oligotex Kit according to protocol (Qiagen). Frag-
mentation of 100 ng polyA-selected mRNA was done for 105 seconds
at 94°C in 1x fragmentation buffer (40 mM Tris acetate, pH 8.2; 100 mM
potassium acetate; 30 mM magnesium acetate). After purification with
RNeasy mini Kit, according to protocol (Qiagen) first strand cDNA
synthesis was performed with random hexamer primers, dNTPS, DTT,
buffer and Superscript Retrotranscriptase (Invitrogen). Second strand
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synthesis was done with E.coli DNA polymerase, E.coli DNA ligase,
dNTPs buffer and RNAseH. After purification with Minelute Reac-
tion Cleanup Kit (Qiagen) the obtained material was used to prepare
sequencing samples according to the manufacturers protocol (Illumina).
6.4.7 Illumina high throughput sequencing (ChIP-seq)
Sequencing samples were prepared according to the manufacturers
protocol (Illumina). Shortly, adapted sequences were linked to the gen-
erated ChIP, the library was size selected (200-250 bp) and amplified
by PCR. Clustering and 36-cycle sequencing were performed using
an Illumina Cluster Station and Genome Analyzer according to the
manufacturer’s instructions. Images acquired from the Genome An-
alyzer were processed through the bundled image analysis pipeline
(Illumina). All 35 bp sequence reads were uniquely mapped to the
human genome (NCBI build 36.1, hg18) with zero or one mismatch
allowed using ELAND software (Illumina). For visualization purposes,
all reads were directionally extended to 200 bp, and the number of
overlapping sequence reads was determined for each position in the
genome, averaged over a 10 bp window and visualized in the UCSC
Genome Browser (http://genome.ucsc.edu).
6.4.8 ChIP-seq data analysis
Two biological replicates were sequenced for all ChIP samples. To incor-
porate the different signal/background ratios of the different biological
replicates and generate high-confidence peaks we called peaks on a set
of combined reads randomly sampled from each combination of two
replicates. We randomly selected 7 million reads from each TAp73α
and each Tap73β replicate and 3 million from each p53 replicate. We
combined these randomly selected reads ( 14 million for both TAp73α
and TAp73β, 6 million for p53) and used this set as input for MACS
(Zhang et al., 2008). Peaks were called using default parameters (p-value
threshold 1e-5), using a Saos2 input DNA sample as control ( 14 million
reads). This random sampling procedure was repeated 10 times, and
only the peaks determined in every single analysis were kept. Peaks
were mapped to RefSeq genes, downloaded from the UCSC Genome
Browser, to determine genomic location.
6.4.9 RNA-seq data analysis
Two biological replicates were sequenced for each sample. Reads were
mapped to the genome and all reads mapping within RefSeq genes
6.4 material and methods 135
(downloaded from the UCSC Genome Browser) were counted. The read
counts per gene per replicate were used as input for DEGseq (Wang
et al., 2010). This R package was used to call differentially regulated
genes using the MARS method, with default parameters. All genes with
a significant change (FDR < 0.001) and an absolute log2 fold change of
1 were called as regulated.
6.4.10 Association strength
The continuous association strength per gene was calculated as de-
scribed in Ouyang et al. (Ouyang et al., 2009). The association strength
of gene i is calculated as the a weighted sum of intensities of all of the
peaks within 2Mb of the gene, according to the following formula:
ai =
∑
k
gke
−dk/d0 (6.1)
where gk is the total normalized number of reads aligned of the kth
binding site, dk is the distance (number of nucleotides) between the
TSS of gene i and the kth binding site and d0 is 5,000. The association
strength values are log2-transformed and quantile-normalized.
6.4.11 Motif analysis
The location and score of the p53 motif within the 200 bp peaks was
determined using p53scan with default settings (http://www.ncmls.nl/
bioinfo/p53scan/) (Smeenk et al., 2008). To determine the p73 motif
three motif prediction tools were run on the 200 bp peaks: MotifSampler
(Thijs et al., 2001), Weeder (Pavesi et al., 2004) and MDmodule (Liu et al.,
2002). A set of 1,000 sequences, randomly selected from the highest
5,000 peak sequences was used as input to predict motifs. We used the
’large’ analysis setting for Weeder, and MDmodule and MotifSampler
were used to predict 10 motifs for each of the even widths between
6 and 20. The significance of the predicted motifs was determined by
scanning the remaining 80% of the 5,000 highest peak sequences (4,000
sequences) and two different backgrounds: a set of random genomic
sequences with a similar genomic distribution as the peak sequences
and a set of random sequences generated according to a 1st order
Markov model (similar dinucleotide distribution as the peak sequences).
P-values were calculated using the hypergeometric distribution with
the Benjamini-Hochberg multiple testing correction. All motifs with a
p-value < 0.001 and at least an absolute enrichment > 1.5 compared to
both backgrounds were determined as significant. The closest matching
motif in the JASPAR database (Vlieghe et al., 2006) was determined
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using STAMP (Mahony and Benos, 2007). The p53scan algorithm was
modified to use the best p73 motif matrix found in the motif analysis,
hereafter referred to as p73scan. The PWM is included as Supplemental
Table SIV. All p73scan analyses reported in this study were carried out
with a spacer length of 0.
The AP1 motif analyses were carried out with the pwmscan.py pro-
gram included with p53scan, using the best performing AP1 matrix
identified in this study as PWM. This matrix is provided as Supplemen-
tal Table SIV. As a threshold for the AP1 pwmscan.py 0.98 was used, to
select for stringent matches.
6.4.12 Data availability
The data has been deposited in NCBI’s Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through GEO Series accession
number GSE15780 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE15780).
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7G E N E R A L D I S C U S S I O N
The expression of a gene is determined by a multitude of factors
including the core promoter architecture, the chromatin environment
and transcription factors. The exact underlying mechanisms remain to
be completely understood. While many core promoter elements are
known, the repertoire of binding factors and the required regulatory
sequences is far from complete. The mechanisms of different chromatin
modifications, their interacting proteins and the associated complexes
are just starting to become clear. Finally, the exact function and mode of
action of many sequence-specific transcription factors are still unknown.
An important approach to tackle these research challenges is the
integration of high-throughput experimental and analysis methods.
The rapid developments in sequencing technologies have enabled high-
throughput analysis on a genome-wide scale. From massively sequenc-
ing the 5’ ends of transcripts to determine transcription start sites
(Chapter 3) to sequencing all DNA regions pulled down by chromatin
immunoprecipitation of a histone modification or transcription factor
(Chapters 4-6), analyses that used to be performed on a select number
of carefully chosen target genes can now be expanded to a complete
and unbiased view of the whole genome.
7.1 the anatomy of the vertebrate core promoter
The diversity in gene regulation is greatly effected by the structure and
function of the core promoter together with the composition of the pre-
initiation complex. The combinatorial effect of different core promoter
elements that form the core promoter is an important determinant of
gene expression, even without taking into account more long-range
promoter-enhancer interactions. For instance, the transcription factor
Caudal preferentially activates transcription from DPE-containing core
promoters, regardless of the presence or absence of an upstream BREu
element (Juven-Gershon et al., 2008a). While Caudal can also moder-
ately activate transcription from the TATA box, this is abrogated in
presence of BREu. In this example, the specific combination of certain
motifs determines the transcriptional outcome. The precise effect of a
motif can greatly depend on the presence and spatial orientation of
other motifs. This combinatorial complexity makes it challenging to
study the core promoter function. While detailed functional essays of
individual promoters are essential to unravel the specific function of
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one or more elements, these elements might function in a completely
different manner within the sequence context of another promoter. This
makes it worthwhile, in a different yet complementary approach, to
study promoter structure on a more genome-wide scale in addition to
detailed functional experiments focused on a single promoter. Meth-
ods such as deepCAGE (The FANTOM Consortium and Riken Omics
Science Center, 2009) and TSS-seq (Tsuchihara et al., 2009) enable the
collection of large numbers of promoters with high precision. This
expedites motif prediction and makes it feasible to detect less abundant
and more degenerate motifs.
We demonstrated the utility of such genome-wide approaches for
identification of core promoter sequence motifs in Chapter 3. However,
the frequency with which these promoter elements occur in promoters
illustrates one of the difficulties in computational motif analysis of
promoters. Almost all of these elements are present in just a small
fraction of promoters, with frequencies of only a few percent. One
of the most abundant motifs, the Ets motif, occurs in 14% of core
promoters, however, this motif is short, and can be bound by members
of a large family of transcription factors (Wei et al., 2010). In contrast
to this low abundance, many computational algorithms are optimized
to predict motifs that are present in a significant fraction of the input
sequence. Therefore, weak or degenerate motifs might be missed by
such approaches. This is illustrated by the fact that some known core
promoter elements, such as DPE, BREu and BREd were not identified by
our de novo approach, although they are present in Xenopus promoters.
This is not surprising, as these degenerate elements were previously
identified by pulldown and mutational essays instead of computational
means, but it does highlight possible improvements of genome-wide
approaches such as used in our study.
The number of different, low-abundant core promoter elements il-
lustrates that the core promoter structure is complex and can vary a
lot between different genes. Single-cell experiments and computational
models have shown that gene expression is essentially a stochastic pro-
cess with high variability between cells (Raj et al., 2006; Taniguchi et al.,
2010; Sanchez et al., 2011). This process needs to implement several
important features such as a balance between expression levels and
transcriptional noise, fast and specific responses to external signals,
integration of different signals and inherent redundancy to provide
robust regulation. Results from several computational models indicate
that a high complexity of the core promoter enables these features
(Hermsen et al., 2006; Müller and Stelling, 2009). While the TATA box,
for instance, enables rapid transcriptional activation, the presence of
such a strong initiation element also confers a higher level of intrinsic
expression noise (Raser and O’Shea, 2004; Blake et al., 2006). A more
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complex promoter design on the other hand, enables high expression
rates with minimal noise (Müller and Stelling, 2009). The presence of
different, possibly overlapping motifs, provide the basis for cooperativ-
ity and competition, which greatly enhances the capacity to integrate
different signals (Hermsen et al., 2006).
To study the many regulatory elements that determine core promoter
composition, integration of several different techniques will be nec-
essary. Careful biochemical assays of single promoters are essential
to illustrate the function of elements within a specific context. This
is important as element function can depend on context-dependent,
combinatorial effects (Juven-Gershon et al., 2008a). However, these
experiments can be laborious and narrow in scope. Computational
modeling techniques together with single-cell essays can provide com-
plementary insights (Elf et al., 2007; Sanchez et al., 2011). Furthermore,
genome-wide analyses such as described in Chapter 3, as well as de-
tailed (RNA-seq) expression profiles to determine groups of promoters
belonging to functionally related genes will provide the necessary data
for both in silico modeling and more detailed biological experiments.
Most of the different core transcription factor motifs we found in
Xenopus promoters are also present in human promoters, with similar
frequencies. However, there are striking differences, most notably with
respect to the local sequence background. The nucleotide content of
Xenopus promoters is markedly different from human promoters. This
difference is generally found between mammals and birds with high
GC levels and cold-blooded vertebrates such as fish and amphibians.
The exact cause is unclear and several hypotheses have been proposed,
as has been reviewed by Eyre-Walker and Hurst (Eyre-Walker and
Hurst, 2001). The first possibility is mutation bias, where variation in
nucleotide content can arise due to preferences in the mechanisms of
replication (Wolfe et al., 1989) or DNA repair efficiency (Filipski, 1987),
or as a consequence of cytosine deamination (Fryxell and Zuckerkandl,
2000). A second hypothesis posits that GC-rich isochores are a function
of natural selection (Costantini et al., 2009; Wang and Lercher, 2010).
This selection would act upon the thermal stability of DNA and could
thereby explain the GC-rich genomes of the homeothermic birds and
mammals. Finally, the hypothesis of biased gene conversion (BGC) is
based on the observation that mismatches have a slight preference to
be repaired to GC (Galtier et al., 2001). This would lead to a higher
GC-content in regions with a higher rate of recombination (Duret and
Arndt, 2008).
The debate still continues and the exact cause has not been unequiv-
ocally demonstrated. The observed effects are usually small, and many
of the studies suffer from a lack of scale, either due to a small set of
model organisms or a lack of genomic data. The ready availability of
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complete genome sequences of many different organisms should help
to clarify the issue. Recent data from a study comparing 33 mammalian
genomes favors the BGC model (Romiguier et al., 2010). Regardless of
the cause, human promoters are generally very GC rich, while Xenopus
promoters have a relatively higher AT-content.
When we took this nucleotide difference into account in the motif
comparison between species, it yielded some interesting results. In-
triguingly, there are some motifs that vary along with the nucleotide
background, such as SP1 and the TATA box. This can reflect an evo-
lutionary adaptation to different promoter compositions. While the
transcriptional machinery, including all the different factors involved
in PIC assembly, is strongly conserved between vertebrates, the relative
usage of different mechanisms might be be adapted to the divergent
promoter nucleotide content. This is in line with other studies, suggest-
ing that gene regulation resulting from transcription factor binding is
likely a major cause of divergence between species (Borneman et al.,
2007; Wilson et al., 2008). The DNA-binding specificities of proteins are
highly conserved. This is especially true for the proteins involved in the
core transcriptional machinery. Plasticity in gene regulation is mainly
caused by the genetic sequence, which can be highly variable. This is
illustrated by a comparison of the binding profiles of two transcription
factors between five vertebrates (Schmidt et al., 2010). While the TF
binding specificities were very similar between species, the observed
binding events were mostly species-specific. These observations are
reinforced by computational network modeling, which shows that tran-
scription factor-target regulatory networks have the fastest evolutionary
changing rates among several biological networks (Shou et al., 2011).
The examples of SP1 and the TATA box, which occur in GC and AT
rich sequences respectively, could serve as an illustration of this phe-
nomenon. Both motifs can recruit TFIID via different mechanisms, SP1
via an interaction between Sp1 and TBP, and the TATA box by direct
binding of TBP. The SP1 motif occurs much more frequent in human
promoters, while the TATA box is more abundant in Xenopus. This is
likely an evolutionary adaption to a differential nucleotide content of
promoters while utilizing a highly similar core transcription machinery.
In addition to the many known and conserved motifs, we identified
several unknown motifs. Some of those were also found in human
promoters, while others seem to occur specifically in Xenopus. Further
characterization will be necessary to unravel their function. These Xeno-
pus-specific motifs might recruit a specific interactor, or they might
reflect specific local sequence composition biases. This illustrates the
limitation of in-silico genomic approaches. Even with known elements
such as the CRE motif, the identity of potential binding factors is un-
certain. The whole family of CREB and ATF proteins binds a similar
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motif, but each factor has specific preferences, which is reflected in
slight variations on the general consensus motif (Hai and Hartman,
2001). Therefore, careful and well-constructed experiments are neces-
sary to characterize these elements. These possibly include techniques
include yeast one-hybrid screens (Li and Herskowitz, 1993; Ouwerkerk
and Meijer, 2011), affinity capture followed by quantitative mass spec-
trometry analysis (SILAC) (Markljung et al., 2009; Mittler et al., 2009),
electrophoretic mobility shift assay (EMSA) and supershift analyses
and luciferase reporter essays using elements and mutated sequences.
In summary, the genome-wide collection of Xenopus promoter ele-
ments identified in Chapter 3 shed insight into vertebrate core promoter
function and may serve as a starting point for analyses to further un-
ravel the exact role of the core promoter diversity in transcription and
gene regulation.
7.2 chip-seq : profiling regulatory proteins
7.2.1 The role of the chromatin environment in early development
Chromatin structure plays an important role in gene expression, DNA
replication, recombination and repair. Histones are decorated with a
profusion of varied posttranslational modifications (PTMs), many of
which are linked to the expression status of genes. The exact deter-
minant of this effect and the role of specific modifications are not yet
completely elucidated. It has become clear that combinations of certain
PTMs can exert a specific effect, but it is uncertain if this constitutes
a full-fledged ’histone code’ which employs the full array of combina-
torial possibilities, or if the conceptual idea of a language is a better
fit (Lee et al., 2010). To understand the context-dependent crosstalk
of different modifications it is necessary to resolve how these marks
are deposited and removed, which additional downstream effector
proteins are recruited and finally, how these different marks interact.
The combination of techniques such as quantitative mass spectrome-
try to determine interactants (the ’readers’) and associated complexes
and ChIP-sequencing to determine genome-wide localization of the
modifications make it possible to study this in detail (Vermeulen et al.,
2010).
In Chapter 4, we used ChIP-seq to characterize the epigenetic en-
vironment that determines the control and regulation of gene expres-
sion during development. We characterized the interplay between the
H3K4me3 modification associated with active transcription and the
repressive mark H3K37me3. Of special interest were the reported ’bi-
valent’ domains, which have been characterized in embryonic stem
cells. These genes, which are marked by both H3K4me3 and H3K27me3
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are repressed and poised for rapid activation. However, we could not
unambiguously confirm this phenomenon in Xenopus embryos. Indeed,
there were many genes on which we found colocalization of both modi-
fications. However, in contrast to what has been found for ES cells, these
genes were not silent. The majority is actually expressed, as shown by
RNAseq evidence, as well as recruitment of RNAPII indicating active
transcription. In addition, of the genes which had been been previ-
ously reported as bivalent and repressed in ES cells, the majority was
expressed, with no evidence for paused RNAPII.
ChIP-reChIP experiments on a variety of double-marked genes illus-
trated that the majority of these regions were not bivalently marked in
the Xenopus model system; the active H3K4me3 mark and repressive
H3K37me3 mark were not present on the same nucleosomal DNA.
Instead, we found that the H3K27me3 mark on double-marked genes
is a manifestation of spatial regulation which follows a hierarchical
temporal pattern. First, the appearance of H3K4me3 coincides with the
activation of transcription. This is followed by spatial-specific deposi-
tion H3K27me3 to repress transcription in a localized fashion. Many
of these repressed genes are transcription factors and developmental
regulators, which is indicative of a cascade of repression that is first set
in motion by spatial deposition of H3K27me3.
Similar to our findings in Xenopus embryos, bivalency is not a com-
mon phenomenon in Drosophila (Schuettengruber et al., 2009). Gan
et al. found that silent, differentiation-associated genes in Drosophila
testes were mainly marked by either H3K27me3 without H3K4me3 or
none of both (Gan et al., 2010). The few putative bivalent genes they
identified in the testis were likely the result of a mixed cell population
as none of them retained their bivalency in cultured Drosophila cells
(Gan et al., 2010). On the other hand, bivalent domains were observed
in blastula stage zebrafish embryos in recent experiments (Vastenhouw
et al., 2010).
It is questionable whether bivalency is truly a general hallmark
for the pluripotent cell state, with genes poised for rapid activation.
ES cells have to undergo significant reprogramming to reach their
immortal, cultured state. It is largely unknown how this changes their
epigenetic make-up compared to their in vivo counterpart. For H3K4
and H3K27, both methylation and demethylation events occur after ES
cell derivation from the ICM (Dahl et al., 2010). Furthermore, while
cell lines are often treated as uniform populations, this is likely not the
case. Some of the H3K27me3 recruitment in ES cells might reflect the
start of differentation in a subpopulation of the cells. Our own findings
in Xenopus embryos indicate that H3K27me3 is a hallmark of lineage
commitment. Concordantly, Polycomb group proteins are not required
for maintenance of pluripotency, but are essential during differentiation
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(Chamberlain et al., 2008; Pasini et al., 2007). Single cell experiments
confirm that downregulation of specific developmental regulators in
opposing lineages, rather than lineage-specific increase, is an important
feature of differentation at very early embryonic stages (Guo et al., 2010).
This is consistent with a crucial role for H3K27me3 and Polycomb in
lineage commitment. However, differences between various cell-types
and organisms are likely to be expected. Notwithstanding, from the
evidence published so far, it seems credible that the bivalent state is a
transient feature, which affects only a minority of the nucleosomes.
Further genome-wide characterization of other marks and modifying
enzymes at fine-grained developmental stages will shed insight into
the combinatorial and spatio-temporal patterns of chromatin marks
and their role in vertebrate development. In addition, Chapter 4 high-
lights the issues with analyzing heterogeneous cell populations. The
epigenetic profiles generated using large amounts of cells reflect the
average distribution of modifications. Cell populations in culture might
not be homogeneous (Narsinh et al., 2011) and the precise epigenetic
characterization of a vertebrate embryo will require cell lineage- and
tissue-specific experiments.
7.2.2 The transcription factors p53 and p73
In Chapter 5 and 6 we have determined the binding locations of two
members of the p53 tumor suppressor family: p53 and p73. These
proteins serve as major safeguards of the genome. The p53 protein is
able to stimulate a wide variety of regulatory responses ranging from
DNA repair and temporary halting of cell division to apoptosis (Murray-
Zmijewski et al., 2008). It is currently not completely understood how
exactly p53 stimulates such a diverse array of responses.
As one of the most well-studied human transcription factors p53
serves as an interesting model for transcriptional regulation. The het-
erogeneity of the response depends on the stress signal, as well as
the tissue- and cell-type. The level and activity of p53 are regulated
transcriptionally, translationally and by post-translational modifications.
It can bind to a well-characterized consensus sequence, two copies of
the palindromic half-site RRRCWWGYYY, although other binding sites
such as specific trinucleotide repeats and microsatellites have been
reported (Jett et al., 2000; Contente et al., 2002; Walter et al., 2005).
Activation can be mediated by p53 though interaction with TFIID and
TFIIH (Chen et al., 1993; Thut et al., 1995; Farmer et al., 1996; Xing et al.,
2001; Lello et al., 2006; Li et al., 2007a).
We performed a genome-wide analysis of p53 binding using ChIP
in combination with microarrays. This ChIP-on-chip approach yielded
roughly 1,500 binding sites, many of which had been previously un-
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known. One characteristic shared with genome-wide experiments of
most other transcription factors was that the majority of binding takes
place outside gene promoters. We showed that some of these intergenic
binding sites can actually regulate unannotated transcripts; others likely
function as enhancers via looping mechanisms as has been demon-
strated for the estrogen receptor ER (Fullwood et al., 2009). While many
of these binding sites are functional, others might reflect true binding
events without a functional role. It has been shown that binding sites
and target genes of p53 are subject to ongoing evolution, with new sites
being introduced relatively recent on an evolutionary timescale. The
PIG3 promoter, for instance, is p53-responsive in apes and humans, but
not in monkeys (Contente et al., 2003). Another example is illustrated by
the numerous p53 binding sites in Alu repeats. The CATG core sequence
of the binding motif in these elements was generated by deamination
of methylated cytosines in the context of CpGs, thereby creating bona
fide p53-binding sites through mutations (Zemojtel et al., 2009). Fur-
thermore, Wang et al. have shown that the primate-specific LTR class I
endogenous retrovirus (ERV) retroelements contain p53 binding sites,
accounting for up to a third of the genome-wide p53 binding repertoire
(Wang et al., 2007). These examples illustrate mechanisms by which p53
binding sites without any specific biological function could have been
acquired recently in the primate lineage.
Using a newly developed motif scanning approach (p53scan) we
found that the majority of the binding sites contained a motif that
conforms to the p53 consensus. The spacer separating the two half-sites
was commonly 0 or 1 bases. While many publications have discussed
p53 sites deviating from the consensus, our results showed that these
are actually the exceptions, and that the majority of the binding sites
contain the prevalent regular motif.
The ChIP-on-chip data indicated that p53 binds target sites on a
genome-wide scale, regardless of the expression status of the targets.
This could indicate that p53 binding occurs relatively ubiquitously with
subsequent transcriptional activation dependent upon other regulatory
steps; the selective context model as proposed by Espinosa (Espinosa,
2008). On the other hand, it has also been shown that established cell
lines, as used in this experiment, show different binding characteristics
as compared to primary cells (Shaked et al., 2008). Care needs to be
taken when interpreting results from cell lines (Millau et al., 2010), as
these are generally cancer-derived, immortalized cells. Key pathways
related to growth and apoptosis, including the p53 pathway, are likely
to be deregulated. Further experiments with primary cells are necessary
clarify this issue.
It still remains to be elucidated how the differential response of p53 to
different stresses is regulated at a molecular level. Our results and those
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of others show that this can not be completely encoded in the actual
sequence of the binding site (Szak et al., 2001; Horvath et al., 2007).
Likely, the final activation of target genes depends on a combination of
the chromatin environment, which can be further be characterized using
genome-wide ChIP-seq experiments, post-translational modifications
of p53, additional co-factors and the core promoter architecture (Gomes
and Espinosa, 2010; Morachis et al., 2010).
Chapter 6, in which we analyzed two isoforms of the p53 family
member p73, confirms many of our observations of p53, and addi-
tionally illustrates how another transcription factor can influence the
differential biological outcomes regulated by two isoforms of the same
protein. The two isoforms, TAp73α and TAp73β, have different effects
on the transcriptional activation of target genes as well as on the cel-
lular apoptotic response. Apoptosis levels after activation of TAp73β
are higher when compared to TAp73α activation (Chapter 6, Gonzalez
et al., 2005; Oshima et al., 2007; Klanrit et al., 2008). In this case, the
cellular outcome clearly depends on the specific p73 isoform that is
expressed, however, the functional mechanisms remain unclear.
Although TAp73α and TAp73β share an identical DNA binding do-
main, we found binding sites specific for the isoforms. The p73 motif
that we identified in these sets was nearly identical, indicating that
this differential recruitment is not based on different DNA-binding
specificities. Indeed, even between different p53-family members the
differences are small. The p53, p63 and p73 motifs are highly similar
with only minor differences (Chapter 5 and 6, Kouwenhoven et al.,
2010). This is confirmed by biophysical experiments that show highly
conserved DNA-binding specificity for p53 family members (Brandt
et al., 2009). However, these conserved proteins do have clearly distinct
functions in development and tumor suppression. While specific bind-
ing sites for individual p53 family members are present, the differential
recruitment to the majority of potential sites is likely regulated by ad-
ditional regulatory mechanisms. Co-factors and interacting proteins
could be one of the major determinants. As the chromatin structure
and DNA accessibility greatly influences transcription factor binding,
family member- or isoform-specific interactions with for instance chro-
matin remodelers could be an important factor in determining binding
specificity. Recently it was shown that different stresses induce very
similar p53 binding patterns on naked DNA (Millau et al., 2011). The
same treatments, on the other hand, led to stress-specific p53 binding
patterns on chromatin. These observations underline the importance of
chromatin and chromatin remodeling.
The de novo motif analysis identified one major and significant feature
of TAp73α-specific targets: enrichment of the AP1 consensus motif. The
AP1 motif, also known as the TRE (TPA-responsive) element, can be
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bound by members of the AP1 protein family (Wagner, 2001; Hess et al.,
2004). The AP1 proteins are formed by dimers, usually heterodimers
of a member of the Jun protein family and a Fos, ATF or JDP protein.
These proteins have diverse functions in proliferation, differentiation,
cellular survival and apoptosis in response to external stimuli such as
stress, radiation, or to growth factor signals. The exact function of AP1
proteins greatly depends on the identity of the subunits of the complex
binding to the AP1 sites. Furthermore, the activity of these subunits
can be influenced by control of their mRNA stability, post-translational
processing and turnover, as well as specific interactions with other
transcription factors and cofactors. We found that one factor of the
AP1 family, c-Jun, can influence the apoptosis-survival balance after
TAp73 activation in osteosarcoma cells in an isoform-specific manner.
However, this is clearly not the complete picture. The identity of the
c-Jun dimerization partner, for instance, remains unknown.
The RNA-seq expression data shows differential patterns for many
of the AP1 proteins (Chapter 6). Fos is expressed at very low levels, but
the two family members Fra-1 and Fra-2 show p73α-specific upregu-
lation. Both proteins are putative c-Jun heterodimerization candidates.
Fra-1 is able to inhibit c-Jun breakdown and thereby promotes c-Jun
accumulation (Talotta et al., 2010). Fra-2 is expressed in bone cells and
controls bone formation, which fits the osteosarcomic origin of the
Saos-2 cell line in our study (Bozec et al., 2010). While we investigated
c-Jun, which is downregulated after TAp73β activation, JunD is also
expressed and shows TAp73β-specific upregulation.
In addition to the AP1 motif, one other motif is enriched in p73 peaks,
the RUNX1 motif. This motif can be bound by the Runx1 transcription
factor (runt-related transcription factor 1), also known as AML1 (acute
myeloid leukemia 1), which is involved in hematopoietic differentiation
(Friedman, 2009). The occurrence of this motif is slightly higher in
TAp73β versus TAp73α peaks. No functional link between Runx1 and
p73 has currently been published.
Just as with Chapter 5, it is necessary to be cautious about interpre-
tations of the results in this specific, relatively artificial system. These
experiments were carried out in a Saos-2 cell line, stably expressing
TAp73α or TAp73β at similar protein levels. This enabled us to objec-
tively compare the binding profiles of the two isoforms. However, the
overexpression of these proteins might result in levels that are much
higher than their in vivo concentrations. In addition, the exact p73 func-
tion in this specific cancer-derived cell line might not be applicable to
an in vivo situation (Shaked et al., 2008; Millau et al., 2010). That being
said, Chapter 6 illustrates how the differential cellular response of two
isoforms of the same protein, that recognize the same binding sites,
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can be partly explained due to a functional interaction with a different
transcription factor.
7.3 analyzing transcription factor binding motifs
7.3.1 Identification of motifs
The rapid advances in experimental techniques have expedited the iden-
tification of sequence motifs, but have at the same time introduced new
complexities. Motif identification algorithms were aimed at deriving
one or more motifs from a limited set of sequences. However, with
the uptake in genome-wide techniques providing a wealth of sequence
data, algorithms need to be able to deal with a much larger number
of sequences. The complexity and long running time of algorithms
is not merely an inconvenience, but limits the feasibility of a specific
approach.
An advantage of current genome-wide techniques is that the res-
olution of binding locations has been much improved, starting with
ChIP-chip and followed by significant improvements using the ChIP-
seq technique. The actual binding location of a factor (the center or
top position of a binding peak) can now be accurately determined.
Where we used sequences of 500 bp around the peak maximum for
the identification of the p53 motif in Chapter 5, the resolution of the
ChIP-seq enabled us to use only 200 bp for p73 in Chapter 6.
An all-round top-performing or golden standard algorithm for mo-
tif identification does not yet exist. Benchmarks studies have shown
that, while there are certain approaches which perform better or have
certain advantages for specific input datasets, in general there is no
single approach that performs well across a range of input of data
from different organisms. In Chapter 2 we show that a combination of
different algorithms and sensitive clustering approach makes it possible
to accurately determine the TF binding motif from ChIP-seq data of a
variety of transcription factors. In this approach, the motif identification
algorithms need not be perfect, as the final results are not dependent on
a single algorithmic approach. This method performs well on ChIP-seq
data of transcription factors (Chapter 6 and 2, Kouwenhoven et al.,
2010), but also on a more diverse set of sequences containing many
different motifs in low abundance, such as Xenopus or human core
promoters (Chapter 3).
New approaches for motif identification especially suited for ChIP-
seq data have been proposed. One aspect of ChIP-seq data that can be
incorporated to improve the algorithm performance is the availability of
the enrichment profile of the sequence reads: the peak shape. It is more
likely for a motif to be found in a region of high enrichment compared
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to a region of low enrichment. Indeed, these positional priors improve
upon existing methods (Bailey et al., 2010; Kulakovskiy et al., 2010).
While it is important that new approaches continue to be developed,
one issue that needs attention is the usability of the software. These
approaches should work on the data that researchers routinely pro-
duce, require no tweaking of different parameters for initial, reasonable
results, and be easily integrated in existing analysis pipelines. This is
one of the reasons that approaches such as GimmeMotifs (Chapter 2)
are valuable, as algorithmic perfection is unimportant if the algorithm
cannot be applied to real-world data.
The elucidation of the binding specificity of transcription factors has
only been highlighted from a certain viewpoint in this thesis: motif
identification from genomic binding locations (ChIP-chip or ChIP-seq).
However, several complementary approaches can be taken to derive
the binding motif of a protein. Using yeast or bacterial one-hybrid
systems allows elucidation of the binding specificity of a protein of
interest without the availability of an antibody (Noyes et al., 2008). In
the microwell-based TF DNA-binding specificity assay the DNA bind-
ing domains of transcription factors are fused to the luciferase enzyme
(Hallikas and Taipale, 2006; Hallikas et al., 2006). The fusion proteins are
expressed and incubated with a biotinylated double-stranded oligonu-
cleotide with high affinity together with an excess of competitor oligos.
After incubation in streptavidin-coated wells, the luciferase activity is
measured. This activity will be high in case of low-affinity competitor
oligos and low or nonexistent with high-affinity oligos. These data, as
they reflect binding data, can be incorporated into a position weight
matrix. Finally, protein binding microarrays test binding specificities
of TFs to double-stranded microarrays that contain all possible DNA
sequence variants of a given length (Berger et al., 2006). Integrating
these different techniques with the in vivo ChIP-seq approaches can
yield insight into binding specificities of complete protein families (Wei
et al., 2010).
7.3.2 Prediction of binding
Much progress has been made, both experimentally and computation-
ally, in the elucidation of the binding specificities of transcription factors.
One of the challenges that remains is the in silico computational predic-
tion of binding sites (Millau et al., 2011). For example, the p73 protein is
bound at around 10,000 to 20,000 sites genome-wide (Chapter 6). While
these numbers are large, they are still an order of magnitude lower than
the number of sites that would be computationally predicted using the
weight matrix summarizing the binding specificity of this protein. Sites
that conform perfectly to the consensus sequence are unoccupied in
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vivo, while other degenerate sites with a low computational score are
unambiguously bound.
One of the main reasons for this discrepancy between computational
predictions and in vivo data is the accessibility of the binding sites.
If chromatin is in a condensed formation this disallows access of a
transcription factor to its cognate site. Incorporation of in vivo data
on histone modifications associated with open or closed chromatin,
or DNAse I cleavage patterns can greatly improve the computational
prediction (Ramsey et al., 2010; Pique-Regi et al., 2011). In addition, it
has been shown that other sequence characteristics such as conservation
and GC content can enhance predictions (Ernst et al., 2010). It is likely
that the accuracy of computational prediction will improve, as the
knowledge about the epigenetic environment increases and genome-
wide data of the chromatin landscape becomes available.
7.4 bioinformatics: developments and challenges
7.4.1 Progressing techniques
Currently, three different approaches are widely used for deep sequenc-
ing: sequencing by synthesis (Illumina), pyrosequencing (454, Roche)
and sequencing by oligonucleotide ligation and detection (SOLiD,
Life Technologies). Vendors routinely improve on the existing sam-
ple preparation and sequencing methods, by hardware improvements
and through optimized reagents and procedures. Meanwhile new tech-
niques are being developed and proof-of-concept experiments pub-
lished by different companies, including Pacific Biosciences (Eid et al.,
2009), Complete Genomics (Drmanac et al., 2010) and Oxford Nanopore
(Olasagasti et al., 2010). These new approaches promise single molecule
sequencing, increased throughput and longer read lengths.
While increased coverage and read length are very beneficial to de
novo sequencing and whole-genome resequencing, these are currently
not the bottleneck in ChIP-seq experiments. However, the amplification
step, which is currently necessary to perform deep sequencing, is
known to introduce a sequence-composition bias. The amplification
is sensitive to the GC content of the sequences and thus results in
underrepresentation of specific genomic regions. This also means that
experiments in organisms with an extremely skewed GC content have to
be designed very carefully. The amplification-free protocols promised by
several new sequencing techniques will be beneficial in the near future.
Meanwhile other strategies for library preparation can offer solutions
for current generation sequencing, such as the the protocol for Illumina
where adapters are ligated that enable direct attachment to the flowcell
surface, without the requirement of a PCR step in the preparation of
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a sequencing library (Kozarewa et al., 2009). One possibility enabled
by the the ever-increasing number of sequence reads obtained in a
single experiment is multiplexing. Multiple samples are barcoded with
a specific unique sequence identifier and are subsequently combined in
a single sequence run. This has been demonstrated to be feasible for up
to 96 samples (Smith et al., 2010).
One other area of improvement is the sensitivity and scale of the
library preparation. The large number of cells necessary to perform
a successful chromatin immunoprecipitation can be a bottleneck for
certain applications. Examples are clinical tissue samples, or material
from different areas within an embryo, which are very informative as
we have shown in Chapter 4. Protocols for ChIP with limited number
of cells have been developed (Acevedo et al., 2007; Dahl et al., 2009;
Adli et al., 2010) and likely microdroplet-based analyses can be adapted
for sequencing. Similar improved protocols will allow, for instance, for
lower amounts of RNA necessary to perform accurate gene expression
profiling (Armour et al., 2009).
7.4.2 Data storage and analysis
One of the most important challenges in the next-generation sequencing
field, regardless of the specific application, is managing the storage
and analysis of raw and processed data. While the price of sequencing
per basepair continues to drop spectacularly, the hardware capacity to
deal with the amounts of data that are being generated is not keeping
pace. For instance, just the pilot project of the 1000 Genomes project
(The 1000 Genomes Project Consortium, 2010) has produced 7.3 TB of
data. As the growth of sequence data is currently estimated to be about
fivefold per year, it is greatly outpacing improvements in processor,
harddisk and network speed capacity, which roughly double each year
(Stein, 2010).
This exponentially growing deluge of data is likely going to require
changes in the manner in which the downstream analysis is performed.
For large-scale experiments, it will not be feasible for single researchers
or small groups to locally store, manage and analyze all the data. The
analysis algorithms and software will need to be adjusted to multi-
core, parallel computation. This can mean a shift towards cloud-based
computing using infrastructure such as Amazon Web Services (Baker,
2010; Schatz et al., 2010; Stein, 2010). Examples of this approach in-
clude CloudBurst, which uses the cloud for mapping of reads based
on Google’s MapReduce algorithm (Schatz, 2009), and Myrna, which
implements RNA-seq differential expression analysis (Langmead et al.,
2010). However, there are important issues to be considered regarding
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the privacy and security of the data. In addition, efficient parallelization
continues to be a major hurdle in software design and implementation.
Currently, the techniques to generate data are sometimes progressing
faster than the software and analysis solutions. For ChIP-seq, methods
need to be refined or even developed for peak recognition, incorporation
of duplicate experiments and comparisons of different profiles. Instead
of relatively straightforward experiments using a single transcription
factor or histone mark, different data from different sources need to
be integrated and compared. This also raises the issue of independent
benchmarking of computational approaches. Take peak-calling as an
example. On the one hand, a multitude of approaches continue to be
developed, while on the other hand, there is no rigorous and objective
benchmark of performance available (Szalkowski and Schmid, 2010),
although some are being proposed (Rye et al., 2011). However, it is
likely that by the time the requirements for such a benchmark are
settled, the needs of new techniques have progressed beyond what the
current generation of software can provide.
7.4.3 Reproducibility and availability
Due to the nature of high-throughput methods such as massive parallel
sequencing a published experiment can consist of a lot of data, analyzed
with new and relatively immature methods and tools. Supplementary
methods of high-profile papers are significantly longer than the actual
article, and the raw (supplementary) data routinely reaches hundreds
of GBs. As the publication review process is not equipped to stringently
validate and assess these complete experiments and as simple errors
or oversights can lead to erroneous results (Baggerly, 2009), the field
needs to strive toward open, available and well-documented methods
and data.
While theoretically superior experimental design decisions, such as
multiple independent ChIP antibodies for a single factor, biological
replicates and well-chosen controls, might not always be practically
feasible, the need for validated and reproducible experiments should
not be underestimated. A certain degree of standardization is likely to
take place as the technique matures. There is, however, a chance the
current rate of progress means a technology will not reach that maturity
before it is superseded.
As a reasonable and practically achievable aim, published results
should use open standards, include mandatory publication of algo-
rithms and documented software and freely accessible data in open
repositories such as the Gene Expression Omnibus (Barrett et al., 2009).
This would include publication of scripts used for analysis complete
with documentation. An example of a tool that enables this kind of
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reproducible research is Sweave (Leisch, 2002), which allows the em-
bedding of R code for analyses in LaTeX documents.
These practices will serve objective benchmarks, as algorithms and
data are freely available, and independent replication of previous ex-
periments. It will also benefit algorithm developers, who might not
have the expertise, means or funding to produce their own data. The
bulk of the work in this thesis would not have been possible without
the many excellent open-source tools and freely accessible data upon
which many of the analyses are based.
7.5 towards regulatory networks
As the affordable sequencing throughput increases, it will finally be-
come feasible to make significant progress towards deciphering regu-
latory networks. A transcription factor does not act in isolation, but
functions in a specific cellular environment within specific epigenetic
surroundings together with many other proteins. Large-scale experi-
ments to obtain insight in these complete environments are now within
reach. Instead of investigating a handful of binding sites in a specific
biological system, it is possible to study binding in different cell types
or tissues, under a wide range of conditions and at different develop-
mental stages. Important epigenetic factors such as DNA methylation
and histone modifications can be profiled.
Several large-scale projects are currently being undertaken. The EN-
CODE consortium provided a first glimpse into the functional data of
the human genome and the data is currently available (Raney et al.,
2010). The sequence-based functional elements of other important
model organisms, Caenorhabditis elegans and Drosophila melanogaster,
are being profiled in the modENCODE projects. The epigenetic envi-
ronment of a large variety of human and mammalian cell lines will be
determined in the NIH Roadmap Epigenomics Program.
Integrating all these different data from different sources will lead
to, for instance, better mapping of transcription factors and predicting
enhancer targets in the short-term (Boyle et al., 2011; Pique-Regi et al.,
2011; Rödelsperger et al., 2011) to finally deciphering the regulatory
networks that play a role in development and disease in the long-
term. The tools and techniques of high-throughput data generation
and analysis are here to give an unprecedented insight into basic
yet complex biology; to decipher the mechanisms of transcriptional
regulation at the systems level.
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S U M M A RY
The expression of a gene is determined by a variety of mechanisms.
The basal transcription machinery, composition of the promoter, tran-
scription factors, including activators and repressors, and the chro-
matin environment all play a role. Together, these determine when and
where a gene is expressed and at what level. The development of high-
throughput methods, such as deep sequencing, enables experiments at
a genome-wide scale to investigate the regulation of gene expression.
This thesis describes the analysis of transcription regulation from a
computational point of view.
Chromatin Immunoprecipitation followed by high-throughput se-
quencing (ChIP-seq) enables genome-wide mapping of DNA or chromatin-
associated proteins. Using these binding locations, we can determine
the preferred DNA binding motif of a transcription factor. Many algo-
rithms have been developed to identify a motif from a set of sequences.
However, there is no single approach that consistently produces good
results on a wide variety of inputs. In addition, many tools are unable
to handle a large amount of input sequences, such as produced in a
ChIP-seq experiment, and there is often no meaningful ranking of the
resulting motifs. To address these issues I developed GimmeMotifs,
which is described in Chapter 2. This ensemble algorithm combines the
output of several motif prediction programs and clusters the resulting
motifs. The clustered motifs are filtered and ranked based on validation
on a held-back portion of the dataset. This enables accurate prediction
of motifs from ChIP-seq datasets as evidenced by benchmark results.
We have used the GimmeMotifs approach in Chapter 3 to study the
core promoter of Xenopus tropicalis, the Western clawed frog. Xenopus
is a widely used model organism for vertebrate development, but the
core promoter had not been previously characterized. We identified
transcription start sites by deep sequencing and predicted motifs in
the core promoter. We compared these motifs to human promoter mo-
tifs. As expected, we found many motifs that are conserved between
human and Xenopus. Interestingly, however, we also found differences.
The promoters of Xenopus and human have a very different nucleotide
composition. Human promoters are very G/C-rich; most promoters
are associated with CpG-islands. In Xenopus promoters, the T/A nu-
cleotides are much more prevalent. We found that the frequency of
some motifs depends on the promoter sequence composition. These
motifs are enriched above the local nucleotide background, but vary in
step with this background. Examples are the G/C rich SP1 motif, which
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occurs more often in human promoters, and the TATA box, which is
relatively prevalent in Xenopus promoters. This shows how the highly
conserved transcriptional machinery can be recruited to promoters with
diverging nucleotide compositions.
In Chapter 4 we investigated the role of the chromatin environment in
early embryonic gene regulation. We performed ChIP-seq for two im-
portant epigenetic modifications: H3K4me3 and H3K27me3. H3K4me3
mostly occurs at promoters of active genes and correlates with ex-
pression. H3K27me3 on the other hand, covers broad domains around
important developmental genes repressed by the Polycomb complexes.
During Xenopus development these modifications are deposited in a
hierarchical manner. H3K4me3 precedes gene expression and marks
genes that become activated. H3K27me3 is mainly deposited during gas-
trulation. It is recruited to genes during lineage commitment to stably
repress these important regulators and prevent ectopic expression.
Next to the core promoter and the chromatin environment, we in-
vestigated regulation by transcription factors in Chapters 5 and 6. We
analyzed the genome-wide binding profiles of two members of the p53
family of genes: p53 and p73. The tumor suppressor p53 is essential in
maintenance of genomic integrity; most human cancers don’t have a
normally functioning p53. We identified ~1,500 binding sites for p53
in a human osteosarcoma cell line. This enabled us to identify many
previously unknown p53 binding locations and target genes. From
these binding sites we extracted the p53 binding motif. Using this motif,
we created a tool to scan sequences for the p53 motif, wich showed
significant improvements in both specificity and sensitivity compared
to previous methods.
In Chapter 6 we identified the binding sites of two different isoforms
of p73, TAp73α and TAp73β. While these isoforms share many similar
targets, they each also bind a distinct set of genes and induce a dif-
ferent cellular response. Apoptosis levels are higher after induction of
TAp73β compared to TAp73α. Motif analysis followed by experimental
validation showed that the transcription factor c-Jun is differentially
recruited to TAp73α and TAp73β sites. This illustrates how the two
isoforms can mediate a different response.
Chapter 7 discusses the results and looks forward to the expected
developments from a bioinformatics point-of-view. It describes the
opportunities and hurdles on the way to providing a complete systems
biology overview of regulation.
S A M E N VAT T I N G
Veel processen in een multicellulair organisme, zoals bijvoorbeeld ont-
wikkeling en differentiatie, worden heel precies geregeld. De genen
die hierbij betrokken zijn moeten op een specifiek moment en op een
specifieke plaats aan- of uitgezet worden. Deze regulatie wordt mo-
gelijk gemaakt door een variëteit aan mechanismen. De genpromoter,
het basale transcriptiecomplex, transcriptiefactoren en epigenetische
factoren zoals de structuur van het chromatine spelen allemaal een
rol. Recentelijk ontwikkelde technieken maken het mogelijk om met
een hoge doorvoer de sequentie van DNA te bepalen: high-throughput
sequencing. Deze technieken kunnen ingezet worden om de regulatie
van genexpressie te bestuderen, waarbij niet slechts een enkel gen maar
het hele genoom onderzocht kan worden. In dit proefschrift beschrijf ik
hoe ik deze data met computationele methodes geanalyseerd heb en
wat dit ons kan leren over genregulatie.
Met chromatine-immunoprecipitatie (ChIP) kunnen de interacties
van eiwitten met DNA of chromatine bepaald worden. Door ChIP te
combineren met high-throughput sequencing kan voor het hele genoom
bepaald worden waar een specifiek eiwit bindt (ChIP-seq). Uit deze
bindingplaatsen kunnen we de DNA sequentie identificeren die bij
voorkeur door een transcriptiefactor gebonden wordt. Hiervoor zijn
vele algoritmes ontwikkeld. Er is echter geen specifieke aanpak die
op verschillende soorten data een goed resultaat geeft. Verder kunnen
veel algoritmes niet omgaan met een grote hoeveelheid aan data en
is er geen consistente manier om de ordening en significantie van
de resultaten te bepalen. In Hoofdstuk 2 beschrijf ik het GimmeMotifs
algoritme, dat ik ontwikkeld heb om motieven te identificeren in ChIP-
seq data. Dit algoritme gebruikt verschillende manieren om motieven
te bepalen en combineert deze motieven tot een overzichtelijk geheel.
De significantie van de samengevoegde motieven wordt bepaald met
behulp van een achtergehouden deel van de dataset. Deze aanpak
is getest op verschillende gepubliceerde ChIP-seq datasets en blijkt
accurate motieven te produceren.
De GimmeMotifs aanpak hebben we gebruikt om de genpromoters
van de westelijke klauwkikker (Xenopus tropicalis) te analyseren in Hoofd-
stuk 3. Xenopus wordt veel gebruikt als model in de ontwikkelingsbiolo-
gie, maar de motieven in de promoter waren nog niet eerder bekeken.
Met behulp van high-throughput sequencing hebben we de precieze lo-
catie van de promoters bepaald, en vervolgens hebben we de promoter
motieven geïdentificeerd. Deze motieven hebben we vergeleken met
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die van de mens. Veel van de promoter motieven zijn geconserveerd;
ze komen met dezelfde frequentie voor in de promoters van kikker en
mens. We vonden echter ook verschillen. De promoters van Xenopus
en mens hebben een andere samenstelling. Menselijke promoters zijn
rijk aan G en C; de meesten overlappen met CpG-eilanden. Promoters
in Xenopus hebben echter relatief meer A en T. De frequentie van som-
mige motieven hangt sterk af van deze nucleotide achtergrond. Hoewel
deze motieven verrijkt zijn ten opzichte van de achtergrond, wordt hun
frequentie ook bepaald door deze achtergrond. Voorbeelden zijn het
SP1 motif en de TATA box. SP1 bevat voornamelijk G/C’s en komt
meer voor in menselijke promoters met hun hoge G/C achtergrond. De
TATA box aan de andere kant is juist in de promoters van Xenopus, met
veel A/T’s, sterk verrijkt. De aan de deze motieven geassocieerde tran-
scriptiefactoren kunnen beide de basale transcriptiefactor TFIID binden.
Dit laat zien hoe het sterk geconserveerde basale transcriptiecomplex
naar promoters met divergente nucleotide samenstelling gerecruteerd
kan worden.
In Hoofdstuk 4 hebben we de rol van de epigenetische histon modifi-
caties H3K4me3 en H3K27me3 in de vroeg-embryonale ontwikkeling
van Xenopus bestudeerd. H3K4me3 is geassocieerd met genactivatie
en bevindt zich bij promoters. H3K27me3 heeft een tegengestelde rol.
Deze modificatie komt vooral voor in brede domeinen rond belangrijke
ontwikkelingsgenen en zorgt voor de repressie van deze genen. Deze
modificaties blijken tijdens de ontwikkeling van Xenopus op hiërar-
chische wijze geplaatst te worden. H3K4me3 wordt al vroeg op de
promoters van geactiveerde genen geplaatst; dit gaat vaak vooraf aan
de eigenlijke activatie. H3K27me3 wordt later tijdens de gastrulatie
geplaatst, meestal na eerdere activatie van het gen. Deze modificatie
is geassocieerd met differentiatie en de keuze van een cel voor een
bepaalde celtype (“lineage commitment“). Dit zorgt ervoor dat genen
die hierbij niet tot expressie moeten komen op een stabiele wijze uit-
geschakeld worden.
Als laatste mechanisme van regulatie hebben we gekeken naar tran-
scriptiefactoren. Hierbij hebben we de bindingsplaatsen in het genoom
geanalyseerd van twee leden van de p53 eiwitfamilie: p53 en p73. Het
p53 eiwit is een belangrijke tumor suppressor. Dit eiwit bewaakt de
integriteit van het genoom. Normaal regelt p53 dat een cel na bijvoor-
beeld DNA schade niet meer kan groeien of zelfs afsterft. Als p53 niet
goed functioneert kan dit grote gevolgen hebben; in de helft van de
kankergevallen bevat p53 mutaties. We hebben ~1,500 bindingsplaatsen
bekeken van p53 in het menselijke genoom, zoals beschreven in Hoofd-
stuk 5. Met behulp van deze bindingsplaatsen hebben we het p53 motief,
de DNA sequentie waar p53 aan bindt, nauwkeurig bepaald. Dit motief
is verwerkt in het p53scan algoritme, dat sequenties scant op het p53
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motief. Dit algoritme is gevoelig en accuraat en presteert beter dan
eerdere methodes.
In Hoofdstuk 6 hebben we de bindingplaatsen van twee p73 isovormen
bepaald: TAp73α and TAp73β. Deze twee vormen van het p73 eiwit lij-
ken erg op elkaar, maar hebben verschillende effecten. Activatie van het
TAp73β eiwit heeft een veel hogere mate van apoptose (gereguleerde
celdood) tot gevolg dan activatie van TAp73α. De analyse van de bin-
dingsplaatsen gaf aan dat er naast een grote overlap ook verschillen
in binding tussen de twee eiwitten waren. Uit motiefanalyse bleek dat
de TAp73α bindingsplaatsen sterk verrijkt waren voor het AP1 motief.
Experimentele analyses bevestigden dat de transcriptiefactor c-Jun, die
aan dit motief bindt, inderdaad meer bij TAp73α dan bij TAp73β bindt.
Dit is een mogelijke verklaring voor het verschil in cellulaire respons
tussen activatie van de ene of de andere isovorm.
Deze verschillende hoofdstukken belichten elk een ander aspect van
genregulatie. Samen laten ze zien dat we met de huidige technieken
krachtige mogelijkheden hebben om de regulatie van transcriptie te
onderzoeken. Fundamenteel onderzoek naar genregulatie helpt om
zowel ontwikkeling als erfelijke afwijkingen en kanker te begrijpen en
zal uiteindelijk leiden naar een compleet overzicht van het systeem van
regulatiemechanismen in een multicellulair organisme.

A C K N O W L E D G E M E N T S
I walk a crooked road to get where I am going
To get where I am going I must walk a crooked road
And only when I’m looking back I see the straight and narrow
I see the straight and narrow when I walk a crooked road
Darrell Scott
It has been a crooked road; I never saw this coming ten years ago.
As it turns out, there were a few people along the way that deserve to
be mentioned.
I’d like to go back a little while before my time at the NCMLS.
Annelies, it all started with a job you brought to my attention. There
I was, working in an outdoor store, happily selling tents and boots.
Thanks to you I got interested in this new opportunity: teaching bioin-
formatics at Hogeschool Leiden. Doing science was still a bridge too
far at that point, but I could see myself teaching. I was basically fresh
out of college, but a confident definition of “bioinformatics“ landed me
the job. I’m still grateful, Hans and Rene! Thanks to both my students
and my colleagues I learned a lot in a short time.
Then, unexpectedly, I had this urge to do science again. I applied
at the department of Molecular Biology and Henk and Marion took a
chance and hired me. I still remember Henk asking me what assurance
they had that I would not go off hiking again. The assurance was never
given, but it turned out they didn’t need it (although some destinations
have never left my mind). A two-year contract turned into four and
suddenly I’m finishing my PhD.
Gert Jan, a big thanks to you. In my opinion you’re the supervisor
anyone should wish for. Good supervision, available for discussions,
never a shortage of good ideas, critical, kindly reminding me of dead-
lines and things to do without being overtly pushy and of course there’s
the great science. Just to mention some things that spring to mind.
Marion, your unbridled enthousiasm was catching. I know I was usu-
ally the pessimistic one, saying but one too many times and mistrusting
results that looked to good to be true. Your positive outlook was a great
counterweight and a good motivation to keep going. I still believe that
surprisingly beautiful results are highly suspicious though.
Thanks to my command-line colleagues Kees-Jan and Hinri for useful
advice, necessary distractions and keeping our room generally a good
place to work. Mark, you introduced me to the wonderful world of
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PrepDVD, tiling paths and peak calling. It was a fun time (although
I’m glad the ChIP-on-chip era is over and done with).
I count myself really lucky. All too often, bioinformatics specialists
just serve as a kind of data analysis service. Here’s my data, I’d like
some results, preferably significant, please make some lists, kthxbye. I have
been able to closely collaborate with a number of people who not only
shared their hard-earned data with me, but also engaged in discussion
on an equal footing. I think we all benefited as a result; I know I did,
the proof is in this thesis. Leonie, Max, Robert, Rike and Waseem, it
has been a pleasure working with you. Ozren, Jo, Evelyn, thanks for
the great collaborations.
To all the past and present colleagues: we had interesting scientific
and lunchtime discussions, great borrels and memorable labuitjes. Let’s
keep ’em coming.
Irene, thanks for sharing your life with me. Let’s go walk our crooked
road together and marvel at the sights along the way.
C U R R I C U L U M V I TA E
Simon Jan van Heeringen is geboren op 7 april 1978 in Leiderdorp. Na
het afronden van de middelbare school startte hij de opleiding Mole-
culaire Wetenschappen aan de Wageningen Universiteit. Tijdens deze
studie specialiseerde hij zich in de bioinformatica: “niet pipetteren maar
programmeren“. De studie werd afgerond met een afstudeerproject bij
Plant Research International (PRI) in Wageningen en een stage bij The
Institute for Genomic Research (TIGR) in Rockville, Maryland, VS. Na
het behalen van zijn diploma in 2003 was hij drie jaar werkzaam als
docent aan de Hogeschool Leiden. Naast het lesgeven hielp hij om het
curriculum van de studie bioinformatica op te zetten en verder te ont-
wikkelen. In 2006 begon hij bij de afdeling Moleculaire Biologie van het
Nijmegen Centre for Molecular Life Sciences in de groep van Marion
Lohrum aan een onderzoek naar de tumor suppressor p53. Hierna
onderzocht hij in de groep van Gert Jan Veenstra de vroeg-embryonale
ontwikkeling van de klauwkikker Xenopus. Belangrijke thema’s in zijn
werk waren motief analyse, computationele epigenetica en analyse van
high-throughput sequencing data. De resultaten van het onderzoek zijn
beschreven in dit proefschrift. Momenteel is hij werkzaam als post-doc
bij Gert Jan Veenstra.
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